WO2015125842A1 - トリアジン化合物及びその医薬用途 - Google Patents
トリアジン化合物及びその医薬用途 Download PDFInfo
- Publication number
- WO2015125842A1 WO2015125842A1 PCT/JP2015/054519 JP2015054519W WO2015125842A1 WO 2015125842 A1 WO2015125842 A1 WO 2015125842A1 JP 2015054519 W JP2015054519 W JP 2015054519W WO 2015125842 A1 WO2015125842 A1 WO 2015125842A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- compound
- mmol
- chloro
- added
- Prior art date
Links
- -1 Triazine compound Chemical class 0.000 title description 135
- 150000001875 compounds Chemical class 0.000 claims abstract description 410
- 150000003839 salts Chemical class 0.000 claims abstract description 89
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 22
- 208000002193 Pain Diseases 0.000 claims abstract description 17
- 230000036407 pain Effects 0.000 claims abstract description 17
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 15
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 15
- 206010037660 Pyrexia Diseases 0.000 claims abstract description 14
- 201000009594 Systemic Scleroderma Diseases 0.000 claims abstract description 14
- 206010042953 Systemic sclerosis Diseases 0.000 claims abstract description 14
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 12
- 206010003210 Arteriosclerosis Diseases 0.000 claims abstract description 12
- 208000017442 Retinal disease Diseases 0.000 claims abstract description 12
- 208000011775 arteriosclerosis disease Diseases 0.000 claims abstract description 12
- 230000000302 ischemic effect Effects 0.000 claims abstract description 12
- 201000011510 cancer Diseases 0.000 claims abstract description 11
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 11
- 206010030043 Ocular hypertension Diseases 0.000 claims abstract description 10
- 101710096361 Prostaglandin E synthase Proteins 0.000 claims abstract 4
- 125000000217 alkyl group Chemical group 0.000 claims description 202
- 125000003545 alkoxy group Chemical group 0.000 claims description 69
- 150000002367 halogens Chemical class 0.000 claims description 69
- 229910052736 halogen Inorganic materials 0.000 claims description 65
- 125000001424 substituent group Chemical group 0.000 claims description 61
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 41
- 125000003118 aryl group Chemical group 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 35
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 32
- 239000001257 hydrogen Substances 0.000 claims description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 25
- 125000005843 halogen group Chemical group 0.000 claims description 25
- 239000003112 inhibitor Substances 0.000 claims description 22
- 150000003951 lactams Chemical class 0.000 claims description 21
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
- 229910052799 carbon Inorganic materials 0.000 claims description 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 17
- 125000004434 sulfur atom Chemical group 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 13
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 13
- 125000000623 heterocyclic group Chemical group 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 239000001301 oxygen Substances 0.000 claims description 13
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 5
- 206010018307 Glaucoma and ocular hypertension Diseases 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 230000000069 prophylactic effect Effects 0.000 claims description 4
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 3
- 125000004414 alkyl thio group Chemical group 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- JMBKDYKNNPBWKL-UHFFFAOYSA-N 4,6-bis(2,5-dimethylphenyl)-1H-1,3,5-triazin-2-one Chemical compound CC1=C(C=C(C=C1)C)C1=NC(=NC(=N1)C1=C(C=CC(=C1)C)C)O JMBKDYKNNPBWKL-UHFFFAOYSA-N 0.000 claims description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 abstract description 8
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 468
- 239000000243 solution Substances 0.000 description 223
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 192
- 239000012044 organic layer Substances 0.000 description 169
- 238000006243 chemical reaction Methods 0.000 description 161
- 238000004519 manufacturing process Methods 0.000 description 156
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 143
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 132
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 121
- 230000002829 reductive effect Effects 0.000 description 120
- 239000012300 argon atmosphere Substances 0.000 description 112
- 238000001914 filtration Methods 0.000 description 107
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 106
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 104
- 229910052938 sodium sulfate Inorganic materials 0.000 description 104
- 235000011152 sodium sulphate Nutrition 0.000 description 104
- 239000000203 mixture Substances 0.000 description 98
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 90
- 238000005160 1H NMR spectroscopy Methods 0.000 description 85
- 239000002904 solvent Substances 0.000 description 77
- 238000010898 silica gel chromatography Methods 0.000 description 74
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 72
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 70
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 69
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 66
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 64
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 63
- 239000003480 eluent Substances 0.000 description 60
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 56
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 56
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- 239000000047 product Substances 0.000 description 49
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 48
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 45
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 43
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 42
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 38
- 239000011541 reaction mixture Substances 0.000 description 38
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 36
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 36
- 238000001816 cooling Methods 0.000 description 36
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 36
- 235000019341 magnesium sulphate Nutrition 0.000 description 36
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 36
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 35
- 229960002986 dinoprostone Drugs 0.000 description 34
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 34
- 239000007787 solid Substances 0.000 description 34
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- 239000002585 base Substances 0.000 description 31
- 238000003756 stirring Methods 0.000 description 31
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 30
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 30
- 229920006395 saturated elastomer Polymers 0.000 description 30
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 28
- 235000017557 sodium bicarbonate Nutrition 0.000 description 28
- 229910000029 sodium carbonate Inorganic materials 0.000 description 28
- 235000017550 sodium carbonate Nutrition 0.000 description 28
- 239000000725 suspension Substances 0.000 description 27
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 23
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 22
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 20
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 description 19
- 238000001035 drying Methods 0.000 description 18
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 18
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 17
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 17
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- 239000012046 mixed solvent Substances 0.000 description 15
- JKAPWXKZLYJQJJ-UHFFFAOYSA-N 2,4-dichloro-6-methoxy-1,3,5-triazine Chemical compound COC1=NC(Cl)=NC(Cl)=N1 JKAPWXKZLYJQJJ-UHFFFAOYSA-N 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 14
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 14
- 238000006069 Suzuki reaction reaction Methods 0.000 description 13
- 239000003054 catalyst Substances 0.000 description 13
- 238000011813 knockout mouse model Methods 0.000 description 13
- 229910052763 palladium Inorganic materials 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 12
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 12
- 235000015165 citric acid Nutrition 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 12
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 12
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 12
- OWTCGJRBQMOICX-UHFFFAOYSA-M phenacyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1C(=O)C[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 OWTCGJRBQMOICX-UHFFFAOYSA-M 0.000 description 12
- 239000012312 sodium hydride Substances 0.000 description 12
- 229910000104 sodium hydride Inorganic materials 0.000 description 12
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 12
- PXKGHCBFNZTDEX-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1=CC=C(C=C1)C1=NC(=NC(=N1)OC)C1=C(C=CC=C1C(F)(F)F)OCOC Chemical compound C(C1=CC=CC=C1)OC1=CC=C(C=C1)C1=NC(=NC(=N1)OC)C1=C(C=CC=C1C(F)(F)F)OCOC PXKGHCBFNZTDEX-UHFFFAOYSA-N 0.000 description 11
- 239000004215 Carbon black (E152) Substances 0.000 description 11
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 11
- OMQUJFBGPRFTIO-UHFFFAOYSA-N [2-chloro-5-(hydroxymethyl)phenyl]boronic acid Chemical compound OCC1=CC=C(Cl)C(B(O)O)=C1 OMQUJFBGPRFTIO-UHFFFAOYSA-N 0.000 description 11
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 11
- 229910000024 caesium carbonate Inorganic materials 0.000 description 11
- 229930195733 hydrocarbon Natural products 0.000 description 11
- 150000002430 hydrocarbons Chemical class 0.000 description 11
- 230000004410 intraocular pressure Effects 0.000 description 11
- 239000012453 solvate Substances 0.000 description 11
- 239000008096 xylene Substances 0.000 description 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 239000012043 crude product Substances 0.000 description 10
- 239000004210 ether based solvent Substances 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- XCAQIUOFDMREBA-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonyl]carbamate Chemical compound CC(C)(C)OC(=O)NC(=O)OC(C)(C)C XCAQIUOFDMREBA-UHFFFAOYSA-N 0.000 description 10
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 10
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 150000007529 inorganic bases Chemical class 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 150000007530 organic bases Chemical class 0.000 description 9
- 229940127293 prostanoid Drugs 0.000 description 9
- 150000003814 prostanoids Chemical class 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- 230000001629 suppression Effects 0.000 description 9
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 8
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 8
- 229960001123 epoprostenol Drugs 0.000 description 8
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 8
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 8
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 8
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000007062 hydrolysis Effects 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- PGHKJMVOHWKSLJ-UHFFFAOYSA-N 2-methoxyethyl n-(2-methoxyethoxycarbonylimino)carbamate Chemical compound COCCOC(=O)N=NC(=O)OCCOC PGHKJMVOHWKSLJ-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 239000004533 oil dispersion Substances 0.000 description 6
- 239000002798 polar solvent Substances 0.000 description 6
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 6
- ASDPKQQQAJWHOS-UHFFFAOYSA-N 3,3,3-trifluoro-2,2-dimethylpropanamide Chemical compound NC(=O)C(C)(C)C(F)(F)F ASDPKQQQAJWHOS-UHFFFAOYSA-N 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 5
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 5
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 5
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 5
- 229910052783 alkali metal Inorganic materials 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 229910052796 boron Inorganic materials 0.000 description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 5
- 229950008138 carmellose Drugs 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 235000011181 potassium carbonates Nutrition 0.000 description 5
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 5
- 150000003180 prostaglandins Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 4
- MRWWWZLJWNIEEJ-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-propan-2-yloxy-1,3,2-dioxaborolane Chemical compound CC(C)OB1OC(C)(C)C(C)(C)O1 MRWWWZLJWNIEEJ-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 4
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000005456 alcohol based solvent Substances 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- AGCOMFFHXJMNLN-UHFFFAOYSA-N dichloromethane;dihydrochloride Chemical compound Cl.Cl.ClCCl AGCOMFFHXJMNLN-UHFFFAOYSA-N 0.000 description 4
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 4
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 4
- 210000001508 eye Anatomy 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229940098779 methanesulfonic acid Drugs 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 229960002900 methylcellulose Drugs 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 235000011056 potassium acetate Nutrition 0.000 description 4
- 229910000160 potassium phosphate Inorganic materials 0.000 description 4
- 235000011009 potassium phosphates Nutrition 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- ZPYVPGSSQPEXKV-SCSAIBSYSA-N (2R)-3,3,3-trifluoro-2-methoxy-2-methylpropanoic acid Chemical compound FC([C@](C(=O)O)(C)OC)(F)F ZPYVPGSSQPEXKV-SCSAIBSYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
- PZWDTJVKCQNWQS-UHFFFAOYSA-N 2-[5-(bromomethyl)-2-chlorophenyl]-4-methoxy-6-phenyl-1,3,5-triazine Chemical compound BrCC=1C=CC(=C(C1)C1=NC(=NC(=N1)OC)C1=CC=CC=C1)Cl PZWDTJVKCQNWQS-UHFFFAOYSA-N 0.000 description 3
- GEZGXVWDVGASEF-UHFFFAOYSA-N 4-tert-butyl-1-(hydroxymethyl)cyclohexane-1-carboxylic acid Chemical compound C(C)(C)(C)C1CCC(CC1)(C(=O)O)CO GEZGXVWDVGASEF-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- OLGWMWSTUCJSJS-UHFFFAOYSA-N COC1=NC(=NC(=N1)C1=C(C=CC=C1C(F)(F)F)OCOC)C1=CC=C(C=C1)C#CC1=CC=CC=C1 Chemical compound COC1=NC(=NC(=N1)C1=C(C=CC=C1C(F)(F)F)OCOC)C1=CC=C(C=C1)C#CC1=CC=CC=C1 OLGWMWSTUCJSJS-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 238000006751 Mitsunobu reaction Methods 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000001742 aqueous humor Anatomy 0.000 description 3
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 239000002198 insoluble material Substances 0.000 description 3
- 125000002346 iodo group Chemical group I* 0.000 description 3
- 229960001160 latanoprost Drugs 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 3
- 230000003228 microsomal effect Effects 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 3
- RPGWZZNNEUHDAQ-UHFFFAOYSA-N phenylphosphine Chemical compound PC1=CC=CC=C1 RPGWZZNNEUHDAQ-UHFFFAOYSA-N 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 3
- XIPFMBOWZXULIA-UHFFFAOYSA-N pivalamide Chemical compound CC(C)(C)C(N)=O XIPFMBOWZXULIA-UHFFFAOYSA-N 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000012264 purified product Substances 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical group COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 3
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 2
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- UOZUKAUFIGREEJ-UHFFFAOYSA-N 1-[[4-chloro-3-(6-oxo-4-phenyl-1H-1,3,5-triazin-2-yl)phenyl]methyl]-3,3-dimethylindol-2-one Chemical compound ClC1=C(C=C(CN2C(C(C3=CC=CC=C23)(C)C)=O)C=C1)C1=NC(=NC(=N1)O)C1=CC=CC=C1 UOZUKAUFIGREEJ-UHFFFAOYSA-N 0.000 description 2
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- MWSBROLPMBGNQM-UHFFFAOYSA-N 2-[2-(methoxymethoxy)-6-(trifluoromethyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound COCOC1=C(C(=CC=C1)C(F)(F)F)B1OC(C(O1)(C)C)(C)C MWSBROLPMBGNQM-UHFFFAOYSA-N 0.000 description 2
- WVJXQLREVYYVOA-UHFFFAOYSA-N 2-[2-chloro-4-methyl-5-(oxan-2-yloxymethyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound ClC1=CC(=C(COC2OCCCC2)C=C1B1OC(C(O1)(C)C)(C)C)C WVJXQLREVYYVOA-UHFFFAOYSA-N 0.000 description 2
- MBQYZOSCRUYPRD-UHFFFAOYSA-N 2-[4-methoxy-6-[4-(2-phenylethynyl)phenyl]-1,3,5-triazin-2-yl]-3-(trifluoromethyl)phenol Chemical compound COC1=NC(=NC(=N1)C1=CC=C(C=C1)C#CC1=CC=CC=C1)C1=C(C=CC=C1C(F)(F)F)O MBQYZOSCRUYPRD-UHFFFAOYSA-N 0.000 description 2
- SNCPMFBSTDOJCK-UHFFFAOYSA-N 2-bromo-1-(methoxymethoxy)-3-(trifluoromethyl)benzene Chemical compound BrC1=C(C=CC=C1C(F)(F)F)OCOC SNCPMFBSTDOJCK-UHFFFAOYSA-N 0.000 description 2
- HUGNLEZLTOVJLD-UHFFFAOYSA-N 2-bromo-3-methylphenol Chemical compound CC1=CC=CC(O)=C1Br HUGNLEZLTOVJLD-UHFFFAOYSA-N 0.000 description 2
- YJOPHWFROJDFLV-UHFFFAOYSA-N 2-chloro-4-(3-chloro-4-methylphenyl)-6-methoxy-1,3,5-triazine Chemical compound ClC1=NC(=NC(=N1)C1=CC(=C(C=C1)C)Cl)OC YJOPHWFROJDFLV-UHFFFAOYSA-N 0.000 description 2
- SFOVNLXDHGDGLG-UHFFFAOYSA-N 2-chloro-4-(3-fluoro-4-methylphenyl)-6-methoxy-1,3,5-triazine Chemical compound ClC1=NC(=NC(=N1)C1=CC(=C(C=C1)C)F)OC SFOVNLXDHGDGLG-UHFFFAOYSA-N 0.000 description 2
- AZKZHFQKDPNSIE-UHFFFAOYSA-N 2-chloro-4-methoxy-6-(4-propan-2-ylphenyl)-1,3,5-triazine Chemical compound COC1=NC(Cl)=NC(C=2C=CC(=CC=2)C(C)C)=N1 AZKZHFQKDPNSIE-UHFFFAOYSA-N 0.000 description 2
- MQHYOZNHLZOZFB-UHFFFAOYSA-N 2-chloro-4-methoxy-6-(4-propoxyphenyl)-1,3,5-triazine Chemical compound C1=CC(OCCC)=CC=C1C1=NC(Cl)=NC(OC)=N1 MQHYOZNHLZOZFB-UHFFFAOYSA-N 0.000 description 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
- KEZHRKOVLKUYCQ-UHFFFAOYSA-N 3,3-dimethyl-1h-indol-2-one Chemical compound C1=CC=C2C(C)(C)C(=O)NC2=C1 KEZHRKOVLKUYCQ-UHFFFAOYSA-N 0.000 description 2
- RGRSCIVQLWNQPC-UHFFFAOYSA-N 3-[[tert-butyl(dimethyl)silyl]oxymethyl]-6-chloro-2-methylaniline Chemical compound [Si](C)(C)(C(C)(C)C)OCC=1C(=C(C(=CC=1)Cl)N)C RGRSCIVQLWNQPC-UHFFFAOYSA-N 0.000 description 2
- GXBPFHVMKLYJLC-UHFFFAOYSA-N 3-propan-2-yl-4-(trifluoromethyl)phenol Chemical compound CC(C)C1=CC(O)=CC=C1C(F)(F)F GXBPFHVMKLYJLC-UHFFFAOYSA-N 0.000 description 2
- UCFSYHMCKWNKAH-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OBOC1(C)C UCFSYHMCKWNKAH-UHFFFAOYSA-N 0.000 description 2
- AEROVQSCBJINAN-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-[3-propan-2-yl-4-(trifluoromethyl)phenyl]-1,3,2-dioxaborolane Chemical compound C(C)(C)C=1C=C(C=CC1C(F)(F)F)B1OC(C(O1)(C)C)(C)C AEROVQSCBJINAN-UHFFFAOYSA-N 0.000 description 2
- NVOOCYZLPYEQLN-UHFFFAOYSA-N 4-[4-[5-(aminomethyl)-2-chlorophenyl]-6-methoxy-1,3,5-triazin-2-yl]phenol hydrochloride Chemical compound Cl.NCC=1C=CC(=C(C1)C1=NC(=NC(=N1)OC)C1=CC=C(C=C1)O)Cl NVOOCYZLPYEQLN-UHFFFAOYSA-N 0.000 description 2
- XFINBDAYXOESBB-UHFFFAOYSA-N 4-[4-methoxy-6-[2-(methoxymethoxy)-6-(trifluoromethyl)phenyl]-1,3,5-triazin-2-yl]phenol Chemical compound COC1=NC(=NC(=N1)C1=C(C=CC=C1C(F)(F)F)OCOC)C1=CC=C(C=C1)O XFINBDAYXOESBB-UHFFFAOYSA-N 0.000 description 2
- NBDFYADLNBEPGG-UHFFFAOYSA-N 4-chloro-2-(methoxymethoxy)-1-methylbenzene Chemical compound COCOC1=CC(Cl)=CC=C1C NBDFYADLNBEPGG-UHFFFAOYSA-N 0.000 description 2
- JFISQRPYNOQTAD-UHFFFAOYSA-N 4-chloro-5-iodo-2-methylbenzoic acid Chemical compound CC1=CC(Cl)=C(I)C=C1C(O)=O JFISQRPYNOQTAD-UHFFFAOYSA-N 0.000 description 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- AOTHQGLHKCBLEE-UHFFFAOYSA-N 6-[2-[(6-methylpyridin-2-yl)methoxy]-6-(trifluoromethyl)phenyl]-4-[4-(2-phenylethynyl)phenyl]-1H-1,3,5-triazin-2-one hydrochloride Chemical compound Cl.CC1=CC=CC(=N1)COC1=C(C(=CC=C1)C(F)(F)F)C1=NC(=NC(=N1)C1=CC=C(C=C1)C#CC1=CC=CC=C1)O AOTHQGLHKCBLEE-UHFFFAOYSA-N 0.000 description 2
- JLVBSBMJQUMAMW-UHFFFAOYSA-N 6-methyl-2-pyridinemethanol Chemical compound CC1=CC=CC(CO)=N1 JLVBSBMJQUMAMW-UHFFFAOYSA-N 0.000 description 2
- XLOYITKMSFYGMT-UHFFFAOYSA-N 7-tert-butyl-2-[[4-chloro-3-(6-oxo-4-phenyl-1H-1,3,5-triazin-2-yl)phenyl]methyl]-2-azaspiro[3.5]nonan-3-one Chemical compound C(C)(C)(C)C1CCC2(CN(C2=O)CC2=CC(=C(C=C2)Cl)C2=NC(=NC(=N2)O)C2=CC=CC=C2)CC1 XLOYITKMSFYGMT-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- PZHBMPAJDRJYQD-UHFFFAOYSA-N C(C)(C)(C)C1CCC(CC1)(C(=O)OC)CO Chemical compound C(C)(C)(C)C1CCC(CC1)(C(=O)OC)CO PZHBMPAJDRJYQD-UHFFFAOYSA-N 0.000 description 2
- DCNCLHCFZSJTEU-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1=CC(=C(C=C1)C(F)(F)F)Br Chemical compound C(C1=CC=CC=C1)OC1=CC(=C(C=C1)C(F)(F)F)Br DCNCLHCFZSJTEU-UHFFFAOYSA-N 0.000 description 2
- VAFOWABKADNNNJ-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1=CC(=C(C=C1)C(F)(F)F)C(=C)C Chemical compound C(C1=CC=CC=C1)OC1=CC(=C(C=C1)C(F)(F)F)C(=C)C VAFOWABKADNNNJ-UHFFFAOYSA-N 0.000 description 2
- UYYZTEUDICUJME-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1=CC=C(C=C1)C1=NC(=NC(=N1)Cl)OC Chemical compound C(C1=CC=CC=C1)OC1=CC=C(C=C1)C1=NC(=NC(=N1)Cl)OC UYYZTEUDICUJME-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- KNLHUBLBIUEHEU-UHFFFAOYSA-N Cl.ClC1=C(C=C(CN)C=C1)C1=NC(=NC(=N1)C1=CC=C(C=C1)C(C)C)OC Chemical compound Cl.ClC1=C(C=C(CN)C=C1)C1=NC(=NC(=N1)C1=CC=C(C=C1)C(C)C)OC KNLHUBLBIUEHEU-UHFFFAOYSA-N 0.000 description 2
- FMJUUBMVCUFINC-UHFFFAOYSA-N Cl.ClC1=C(C=C(CN)C=C1)C1=NC(=NC(=N1)C1=CC=C(C=C1)CC(C)C)OC Chemical compound Cl.ClC1=C(C=C(CN)C=C1)C1=NC(=NC(=N1)C1=CC=C(C=C1)CC(C)C)OC FMJUUBMVCUFINC-UHFFFAOYSA-N 0.000 description 2
- APOLXJQYQOQWCJ-UHFFFAOYSA-N Cl.ClC1=C(C=C(CN)C=C1)C1=NC(=NC(=N1)C1=CC=C(C=C1)OCC(C)C)OC Chemical compound Cl.ClC1=C(C=C(CN)C=C1)C1=NC(=NC(=N1)C1=CC=C(C=C1)OCC(C)C)OC APOLXJQYQOQWCJ-UHFFFAOYSA-N 0.000 description 2
- ZGOMDFAQTICOOU-UHFFFAOYSA-N Cl.ClC1=C(C=C(CN)C=C1)C1=NC(=NC(=N1)OC)C1=CC=C(C=C1)OCCC Chemical compound Cl.ClC1=C(C=C(CN)C=C1)C1=NC(=NC(=N1)OC)C1=CC=C(C=C1)OCCC ZGOMDFAQTICOOU-UHFFFAOYSA-N 0.000 description 2
- WRSZEZVSDQRIKC-UHFFFAOYSA-N ClC1=C(C=C(C=C1)CO)C1=NC(=NC(=N1)C1=CC=C(C=C1)C(C)C)OC Chemical compound ClC1=C(C=C(C=C1)CO)C1=NC(=NC(=N1)C1=CC=C(C=C1)C(C)C)OC WRSZEZVSDQRIKC-UHFFFAOYSA-N 0.000 description 2
- NUUXJNDEGIERSN-UHFFFAOYSA-N ClC1=C(C=C(C=C1)CO)C1=NC(=NC(=N1)C1=CC=C(C=C1)CC(C)C)OC Chemical compound ClC1=C(C=C(C=C1)CO)C1=NC(=NC(=N1)C1=CC=C(C=C1)CC(C)C)OC NUUXJNDEGIERSN-UHFFFAOYSA-N 0.000 description 2
- IAHHGPYICDTQCR-UHFFFAOYSA-N ClC1=C(C=C(C=C1)CO)C1=NC(=NC(=N1)C1=CC=C(C=C1)OCC(C)C)OC Chemical compound ClC1=C(C=C(C=C1)CO)C1=NC(=NC(=N1)C1=CC=C(C=C1)OCC(C)C)OC IAHHGPYICDTQCR-UHFFFAOYSA-N 0.000 description 2
- KCFRKKIUMJHSLV-UHFFFAOYSA-N ClC1=C(C=C(C=C1)CO)C1=NC(=NC(=N1)OC)C1=CC=C(C=C1)OCCC Chemical compound ClC1=C(C=C(C=C1)CO)C1=NC(=NC(=N1)OC)C1=CC=C(C=C1)OCCC KCFRKKIUMJHSLV-UHFFFAOYSA-N 0.000 description 2
- RZDCQQVVFZSKCF-UHFFFAOYSA-N ClC1=C(C=C(C=C1)CO)C1=NC(=NC(=N1)OC)C1=CC=C(C=C1)OCOC Chemical compound ClC1=C(C=C(C=C1)CO)C1=NC(=NC(=N1)OC)C1=CC=C(C=C1)OCOC RZDCQQVVFZSKCF-UHFFFAOYSA-N 0.000 description 2
- CCLCQSBNCKBGOL-UHFFFAOYSA-N ClC1=C(C=C(CCCN)C=C1)C1=NC(=NC(=N1)OC)C1=CC=CC=C1 Chemical compound ClC1=C(C=C(CCCN)C=C1)C1=NC(=NC(=N1)OC)C1=CC=CC=C1 CCLCQSBNCKBGOL-UHFFFAOYSA-N 0.000 description 2
- NACGSSGQAQPJJF-UHFFFAOYSA-N ClC1=CC(=C(C=C1I)CO)C Chemical compound ClC1=CC(=C(C=C1I)CO)C NACGSSGQAQPJJF-UHFFFAOYSA-N 0.000 description 2
- QIHTWNUJHDZLAZ-UHFFFAOYSA-N ClC1=CC(=C(COC2OCCCC2)C=C1I)C Chemical compound ClC1=CC(=C(COC2OCCCC2)C=C1I)C QIHTWNUJHDZLAZ-UHFFFAOYSA-N 0.000 description 2
- PNEJDKUEWWHNIN-UHFFFAOYSA-N ClC1=CC=C(C(=C1B1OC(C(O1)(C)C)(C)C)OCOC)C Chemical compound ClC1=CC=C(C(=C1B1OC(C(O1)(C)C)(C)C)OCOC)C PNEJDKUEWWHNIN-UHFFFAOYSA-N 0.000 description 2
- SASDRWGBBDLLMM-UHFFFAOYSA-N ClC1=NC(=NC(=N1)C1=CC(=C(C=C1)C(F)(F)F)C(C)C)OC Chemical compound ClC1=NC(=NC(=N1)C1=CC(=C(C=C1)C(F)(F)F)C(C)C)OC SASDRWGBBDLLMM-UHFFFAOYSA-N 0.000 description 2
- GMYMBRQPKONJGQ-UHFFFAOYSA-N ClC1=NC(=NC(=N1)C1=CC(=C(C=C1)Cl)C)OC Chemical compound ClC1=NC(=NC(=N1)C1=CC(=C(C=C1)Cl)C)OC GMYMBRQPKONJGQ-UHFFFAOYSA-N 0.000 description 2
- WDGWXCLJLSJLGQ-UHFFFAOYSA-N ClC1=NC(=NC(=N1)C1=CC(=C(C=C1)F)C1CC1)OC Chemical compound ClC1=NC(=NC(=N1)C1=CC(=C(C=C1)F)C1CC1)OC WDGWXCLJLSJLGQ-UHFFFAOYSA-N 0.000 description 2
- FUSBVKINUNJRMI-UHFFFAOYSA-N ClC1=NC(=NC(=N1)C1=CC=C(C=C1)CC(C)C)OC Chemical compound ClC1=NC(=NC(=N1)C1=CC=C(C=C1)CC(C)C)OC FUSBVKINUNJRMI-UHFFFAOYSA-N 0.000 description 2
- VKGBXXJIPLNEJW-UHFFFAOYSA-N ClC1=NC(=NC(=N1)C1=CC=C(C=C1)OCC(C)(C)C)OC Chemical compound ClC1=NC(=NC(=N1)C1=CC=C(C=C1)OCC(C)(C)C)OC VKGBXXJIPLNEJW-UHFFFAOYSA-N 0.000 description 2
- UWLHYXYTFPMXDL-UHFFFAOYSA-N ClC1=NC(=NC(=N1)C1=CC=C(C=C1)OCC(C)C)OC Chemical compound ClC1=NC(=NC(=N1)C1=CC=C(C=C1)OCC(C)C)OC UWLHYXYTFPMXDL-UHFFFAOYSA-N 0.000 description 2
- GBXDLOUSZDKYHW-UHFFFAOYSA-N ClC1=NC(=NC(=N1)OC)C1=CC=C(C=C1)OCOC Chemical compound ClC1=NC(=NC(=N1)OC)C1=CC=C(C=C1)OCOC GBXDLOUSZDKYHW-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- YIIMEMSDCNDGTB-UHFFFAOYSA-N Dimethylcarbamoyl chloride Chemical compound CN(C)C(Cl)=O YIIMEMSDCNDGTB-UHFFFAOYSA-N 0.000 description 2
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 2
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical compound C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 2
- AXGHDISDFUJTCV-UHFFFAOYSA-N FC(S(=O)(=O)OC1=CC(=C(C=C1)C(F)(F)F)C(C)C)(F)F Chemical compound FC(S(=O)(=O)OC1=CC(=C(C=C1)C(F)(F)F)C(C)C)(F)F AXGHDISDFUJTCV-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001135391 Homo sapiens Prostaglandin E synthase Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- PUGZWJGTISJITO-UHFFFAOYSA-N N-[[4-chloro-3-[4-[4-(2-methylpropyl)phenyl]-6-oxo-1H-1,3,5-triazin-2-yl]phenyl]methyl]-2,2-dimethylpropanamide Chemical compound ClC1=C(C=C(CNC(C(C)(C)C)=O)C=C1)C1=NC(=NC(=N1)C1=CC=C(C=C1)CC(C)C)O PUGZWJGTISJITO-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000000150 Sympathomimetic Substances 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- GLYOPNLBKCBTMI-UHFFFAOYSA-N [2-chloro-2-(1-chloro-2-phenylethoxy)ethyl]benzene Chemical compound C=1C=CC=CC=1CC(Cl)OC(Cl)CC1=CC=CC=C1 GLYOPNLBKCBTMI-UHFFFAOYSA-N 0.000 description 2
- BQLAQNYVAYGYQT-UHFFFAOYSA-N [4-(2,2-dimethylpropoxy)phenyl]boronic acid Chemical compound CC(C)(C)COC1=CC=C(B(O)O)C=C1 BQLAQNYVAYGYQT-UHFFFAOYSA-N 0.000 description 2
- DSVGQVZAZSZEEX-UHFFFAOYSA-N [C].[Pt] Chemical compound [C].[Pt] DSVGQVZAZSZEEX-UHFFFAOYSA-N 0.000 description 2
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 239000002160 alpha blocker Substances 0.000 description 2
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N beta-hydroxyethanesulfonic acid Natural products OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004979 bone marrow derived macrophage Anatomy 0.000 description 2
- 150000001639 boron compounds Chemical class 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229960000722 brinzolamide Drugs 0.000 description 2
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 210000004240 ciliary body Anatomy 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- OSRUSFPMRGDLAG-QMGYSKNISA-N dorzolamide hydrochloride Chemical compound [Cl-].CC[NH2+][C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 OSRUSFPMRGDLAG-QMGYSKNISA-N 0.000 description 2
- 229960002506 dorzolamide hydrochloride Drugs 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- RVZFTSUCJJLOBV-UHFFFAOYSA-N methyl 4-tert-butyl-1-(phenylmethoxymethyl)cyclohexane-1-carboxylate Chemical compound C(C1=CC=CC=C1)OCC1(CCC(CC1)C(C)(C)C)C(=O)OC RVZFTSUCJJLOBV-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- OFCCYDUUBNUJIB-UHFFFAOYSA-N n,n-diethylcarbamoyl chloride Chemical compound CCN(CC)C(Cl)=O OFCCYDUUBNUJIB-UHFFFAOYSA-N 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 125000002524 organometallic group Chemical group 0.000 description 2
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000003590 rho kinase inhibitor Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 229960004458 tafluprost Drugs 0.000 description 2
- WSNODXPBBALQOF-VEJSHDCNSA-N tafluprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1 WSNODXPBBALQOF-VEJSHDCNSA-N 0.000 description 2
- PNVSGDIZNKHATA-UHFFFAOYSA-N tert-butyl-[(4-chloro-3-iodo-2-methylphenyl)methoxy]-dimethylsilane Chemical compound C(C)(C)(C)[Si](C)(C)OCC1=C(C(=C(C=C1)Cl)I)C PNVSGDIZNKHATA-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 229960005221 timolol maleate Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 2
- 229960002368 travoprost Drugs 0.000 description 2
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 2
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- PIZQWRXTMGASCZ-UHFFFAOYSA-N (1-methylcyclopropyl)methanol Chemical compound OCC1(C)CC1 PIZQWRXTMGASCZ-UHFFFAOYSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- GVLBLUWVAOYKAT-OAQYLSRUSA-N (2R)-N-[[4-chloro-3-[4-(4-chloro-3-methylphenyl)-6-oxo-1H-1,3,5-triazin-2-yl]phenyl]methyl]-3,3,3-trifluoro-2-methoxy-2-methylpropanamide Chemical compound CO[C@](C)(C(=O)NCC1=CC(=C(Cl)C=C1)C1=NC(O)=NC(=N1)C1=CC(C)=C(Cl)C=C1)C(F)(F)F GVLBLUWVAOYKAT-OAQYLSRUSA-N 0.000 description 1
- VQAFZDCLZAMOEA-HSZRJFAPSA-N (2R)-N-[[4-chloro-3-[6-oxo-4-(4-propoxyphenyl)-1H-1,3,5-triazin-2-yl]phenyl]methyl]-3,3,3-trifluoro-2-methoxy-2-methylpropanamide Chemical compound CCCOC1=CC=C(C=C1)C1=NC(O)=NC(=N1)C1=C(Cl)C=CC(CNC(=O)[C@@](C)(OC)C(F)(F)F)=C1 VQAFZDCLZAMOEA-HSZRJFAPSA-N 0.000 description 1
- CTGJACFEVDCYMC-GSVOUGTGSA-N (2r)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoic acid Chemical compound OC(=O)[C@](O)(C)C(F)(F)F CTGJACFEVDCYMC-GSVOUGTGSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- YTJUYWRCAZWVSX-UHFFFAOYSA-N (3-chloro-4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=C1Cl YTJUYWRCAZWVSX-UHFFFAOYSA-N 0.000 description 1
- WPVBHUUZDFUIJA-UHFFFAOYSA-N (3-fluoro-4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=C1F WPVBHUUZDFUIJA-UHFFFAOYSA-N 0.000 description 1
- UZDPQDBLCJDUAX-UHFFFAOYSA-N (4-chloro-3-methylphenyl)boronic acid Chemical compound CC1=CC(B(O)O)=CC=C1Cl UZDPQDBLCJDUAX-UHFFFAOYSA-N 0.000 description 1
- DMJHEIDWSIAXCS-UHFFFAOYSA-N (4-phenylmethoxyphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1OCC1=CC=CC=C1 DMJHEIDWSIAXCS-UHFFFAOYSA-N 0.000 description 1
- IAEUFBDMVKQCLU-UHFFFAOYSA-N (4-propan-2-ylphenyl)boronic acid Chemical compound CC(C)C1=CC=C(B(O)O)C=C1 IAEUFBDMVKQCLU-UHFFFAOYSA-N 0.000 description 1
- SOKFEJKZYHYKSY-UHFFFAOYSA-N (4-propoxyphenyl)boronic acid Chemical compound CCCOC1=CC=C(B(O)O)C=C1 SOKFEJKZYHYKSY-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N 1,1'-Carbonyldiimidazole Substances C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- CRCTZWNJRMZUIO-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropane Chemical group FC(F)(F)[CH]C(F)(F)F CRCTZWNJRMZUIO-UHFFFAOYSA-N 0.000 description 1
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 description 1
- BLFYNZPJCYTXPV-UHFFFAOYSA-N 1-(3-bromo-4-chlorophenyl)butan-1-one Chemical compound CCCC(=O)C1=CC=C(Cl)C(Br)=C1 BLFYNZPJCYTXPV-UHFFFAOYSA-N 0.000 description 1
- URNVRYXURNXFLW-UHFFFAOYSA-N 1-(3-bromo-4-chlorophenyl)propan-1-one Chemical compound CCC(=O)C1=CC=C(Cl)C(Br)=C1 URNVRYXURNXFLW-UHFFFAOYSA-N 0.000 description 1
- SKCBKBCACWDALV-UHFFFAOYSA-N 1-(trifluoromethyl)cyclopropane-1-carboxylic acid Chemical compound OC(=O)C1(C(F)(F)F)CC1 SKCBKBCACWDALV-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- LQJNWLHPMPIZRY-UHFFFAOYSA-N 2-(3-cyclopropyl-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(F)C(C2CC2)=C1 LQJNWLHPMPIZRY-UHFFFAOYSA-N 0.000 description 1
- GXXXUZIRGXYDFP-UHFFFAOYSA-N 2-(4-methylphenyl)acetic acid Chemical compound CC1=CC=C(CC(O)=O)C=C1 GXXXUZIRGXYDFP-UHFFFAOYSA-N 0.000 description 1
- KDYOFXPLHVSIHS-UHFFFAOYSA-N 2-(4-methylphenyl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=C(C)C=C1 KDYOFXPLHVSIHS-UHFFFAOYSA-N 0.000 description 1
- PXPMCAKTYKAROX-UHFFFAOYSA-N 2-[4-(carboxymethyl)-5-oxo-1,3-dioxolan-4-yl]acetic acid Chemical compound OC(=O)CC1(CC(O)=O)OCOC1=O PXPMCAKTYKAROX-UHFFFAOYSA-N 0.000 description 1
- UERAGXKMOXUWPC-UHFFFAOYSA-N 2-bromo-1-fluoro-3-(trifluoromethyl)benzene Chemical compound FC1=CC=CC(C(F)(F)F)=C1Br UERAGXKMOXUWPC-UHFFFAOYSA-N 0.000 description 1
- XBBGYSIEJHXPLL-UHFFFAOYSA-N 2-bromo-4-fluoro-1-(trifluoromethyl)benzene Chemical compound FC1=CC=C(C(F)(F)F)C(Br)=C1 XBBGYSIEJHXPLL-UHFFFAOYSA-N 0.000 description 1
- JWCMJJIZYDCGTE-UHFFFAOYSA-N 2-bromo-4-methylbenzonitrile Chemical compound CC1=CC=C(C#N)C(Br)=C1 JWCMJJIZYDCGTE-UHFFFAOYSA-N 0.000 description 1
- 125000005999 2-bromoethyl group Chemical group 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- NHUBNHMFXQNNMV-UHFFFAOYSA-N 2-ethynylpyridine Chemical compound C#CC1=CC=CC=N1 NHUBNHMFXQNNMV-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- QALSEIBHJDDTQA-UHFFFAOYSA-N 2-methoxy-2-methylpropanamide Chemical compound COC(C)(C)C(N)=O QALSEIBHJDDTQA-UHFFFAOYSA-N 0.000 description 1
- YGLTVMFLDHIQGX-UHFFFAOYSA-N 2-methoxy-4-[2-[(6-methylpyridin-2-yl)methoxy]-6-(trifluoromethyl)phenyl]-6-[4-(2-phenylethynyl)phenyl]-1,3,5-triazine Chemical compound COC1=NC(=NC(=N1)C1=C(C=CC=C1C(F)(F)F)OCC1=NC(=CC=C1)C)C1=CC=C(C=C1)C#CC1=CC=CC=C1 YGLTVMFLDHIQGX-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- KFTYFTKODBWKOU-UHFFFAOYSA-N 2-methylsulfonylethanol Chemical compound CS(=O)(=O)CCO KFTYFTKODBWKOU-UHFFFAOYSA-N 0.000 description 1
- UOBYKYZJUGYBDK-UHFFFAOYSA-N 2-naphthoic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CC=C21 UOBYKYZJUGYBDK-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- CTGJACFEVDCYMC-UHFFFAOYSA-N 3,3,3-trifluoro-2-hydroxy-2-methylpropanoic acid Chemical compound OC(=O)C(O)(C)C(F)(F)F CTGJACFEVDCYMC-UHFFFAOYSA-N 0.000 description 1
- BBSLOKZINKEUCR-UHFFFAOYSA-N 3-(4-chlorophenyl)propanoic acid Chemical compound OC(=O)CCC1=CC=C(Cl)C=C1 BBSLOKZINKEUCR-UHFFFAOYSA-N 0.000 description 1
- RGQUXGFSHXDXIE-UHFFFAOYSA-N 3-[[tert-butyl(dimethyl)silyl]oxymethyl]-2-methylaniline Chemical compound CC1=C(N)C=CC=C1CO[Si](C)(C)C(C)(C)C RGQUXGFSHXDXIE-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- MAEGWJOXNJCHLG-UHFFFAOYSA-N 3-fluoro-2,2-dimethylpropanamide Chemical compound FCC(C)(C)C(N)=O MAEGWJOXNJCHLG-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- SVSUYEJKNSMKKW-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-prop-1-en-2-yl-1,3,2-dioxaborolane Chemical compound CC(=C)B1OC(C)(C)C(C)(C)O1 SVSUYEJKNSMKKW-UHFFFAOYSA-N 0.000 description 1
- YJMDORBRISAZSC-UHFFFAOYSA-N 4-(4-chlorophenyl)butanoic acid Chemical compound OC(=O)CCCC1=CC=C(Cl)C=C1 YJMDORBRISAZSC-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- XXFKOBGFMUIWDH-UHFFFAOYSA-N 4-chloro-2-methylbenzoic acid Chemical compound CC1=CC(Cl)=CC=C1C(O)=O XXFKOBGFMUIWDH-UHFFFAOYSA-N 0.000 description 1
- CDPKJZJVTHSESZ-UHFFFAOYSA-N 4-chlorophenylacetic acid Chemical compound OC(=O)CC1=CC=C(Cl)C=C1 CDPKJZJVTHSESZ-UHFFFAOYSA-N 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- JWQFKVGACKJIAV-UHFFFAOYSA-N 5-[(3-carboxy-4-hydroxyphenyl)methyl]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(CC=2C=C(C(O)=CC=2)C(O)=O)=C1 JWQFKVGACKJIAV-UHFFFAOYSA-N 0.000 description 1
- KKFPXGXMSBBNJI-UHFFFAOYSA-N 5-chloro-2-methylphenol Chemical compound CC1=CC=C(Cl)C=C1O KKFPXGXMSBBNJI-UHFFFAOYSA-N 0.000 description 1
- RUXROPHXYDNXOE-UHFFFAOYSA-N 6-[2-[(6-methylpyridin-2-yl)methoxy]-6-(trifluoromethyl)phenyl]-4-[4-(2-phenylethynyl)phenyl]-1H-1,3,5-triazin-2-one Chemical compound CC1=CC=CC(=N1)COC1=C(C(=CC=C1)C(F)(F)F)C1=NC(=NC(=N1)C1=CC=C(C=C1)C#CC1=CC=CC=C1)O RUXROPHXYDNXOE-UHFFFAOYSA-N 0.000 description 1
- SEIZEAHZTHCOJM-UHFFFAOYSA-N 7-tert-butyl-2-[[4-chloro-3-(4-methoxy-6-phenyl-1,3,5-triazin-2-yl)phenyl]methyl]-2-azaspiro[3.5]nonan-3-one Chemical compound C(C)(C)(C)C1CCC2(CN(C2=O)CC2=CC(=C(C=C2)Cl)C2=NC(=NC(=N2)OC)C2=CC=CC=C2)CC1 SEIZEAHZTHCOJM-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- DGAKHGXRMXWHBX-ONEGZZNKSA-N Azoxymethane Chemical compound C\N=[N+](/C)[O-] DGAKHGXRMXWHBX-ONEGZZNKSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FFDRPAYEYLGPIF-UHFFFAOYSA-N C(CCC)OC1=CC=C(C=C1)C1=NC(=NC(=N1)OC)C=1C=C(CNC(C(C(F)(F)F)(C)C)=O)C=CC1Cl Chemical compound C(CCC)OC1=CC=C(C=C1)C1=NC(=NC(=N1)OC)C=1C=C(CNC(C(C(F)(F)F)(C)C)=O)C=CC1Cl FFDRPAYEYLGPIF-UHFFFAOYSA-N 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- XQTSKZCNOQJAPU-UHFFFAOYSA-N CC(C)(C)COc1ccccc1B(O)O Chemical compound CC(C)(C)COc1ccccc1B(O)O XQTSKZCNOQJAPU-UHFFFAOYSA-N 0.000 description 1
- ZMTBJRNJWVXZQP-JOCHJYFZSA-N COC1=NC(=NC(=N1)C1=C(Cl)C=CC(CNC(=O)[C@@](C)(OC)C(F)(F)F)=C1)C1=CC(C)=C(Cl)C=C1 Chemical compound COC1=NC(=NC(=N1)C1=C(Cl)C=CC(CNC(=O)[C@@](C)(OC)C(F)(F)F)=C1)C1=CC(C)=C(Cl)C=C1 ZMTBJRNJWVXZQP-JOCHJYFZSA-N 0.000 description 1
- NELDCISEQSODFF-UHFFFAOYSA-N COC1=NC(=NC(=N1)C1=C(Cl)C=CC(CO)=C1)C1=CC=C(OCC(C)(C)C)C=C1 Chemical compound COC1=NC(=NC(=N1)C1=C(Cl)C=CC(CO)=C1)C1=CC=C(OCC(C)(C)C)C=C1 NELDCISEQSODFF-UHFFFAOYSA-N 0.000 description 1
- HTUPJNLMNBLKGN-UHFFFAOYSA-N COC1=NC(=NC(=N1)C1=CC(C)=C(Cl)C=C1)C1=CC(CN)=CC=C1Cl Chemical compound COC1=NC(=NC(=N1)C1=CC(C)=C(Cl)C=C1)C1=CC(CN)=CC=C1Cl HTUPJNLMNBLKGN-UHFFFAOYSA-N 0.000 description 1
- MNXBQCWPWWOMOG-UHFFFAOYSA-N COC1=NC(=NC(=N1)C1=CC(F)=C(C)C=C1)C1=CC(CN)=CC=C1Cl Chemical compound COC1=NC(=NC(=N1)C1=CC(F)=C(C)C=C1)C1=CC(CN)=CC=C1Cl MNXBQCWPWWOMOG-UHFFFAOYSA-N 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- XJKSPCLUDLPHIA-UHFFFAOYSA-N Cl.ClC1=C(C=C(CN)C=C1)C1=NC(=NC(=N1)C1=CC(=C(C=C1)C(F)(F)F)C(C)C)OC Chemical compound Cl.ClC1=C(C=C(CN)C=C1)C1=NC(=NC(=N1)C1=CC(=C(C=C1)C(F)(F)F)C(C)C)OC XJKSPCLUDLPHIA-UHFFFAOYSA-N 0.000 description 1
- MOPBYDGFJDCYSZ-UHFFFAOYSA-N Cl.ClC1=C(C=C(CN)C=C1)C1=NC(=NC(=N1)C1=CC(=C(C=C1)C)Cl)OC Chemical compound Cl.ClC1=C(C=C(CN)C=C1)C1=NC(=NC(=N1)C1=CC(=C(C=C1)C)Cl)OC MOPBYDGFJDCYSZ-UHFFFAOYSA-N 0.000 description 1
- UDZRXBAGHGWFFI-UHFFFAOYSA-N Cl.ClC1=C(C=C(CN)C=C1)C1=NC(=NC(=N1)C1=CC(=C(C=C1)C)F)OC Chemical compound Cl.ClC1=C(C=C(CN)C=C1)C1=NC(=NC(=N1)C1=CC(=C(C=C1)C)F)OC UDZRXBAGHGWFFI-UHFFFAOYSA-N 0.000 description 1
- OBHXDBYPRSZRIN-UHFFFAOYSA-N Cl.ClC1=C(C=C(CN)C=C1)C1=NC(=NC(=N1)C1=CC(=C(C=C1)Cl)C)OC Chemical compound Cl.ClC1=C(C=C(CN)C=C1)C1=NC(=NC(=N1)C1=CC(=C(C=C1)Cl)C)OC OBHXDBYPRSZRIN-UHFFFAOYSA-N 0.000 description 1
- ZPXQADCDQRYTPL-UHFFFAOYSA-N Cl.ClC1=C(C=C(CN)C=C1)C1=NC(=NC(=N1)C1=CC(=C(C=C1)F)C1CC1)OC Chemical compound Cl.ClC1=C(C=C(CN)C=C1)C1=NC(=NC(=N1)C1=CC(=C(C=C1)F)C1CC1)OC ZPXQADCDQRYTPL-UHFFFAOYSA-N 0.000 description 1
- KGCOVQQLZQOMRC-UHFFFAOYSA-N Cl.ClC1=C(C=C(CN)C=C1)C1=NC(=NC(=N1)C1=CC=C(C=C1)OCC(C)(C)C)OC Chemical compound Cl.ClC1=C(C=C(CN)C=C1)C1=NC(=NC(=N1)C1=CC=C(C=C1)OCC(C)(C)C)OC KGCOVQQLZQOMRC-UHFFFAOYSA-N 0.000 description 1
- YMQIBGPTJIOLJG-UHFFFAOYSA-N Cl.ClC1=C(C=C(CN)C=C1)C1=NC(=NC(=N1)OC)C1=CC=CC=C1 Chemical compound Cl.ClC1=C(C=C(CN)C=C1)C1=NC(=NC(=N1)OC)C1=CC=CC=C1 YMQIBGPTJIOLJG-UHFFFAOYSA-N 0.000 description 1
- LADHYAJZSDYEAN-UHFFFAOYSA-N ClC1=C(C=C(C=C1)CO)C1=NC(=NC(=N1)C1=CC(=C(C=C1)C)Cl)OC Chemical compound ClC1=C(C=C(C=C1)CO)C1=NC(=NC(=N1)C1=CC(=C(C=C1)C)Cl)OC LADHYAJZSDYEAN-UHFFFAOYSA-N 0.000 description 1
- UDMUWTBGFOFSCS-UHFFFAOYSA-N ClC1=C(C=C(C=C1)CO)C1=NC(=NC(=N1)C1=CC(=C(C=C1)C)F)OC Chemical compound ClC1=C(C=C(C=C1)CO)C1=NC(=NC(=N1)C1=CC(=C(C=C1)C)F)OC UDMUWTBGFOFSCS-UHFFFAOYSA-N 0.000 description 1
- WEHDPGBARCLTFD-UHFFFAOYSA-N ClC1=C(C=C(C=C1)CO)C1=NC(=NC(=N1)C1=CC(=C(C=C1)Cl)C)OC Chemical compound ClC1=C(C=C(C=C1)CO)C1=NC(=NC(=N1)C1=CC(=C(C=C1)Cl)C)OC WEHDPGBARCLTFD-UHFFFAOYSA-N 0.000 description 1
- WNFPHUFNLJWJAR-UHFFFAOYSA-N ClC1=C(C=C(C=C1)CO)C1=NC(=NC(=N1)C1=CC(=C(C=C1)F)C1CC1)OC Chemical compound ClC1=C(C=C(C=C1)CO)C1=NC(=NC(=N1)C1=CC(=C(C=C1)F)C1CC1)OC WNFPHUFNLJWJAR-UHFFFAOYSA-N 0.000 description 1
- UXAUKNVEQQCSPK-UHFFFAOYSA-N ClC1=C(C=C(CN2C(C(C3=CC=CC=C23)(C)C)=O)C=C1)C1=NC(=NC(=N1)OC)C1=CC=CC=C1 Chemical compound ClC1=C(C=C(CN2C(C(C3=CC=CC=C23)(C)C)=O)C=C1)C1=NC(=NC(=N1)OC)C1=CC=CC=C1 UXAUKNVEQQCSPK-UHFFFAOYSA-N 0.000 description 1
- PGAMVDMPULVBDE-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)C1=CC(=C(C=C1)C(F)(F)F)C(C)C)OC Chemical compound ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)C1=CC(=C(C=C1)C(F)(F)F)C(C)C)OC PGAMVDMPULVBDE-UHFFFAOYSA-N 0.000 description 1
- WGFQYKDJILLDFE-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)C1=CC(=C(C=C1)C)Cl)OC Chemical compound ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)C1=CC(=C(C=C1)C)Cl)OC WGFQYKDJILLDFE-UHFFFAOYSA-N 0.000 description 1
- LGAIBVPAZYIBLQ-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)C1=CC(=C(C=C1)C)F)OC Chemical compound ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)C1=CC(=C(C=C1)C)F)OC LGAIBVPAZYIBLQ-UHFFFAOYSA-N 0.000 description 1
- MTZCJPYNOWRAGP-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)C1=CC(=C(C=C1)F)C1CC1)OC Chemical compound ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)C1=CC(=C(C=C1)F)C1CC1)OC MTZCJPYNOWRAGP-UHFFFAOYSA-N 0.000 description 1
- HPNAVDXDPAGSFZ-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)C1=CC=C(C=C1)C(C)C)OC Chemical compound ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)C1=CC=C(C=C1)C(C)C)OC HPNAVDXDPAGSFZ-UHFFFAOYSA-N 0.000 description 1
- FABKDWVERMCMOV-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)C1=CC=C(C=C1)OCC(C)(C)C)OC Chemical compound ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)C1=CC=C(C=C1)OCC(C)(C)C)OC FABKDWVERMCMOV-UHFFFAOYSA-N 0.000 description 1
- BONHGDKRUUZTJW-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)C1=CC=C(C=C1)OCC(C)C)OC Chemical compound ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)C1=CC=C(C=C1)OCC(C)C)OC BONHGDKRUUZTJW-UHFFFAOYSA-N 0.000 description 1
- TXPYVZKLKGHPOO-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)OC)C1=CC=C(C=C1)OCC1(CC1)C Chemical compound ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)OC)C1=CC=C(C=C1)OCC1(CC1)C TXPYVZKLKGHPOO-UHFFFAOYSA-N 0.000 description 1
- BBIQJWASNUHHAA-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)OC)C1=CC=C(C=C1)OCCC Chemical compound ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)OC)C1=CC=C(C=C1)OCCC BBIQJWASNUHHAA-UHFFFAOYSA-N 0.000 description 1
- CWWLFFJHXWGLAR-UHFFFAOYSA-N ClC1=C(C=C(CNC(C(C)(C)C)=O)C=C1)C1=NC(=NC(=N1)C1=CC=C(C=C1)CC(C)C)OC Chemical compound ClC1=C(C=C(CNC(C(C)(C)C)=O)C=C1)C1=NC(=NC(=N1)C1=CC=C(C=C1)CC(C)C)OC CWWLFFJHXWGLAR-UHFFFAOYSA-N 0.000 description 1
- FIYKYGOWVNGGHF-XMMPIXPASA-N ClC1=C(C=C(CNC([C@@](C(F)(F)F)(C)OC)=O)C=C1)C1=NC(=NC(=N1)OC)C1=CC=C(C=C1)OCCC Chemical compound ClC1=C(C=C(CNC([C@@](C(F)(F)F)(C)OC)=O)C=C1)C1=NC(=NC(=N1)OC)C1=CC=C(C=C1)OCCC FIYKYGOWVNGGHF-XMMPIXPASA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000019028 Epidermal thickening Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- OLBZSJZSGNZVHD-LLVKDONJSA-N FC([C@](C(=O)OCC1=CC=CC=C1)(C)OC)(F)F Chemical compound FC([C@](C(=O)OCC1=CC=CC=C1)(C)OC)(F)F OLBZSJZSGNZVHD-LLVKDONJSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- OMCPLEZZPVJJIS-UHFFFAOYSA-N Hypadil (TN) Chemical compound C1C(O[N+]([O-])=O)COC2=C1C=CC=C2OCC(O)CNC(C)C OMCPLEZZPVJJIS-UHFFFAOYSA-N 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108091077604 MAPEG family Proteins 0.000 description 1
- 102000042256 MAPEG family Human genes 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010069364 Meniscal degeneration Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- WORLHBAUPROREK-UHFFFAOYSA-N N-[[3-[4-(4-butoxyphenyl)-6-oxo-1H-1,3,5-triazin-2-yl]-4-chlorophenyl]methyl]-3,3,3-trifluoro-2,2-dimethylpropanamide Chemical compound C(CCC)OC1=CC=C(C=C1)C1=NC(=NC(=N1)O)C=1C=C(CNC(C(C(F)(F)F)(C)C)=O)C=CC1Cl WORLHBAUPROREK-UHFFFAOYSA-N 0.000 description 1
- BJKJBLKKTVQSTP-UHFFFAOYSA-N N-[[4-chloro-3-(4-methoxy-6-phenyl-1,3,5-triazin-2-yl)phenyl]methyl]-N-ethyl-3,3,3-trifluoro-2,2-dimethylpropanamide Chemical compound ClC1=C(C=C(CN(C(C(C(F)(F)F)(C)C)=O)CC)C=C1)C1=NC(=NC(=N1)OC)C1=CC=CC=C1 BJKJBLKKTVQSTP-UHFFFAOYSA-N 0.000 description 1
- SIHHDFNEZPNGMP-UHFFFAOYSA-N N-[[4-chloro-3-(6-oxo-4-phenyl-1H-1,3,5-triazin-2-yl)phenyl]methyl]-N-ethyl-3,3,3-trifluoro-2,2-dimethylpropanamide Chemical compound ClC1=C(C=C(CN(C(C(C(F)(F)F)(C)C)=O)CC)C=C1)C1=NC(=NC(=N1)O)C1=CC=CC=C1 SIHHDFNEZPNGMP-UHFFFAOYSA-N 0.000 description 1
- PLPMUMRLVBCTAB-UHFFFAOYSA-N N-[[4-chloro-3-[4-(3-chloro-4-methylphenyl)-6-oxo-1H-1,3,5-triazin-2-yl]phenyl]methyl]-3,3,3-trifluoro-2,2-dimethylpropanamide Chemical compound ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)C1=CC(=C(C=C1)C)Cl)O PLPMUMRLVBCTAB-UHFFFAOYSA-N 0.000 description 1
- ZFLSHPHTWQQAIT-UHFFFAOYSA-N N-[[4-chloro-3-[4-(3-cyclopropyl-4-fluorophenyl)-6-oxo-1H-1,3,5-triazin-2-yl]phenyl]methyl]-3,3,3-trifluoro-2,2-dimethylpropanamide Chemical compound ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)C1=CC(=C(C=C1)F)C1CC1)O ZFLSHPHTWQQAIT-UHFFFAOYSA-N 0.000 description 1
- MFHLJGBKBASIES-UHFFFAOYSA-N N-[[4-chloro-3-[4-(3-fluoro-4-methylphenyl)-6-oxo-1H-1,3,5-triazin-2-yl]phenyl]methyl]-3,3,3-trifluoro-2,2-dimethylpropanamide Chemical compound ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)C1=CC(=C(C=C1)C)F)O MFHLJGBKBASIES-UHFFFAOYSA-N 0.000 description 1
- IKWKZDXBKGIMOT-UHFFFAOYSA-N N-[[4-chloro-3-[4-(4-hydroxyphenyl)-6-methoxy-1,3,5-triazin-2-yl]phenyl]methyl]-3,3,3-trifluoro-2,2-dimethylpropanamide Chemical compound ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)C1=CC=C(C=C1)O)OC IKWKZDXBKGIMOT-UHFFFAOYSA-N 0.000 description 1
- BKPLWWXSSZTNFC-UHFFFAOYSA-N N-[[4-chloro-3-[4-[4-(2,2-dimethylpropoxy)phenyl]-6-oxo-1H-1,3,5-triazin-2-yl]phenyl]methyl]-3,3,3-trifluoro-2,2-dimethylpropanamide Chemical compound ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)C1=CC=C(C=C1)OCC(C)(C)C)O BKPLWWXSSZTNFC-UHFFFAOYSA-N 0.000 description 1
- SHNOXYWBWKUQNL-UHFFFAOYSA-N N-[[4-chloro-3-[4-[4-(2-methylpropoxy)phenyl]-6-oxo-1H-1,3,5-triazin-2-yl]phenyl]methyl]-3,3,3-trifluoro-2,2-dimethylpropanamide Chemical compound ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)O)C1=CC=C(C=C1)OCC(C)C SHNOXYWBWKUQNL-UHFFFAOYSA-N 0.000 description 1
- CKWIPSDBOOBUDZ-UHFFFAOYSA-N N-[[4-chloro-3-[4-[4-[(1-methylcyclopropyl)methoxy]phenyl]-6-oxo-1H-1,3,5-triazin-2-yl]phenyl]methyl]-3,3,3-trifluoro-2,2-dimethylpropanamide Chemical compound ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)O)C1=CC=C(C=C1)OCC1(CC1)C CKWIPSDBOOBUDZ-UHFFFAOYSA-N 0.000 description 1
- DPJGQCJHLDOHSI-UHFFFAOYSA-N N-[[4-chloro-3-[6-oxo-4-(4-propan-2-ylphenyl)-1H-1,3,5-triazin-2-yl]phenyl]methyl]-3,3,3-trifluoro-2,2-dimethylpropanamide Chemical compound ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)O)C1=CC=C(C=C1)C(C)C DPJGQCJHLDOHSI-UHFFFAOYSA-N 0.000 description 1
- GEBRVPWPEPPPJS-UHFFFAOYSA-N N-[[4-chloro-3-[6-oxo-4-(4-propoxyphenyl)-1H-1,3,5-triazin-2-yl]phenyl]methyl]-3,3,3-trifluoro-2,2-dimethylpropanamide Chemical compound ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)O)C1=CC=C(C=C1)OCCC GEBRVPWPEPPPJS-UHFFFAOYSA-N 0.000 description 1
- KVCXRAFFNKIVMS-UHFFFAOYSA-N N-[[4-chloro-3-[6-oxo-4-[3-propan-2-yl-4-(trifluoromethyl)phenyl]-1H-1,3,5-triazin-2-yl]phenyl]methyl]-3,3,3-trifluoro-2,2-dimethylpropanamide Chemical compound ClC1=C(C=C(CNC(C(C(F)(F)F)(C)C)=O)C=C1)C1=NC(=NC(=N1)O)C1=CC(=C(C=C1)C(F)(F)F)C(C)C KVCXRAFFNKIVMS-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 1
- IVJLHZSLZZWFOZ-UHFFFAOYSA-N N1=C(N=C(N=C1C1=CC(Cl)=C(C)C=C1)C1=C(Cl)C=CC(CN)=C1)OC Chemical compound N1=C(N=C(N=C1C1=CC(Cl)=C(C)C=C1)C1=C(Cl)C=CC(CN)=C1)OC IVJLHZSLZZWFOZ-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000004226 Prostaglandin-E Synthases Human genes 0.000 description 1
- 108090000748 Prostaglandin-E Synthases Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 101001135388 Rattus norvegicus Prostaglandin E synthase Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000028911 Temporomandibular Joint disease Diseases 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- UCIPLLNDFCCBAC-UHFFFAOYSA-N [4-(2-methylpropoxy)phenyl]boronic acid Chemical compound CC(C)COC1=CC=C(B(O)O)C=C1 UCIPLLNDFCCBAC-UHFFFAOYSA-N 0.000 description 1
- YZSPHVWALUJQNK-UHFFFAOYSA-N [4-(2-methylpropyl)phenyl]boronic acid Chemical compound CC(C)CC1=CC=C(B(O)O)C=C1 YZSPHVWALUJQNK-UHFFFAOYSA-N 0.000 description 1
- MERYVSUVKVVJMP-UHFFFAOYSA-N [4-(methoxymethoxy)phenyl]boronic acid Chemical compound COCOC1=CC=C(B(O)O)C=C1 MERYVSUVKVVJMP-UHFFFAOYSA-N 0.000 description 1
- SQPTZSAATGESBQ-UHFFFAOYSA-N [4-chloro-3-(4-methoxy-6-phenyl-1,3,5-triazin-2-yl)phenyl]methanol Chemical compound ClC1=C(C=C(C=C1)CO)C1=NC(=NC(=N1)OC)C1=CC=CC=C1 SQPTZSAATGESBQ-UHFFFAOYSA-N 0.000 description 1
- WPOJTANEFXGXKQ-UHFFFAOYSA-N [4-chloro-3-[4-methoxy-6-[3-propan-2-yl-4-(trifluoromethyl)phenyl]-1,3,5-triazin-2-yl]phenyl]methanol Chemical compound ClC1=C(C=C(C=C1)CO)C1=NC(=NC(=N1)C1=CC(=C(C=C1)C(F)(F)F)C(C)C)OC WPOJTANEFXGXKQ-UHFFFAOYSA-N 0.000 description 1
- JEDZLBFUGJTJGQ-UHFFFAOYSA-N [Na].COCCO[AlH]OCCOC Chemical compound [Na].COCCO[AlH]OCCOC JEDZLBFUGJTJGQ-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000004996 alkyl benzenes Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004509 aqueous humor production Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- ZIXXABZSYXRCJO-SNVBAGLBSA-N benzyl (2r)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoate Chemical compound FC(F)(F)[C@@](O)(C)C(=O)OCC1=CC=CC=C1 ZIXXABZSYXRCJO-SNVBAGLBSA-N 0.000 description 1
- IUGQFMIATSVYLK-UHFFFAOYSA-N benzyl 2-(4-hydroxyphenyl)acetate Chemical compound C1=CC(O)=CC=C1CC(=O)OCC1=CC=CC=C1 IUGQFMIATSVYLK-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- XKXHCNPAFAXVRZ-UHFFFAOYSA-N benzylazanium;chloride Chemical compound [Cl-].[NH3+]CC1=CC=CC=C1 XKXHCNPAFAXVRZ-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 229960004347 betaxolol hydrochloride Drugs 0.000 description 1
- 229960002470 bimatoprost Drugs 0.000 description 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 229960001724 brimonidine tartrate Drugs 0.000 description 1
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 229960003612 bunazosin hydrochloride Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 230000004712 cancer cell adhesion Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 1
- BUZRUIZTMOKRPB-UHFFFAOYSA-N carboxycarbamic acid Chemical compound OC(=O)NC(O)=O BUZRUIZTMOKRPB-UHFFFAOYSA-N 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- FYBXRCFPOTXTJF-UHFFFAOYSA-N carteolol hydrochloride Chemical compound [Cl-].N1C(=O)CCC2=C1C=CC=C2OCC(O)C[NH2+]C(C)(C)C FYBXRCFPOTXTJF-UHFFFAOYSA-N 0.000 description 1
- 229960002165 carteolol hydrochloride Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 1
- KMPWYEUPVWOPIM-LSOMNZGLSA-N cinchonine Chemical compound C1=CC=C2C([C@@H]([C@H]3N4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-LSOMNZGLSA-N 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- CJXAEXPPLWQRFR-UHFFFAOYSA-N clemizole Chemical compound C1=CC(Cl)=CC=C1CN1C2=CC=CC=C2N=C1CN1CCCC1 CJXAEXPPLWQRFR-UHFFFAOYSA-N 0.000 description 1
- 229950002020 clemizole Drugs 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- VSSAZBXXNIABDN-UHFFFAOYSA-N cyclohexylmethanol Chemical compound OCC1CCCCC1 VSSAZBXXNIABDN-UHFFFAOYSA-N 0.000 description 1
- GCUVBACNBHGZRS-UHFFFAOYSA-N cyclopenta-1,3-diene cyclopenta-2,4-dien-1-yl(diphenyl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.c1cc[c-](c1)P(c1ccccc1)c1ccccc1 GCUVBACNBHGZRS-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- LCSNDSFWVKMJCT-UHFFFAOYSA-N dicyclohexyl-(2-phenylphenyl)phosphane Chemical compound C1CCCCC1P(C=1C(=CC=CC=1)C=1C=CC=CC=1)C1CCCCC1 LCSNDSFWVKMJCT-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- VKFAUCPBMAGVRG-UHFFFAOYSA-N dipivefrin hydrochloride Chemical compound [Cl-].C[NH2+]CC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 VKFAUCPBMAGVRG-UHFFFAOYSA-N 0.000 description 1
- 229940090570 dipivefrin hydrochloride Drugs 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- RAGZEDHHTPQLAI-UHFFFAOYSA-L disodium;2',4',5',7'-tetraiodo-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C([O-])C(I)=C1OC1=C(I)C([O-])=C(I)C=C21 RAGZEDHHTPQLAI-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960001446 distigmine Drugs 0.000 description 1
- GJHSNEVFXQVOHR-UHFFFAOYSA-L distigmine bromide Chemical compound [Br-].[Br-].C=1C=C[N+](C)=CC=1OC(=O)N(C)CCCCCCN(C)C(=O)OC1=CC=C[N+](C)=C1 GJHSNEVFXQVOHR-UHFFFAOYSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000011982 enantioselective catalyst Substances 0.000 description 1
- 239000003759 ester based solvent Substances 0.000 description 1
- XBIMXRVVZSNNGI-UHFFFAOYSA-N ethanamine;oxolane Chemical compound CCN.C1CCOC1 XBIMXRVVZSNNGI-UHFFFAOYSA-N 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- AIMCUTZXDCCWFQ-UHFFFAOYSA-N ethanol hydrate Chemical compound O.C(C)O.C(C)O.C(C)O.C(C)O AIMCUTZXDCCWFQ-UHFFFAOYSA-N 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical class O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- SSDZYLQUYMOSAK-UHFFFAOYSA-N ethynylcyclohexane Chemical group C#CC1CCCCC1 SSDZYLQUYMOSAK-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 239000000989 food dye Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- JYVHOGDBFNJNMR-UHFFFAOYSA-N hexane;hydrate Chemical compound O.CCCCCC JYVHOGDBFNJNMR-UHFFFAOYSA-N 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 102000047789 human PTGES Human genes 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- SKOWZLGOFVSKLB-UHFFFAOYSA-N hypodiboric acid Chemical compound OB(O)B(O)O SKOWZLGOFVSKLB-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- DNTDOBSIBZKFCP-YDALLXLXSA-N levobunolol hydrochloride Chemical compound [Cl-].O=C1CCCC2=C1C=CC=C2OC[C@@H](O)C[NH2+]C(C)(C)C DNTDOBSIBZKFCP-YDALLXLXSA-N 0.000 description 1
- 229960004834 levobunolol hydrochloride Drugs 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- BWJSSYBIZVGKBG-UHFFFAOYSA-N methyl 4-tert-butylcyclohexane-1-carboxylate Chemical compound COC(=O)C1CCC(C(C)(C)C)CC1 BWJSSYBIZVGKBG-UHFFFAOYSA-N 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-N methyl sulfate Chemical compound COS(O)(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- PGXWDLGWMQIXDT-UHFFFAOYSA-N methylsulfinylmethane;hydrate Chemical compound O.CS(C)=O PGXWDLGWMQIXDT-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229940037525 nasal preparations Drugs 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229950000754 nipradilol Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- PJMKKSGLJJBQMY-UHFFFAOYSA-N nonan-1-one Chemical compound CCCCCCCC[C]=O PJMKKSGLJJBQMY-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920003175 pectinic acid Polymers 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 229960002139 pilocarpine hydrochloride Drugs 0.000 description 1
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000007867 post-reaction treatment Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- PXGPLTODNUVGFL-UHFFFAOYSA-N prostaglandin F2alpha Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CC=CCCCC(O)=O PXGPLTODNUVGFL-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- SHNUBALDGXWUJI-UHFFFAOYSA-N pyridin-2-ylmethanol Chemical compound OCC1=CC=CC=N1 SHNUBALDGXWUJI-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- MHZSEPBBOTVGFW-UHFFFAOYSA-N pyrrolidin-1-ylphosphane Chemical compound PN1CCCC1 MHZSEPBBOTVGFW-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 102210015708 rs4613763 Human genes 0.000 description 1
- 102210008910 rs6896969 Human genes 0.000 description 1
- 102210008280 rs9292777 Human genes 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000012419 sodium bis(2-methoxyethoxy)aluminum hydride Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- PNGLEYLFMHGIQO-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methoxyanilino)-2-hydroxypropane-1-sulfonate;dihydrate Chemical compound O.O.[Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(OC)=C1 PNGLEYLFMHGIQO-UHFFFAOYSA-M 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000021550 spleen neoplasm Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- 239000012414 tert-butyl nitrite Substances 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- XNRNNGPBEPRNAR-JQBLCGNGSA-N thromboxane B2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O XNRNNGPBEPRNAR-JQBLCGNGSA-N 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 229950008081 unoprostone isopropyl Drugs 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940002639 xalatan Drugs 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to a triazine compound having a microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitory activity or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the triazine compound, a pharmaceutical use thereof, and the like.
- mPGES-1 microsomal prostaglandin E2 synthase-1
- Non-steroidal anti-inflammatory drugs are widely used in the treatment of diseases accompanied by inflammation, fever and pain, such as rheumatism, osteoarthritis, and headache.
- NSAIDs exert anti-inflammatory, antipyretic and analgesic effects by inhibiting cyclooxygenase (COX) and inhibiting prostanoid production.
- COX cyclooxygenase
- COX-1 and COX-2 are enzymes that convert biomembrane-derived arachidonic acid into prostaglandin H2 (PGH2), which is a prostanoid precursor. Conversion from PGH2 to each prostanoid (prostaglandin E2 (PGE2), prostaglandin F2 ⁇ (PGF2 ⁇ ), prostaglandin I2 (PGI2), prostaglandin D2 (PGD2), thromboxane A2 (TXA2), etc.) Enzyme is responsible.
- PGE2 is the most abundant prostaglandin in the living body, and is known to be strongly involved in inflammation, pain, and fever. Therefore, suppression of PGE2 production is considered to be the main mechanism of action of NSAIDs.
- COX-1 or COX-2 suppresses all downstream prostanoid production. This is thought to be a cause of side effects of NSAIDs. NSAIDs that non-selectively inhibit COX also suppress PGE2 production by COX-1, and PGE2 protects against gastric mucosal damage, so NSAIDs suppress gastric mucus secretion and gastric mucosal blood flow, It is thought to increase the risk of bleeding.
- the selective inhibitor of COX-2 suppresses the production of PGI2, which has vasodilatory action and platelet aggregation inhibitory action in vascular endothelial cells, but produces TXA2, a blood coagulation factor produced by platelet COX-1. Does not suppress. Therefore, it is thought that the balance of the blood coagulation system is lost and the risk of cardiovascular disorder is increased.
- Microsomal prostaglandin E2 synthase-1 (mPGES-1) is an enzyme that catalyzes the final stage of PGE2 biosynthesis, and belongs to the membrane-associated proteinin eicosanoid and glutathione metabolism family (MAPEG family).
- MAPEG family membrane-associated proteinin eicosanoid and glutathione metabolism family
- the human mPGES-1 gene was cloned in 1999 and shown to be constitutively expressed in the placenta, prostate, testis and mammary gland (Non-patent Document 1). In other organs, expression of human mPGES-1 is induced by various inflammatory stimuli coupled with COX-2.
- inflammatory cytokines IL-1 ⁇ and Tumor Necrosis Factor- ⁇ are synovial cells, osteoblasts, endothelial cells, orbital fibroblasts, gingival cells, chondrocytes, endothelial cells, cardiomyocytes, etc. Induces mPGES-1 expression.
- IL-1 ⁇ and Tumor Necrosis Factor- ⁇ are synovial cells, osteoblasts, endothelial cells, orbital fibroblasts, gingival cells, chondrocytes, endothelial cells, cardiomyocytes, etc.
- LPS Lipopolysaccharide
- a bacterial endotoxin induces mPGES-1 expression in macrophages and smooth muscle.
- mPGES-1 inhibitors selectively suppress PGE2 production only in inflammation or in tissues where mPGES-1 is expressed, but not prostanoids other than PGE2 (PGI2, PGD2, PGF2 ⁇ , TXA2, etc.) (Non-Patent Documents 2 and 3). Therefore, mPGES-1 inhibitors are considered to be drugs that have the same efficacy as NSAIDs but do not have side effects of NSAIDs due to decreased prostanoid production other than PGE2.
- mPGES-1 inhibitor Pain In mPGES-1 knockout mice, the amount of intraperitoneal PGE2 production and the number of painful responses per unit time in the evaluation of painful responses by LPS stimulation, an acute inflammatory pain model, are significantly lower than in WT mice . Therefore, mPGES-1 inhibitor is considered to be an analgesic for acute inflammatory pain (Non-patent Documents 3 and 6).
- Rheumatism There are several single nucleotide polymorphisms that increase the risk and severity of rheumatism in the Swedish female mPGES-1 gene.
- Non-Patent Document 5 The synovial membrane of rheumatic patients with a single nucleotide polymorphism (Reference SNP ID number: rs23202821) that increases the severity of immunohistochemistry confirmed an increase in mPGES-1 expression compared to patients without the mutation.
- Non-Patent Document 5 In mPGES-1 knockout mice, inflammatory cell infiltration, joint destruction and swelling of the limbs are significantly suppressed in the collagen-induced arthritis model, which is an animal model of rheumatism, compared to WT mice (non-patented). Reference 6). Therefore, mPGES-1 inhibitor is considered to be a therapeutic agent for rheumatism.
- Osteoarthritis mPGES-1 mRNA expression is increased in meniscal chondrocytes of patients with osteoarthritis (Non-patent Document 7).
- the mPGES-1 inhibitor reduces the pain response of the osteoarthritis model using monoiodoacetic acid as compared with WT mice (Patent Document 1). Therefore, mPGES-1 inhibitors are considered to be therapeutic agents for osteoarthritis.
- mPGES-1 knockout mouse an increase in body temperature due to LPS stimulation is suppressed as compared with the WT mouse (Non-patent Document 8). Therefore, mPGES-1 inhibitors are considered to be antipyretic drugs.
- Alzheimer's disease Long-term use of NSAIDs alleviates the onset and progression of Alzheimer's disease. In primary cultured brain neurons of mPGES-1 knockout mice, PGE2 production during amyloid ⁇ peptide treatment is suppressed and neuronal cell death does not occur as compared with brain neurons of WT mice (Non-patent Document 9). Therefore, mPGES-1 inhibitors are considered to be therapeutic agents for Alzheimer's disease.
- (6) Multiple sclerosis There are several single nucleotide polymorphisms that increase the risk of onset in the EP4 gene of patients with multiple sclerosis (Reference SNP ID number: rs9292777, rs4613763, rs1044063, rs6896969).
- mPGES-1 protein is confirmed in macrophages present in the demyelinating region around the ventricle of patients with multiple sclerosis.
- PGE2 production in the spinal cord of experimental autoimmune encephalomyelitis model mice which are animal models of multiple sclerosis, is suppressed, and the progression of paralysis is suppressed compared to WT mice ( Non-patent document 10). Therefore, mPGES-1 inhibitor is considered to be a therapeutic agent for multiple sclerosis.
- mPGES-1 knockout mice PGE2 production from vascular endothelial cells of high-fat diet-loaded low-density lipoprotein receptor-deficient mice, which is a model of atherosclerosis, is reduced compared to WT mice. , Atherogenesis is delayed. From vascular endothelial cells, production of PGI2, which is known to have an inhibitory effect on platelet function, increases (Non-patent Document 11). Therefore, mPGES-1 inhibitor is considered to be a preventive or therapeutic agent for arteriosclerosis.
- Glaucoma and ocular hypertension Glaucoma is a disease that causes a characteristic change in the optic nerve and visual field, and this optic neuropathy can usually be improved or suppressed by sufficiently lowering the intraocular pressure. Glaucoma can be classified into open angle glaucoma and closed angle glaucoma.
- the mPGES-1 gene is constantly highly expressed in the human conjunctiva (GEO accession No: GSE2513 (Gene Expression Omnibus: http://www.ncbi.nlm.nih.gov/geo/)). In the retina of glaucoma patients, the expression of mPGES-1 is increased compared to healthy individuals.
- mPGES-1 The expression of mPGES-1 is increased in the retina of high-intensity dogs and high-intensity mice, which are glaucoma models, compared to normal animals (GEO accession No: human GSE2378, dog GSE21879, mouse GSE3554).
- PGE2 When PGE2 is instilled in healthy individuals, an increase in intraocular pressure with vasodilation is observed over 2 hours after instillation (Non-patent Document 12).
- PGE2 When PGE2 is administered under the rabbit conjunctiva, intraocular pressure increases due to swelling of the ciliary body and increased production of aqueous humor (Non-patent Document 13).
- PGF2 ⁇ and PGD2 which are prostaglandins that can increase when mPGES-1 is inhibited, reduce the intraocular pressure in rabbits (Non-patent Document 14).
- the PGF2 ⁇ preparation is used as a glaucoma therapeutic agent that promotes aqueous humor drainage and reduces intraocular pressure.
- PGI2 has no clear effect on rabbit intraocular pressure. That is, it is considered that the intraocular pressure decreases because PGE2 decrease due to mPGES-1 inhibition suppresses aqueous humor production and / or increase of PGD2 and PGF2 ⁇ by shunt promotes aqueous humor outflow.
- VEGF vascular endothelial growth factor
- Non-patent Document 15 Since VEGF produced in the retina is transferred to the anterior segment of the eye, angiogenesis occurs in the iris, and occlusion of the corners results in neovascular glaucoma that increases intraocular pressure. It is thought that it also shows an improvement / preventive effect. Furthermore, since anti-inflammatory action due to inhibition of PGE2 production is considered, it is considered to be applicable to patients with intraocular inflammation that are carefully administered with existing prostaglandin preparations (latanoprost etc.). Therefore, mPGES-1 inhibitor is considered to be an effective therapeutic agent for glaucoma having various background diseases.
- VEGF vascular endothelial growth factor
- mPGES-1 is increased in the skin of a bleomycin-induced scleroderma model mouse, which is a systemic scleroderma model, compared to the skin of a normal mouse.
- mPGES-1 knockout mice have decreased macrophage accumulation in the skin of the lesions of bleomycin-induced scleroderma model mice, increased epidermal thickening, extracellular matrix deposition, and increased collagen fiber content. It was reduced (Non-Patent Document 16). Therefore, mPGES-1 inhibitors are considered to be therapeutic agents for systemic scleroderma.
- mPGES-1 inhibitors are considered to be anticancer drugs that suppress the growth and metastasis of cancers including colorectal cancer.
- Inflammatory symptoms and / or pain associated with the condition where NSAIDs are effective include, for example, arthritis, gout, kidney stones, urinary calculus, headache, menstrual pain, Examples include toothache, low back pain, muscular pain, shoulder periarthritis, neck-shoulder arm syndrome, temporomandibular disorders, and inflammation / pain after surgery, after trauma and after extraction. Other examples include acute and chronic non-bacterial inflammation of the eye, such as uveitis, allergic conjunctivitis, and postoperative inflammation and eye pain in internal eye surgery. The main mechanism by which NSAIDs exert their effectiveness is thought to be by suppressing the production of PGE2, a pro-inflammatory substance. Since mPGES-1 inhibitors also have a PGE2 production inhibitory effect, they are considered to be therapeutic agents for these diseases.
- mPGES-1 inhibitors include pain, rheumatism, osteoarthritis, fever, Alzheimer's disease, multiple sclerosis, arteriosclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma, and colorectal cancer. It is considered useful for prevention or treatment of malignant tumors and diseases in which suppression of PGE2 production is effective.
- JAKOBSSON PJ et al. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A.. pages 7220-7225.
- SAMUELSSON B et al. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev. Sep 2007, Vol.59, No.3, pages207-224.
- KAMEI D et al. Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin e synthase-1. J Biol Chem. Aug 6 2004, Vol.279, No.32, pages 33684-33695.
- TREBINO CE et al. Redirection of eicosanoid metabolism in mPGES-1-deficient macrophages. J Biol Chem. Apr 29 2005, Vol.280, No.17, pages 16579-16585.
- KOROTKOVA M et al. Variants of gene for microsomal prostaglandin E2 synthase show association with disease and severe inflammation in rheumatoid arthritis. Eur J Hum Genet. Aug 2011, No908 s.914 TREBINO, CE et al. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci U S A.
- MCCANN MR et al. MPGES-1 null mice are resistant to bleomycin-induced skin fibrosis. Arthritis Res Ther. 2011, Vol.13, No.1, pages R6. SASAKI, Y et al. Microsomal prostaglandin E synthase-1 is involved in multi steps of colon carcinogenesis. Oncogene. Jun 14 2012, Vol.31, No.24, pages 2943-2952.
- An object of the present invention is to provide a triazine compound having mPGES-1 inhibitory activity or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the same, a pharmaceutical use thereof, and the like.
- target diseases include pain, rheumatism, osteoarthritis, fever, Alzheimer's disease, multiple sclerosis, arteriosclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma, and colon cancer.
- Examples include malignant tumors and diseases in which suppression of PGE2 production is effective.
- the present inventors have found a triazine compound having mPGES-1 inhibitory activity represented by the following formula [I] and completed the present invention. That is, the present invention is as follows.
- R 1 is (1) Halogen, (2) C 1-6 alkyl, (3) Cyano or (4) halo C 1-4 alkyl
- R 2 is (1) Halogen, (2) hydroxy, (3) Carboxy, (4) C 1-6 alkyl, (5) C 1-6 alkoxy, (6) Halo C 1-4 alkoxy, (7) Halo C 1-4 alkyl, (8) C 1-6 alkyl-carbonyl, (9) -C (O) NR a1 R a2 (R a1 and R a2 are each independently hydrogen or C 1-6 alkyl), or (10)-(C n H 2n ) -R b (N is 1, 2, 3 or 4, and-(C n H 2n ) -may be either linear or branched
- R b is (a) hydroxy, (b) carboxy, (c) C 1-6 alkoxy, (d) C 1-6 alkyl-carbonyloxy, (e) -C (O) NR b1 R b2 (R b)
- R 3 is (1) Halogen, (2) hydroxy, (3) C 1-6 alkyl, or (4) -OR c ⁇ R c is C 1-6 alkyl optionally substituted with 1, 2 or 3 substituents selected from the group consisting of (a) to (f) below; (a) halogen, (b) hydroxy, (c) C 1-6 alkoxy, (d) -C (O) NR c1 R c2 (R c1 and R c2 are each independently hydrogen or C 1-6 alkyl), (e) C 6-10 aryl (the C 6-10 aryl is (i) halogen, (ii) hydroxy, (iii) C 1-6 alkyl, (iv) C 1-6 alkoxy and (v) may be substituted with 1, 2 or 3 substituents selected from the group consisting of haloC 1-4 alkyl
- heteroaryl containing 1, 2 or 3 nitrogen, oxygen or sulfur atoms
- the heteroaryl is (i) halogen, (ii) hydroxy, (iii) C 1-6 alkyl, (iv) C 1-6 alkoxy and (v) may be substituted with 1, 2 or 3 substituents selected from the group consisting of haloC 1-4 alkyl.
- R 4 is (1) hydrogen, (2) Halogen, (3) C 1-6 alkyl, or (4) C 1-6 alkoxy.
- R 5 is (1) Halogen, (2) hydroxy, (3) C 1-6 alkylsulfanyl, (4) C 1-6 alkyl (the C 1-6 alkyl is substituted with 1, 2 or 3 substituents selected from the group consisting of halogen, C 6-10 aryl and C 1-6 alkoxy) May be good), (5) C 3-7 cycloalkyl, (6) -OR d ⁇ R d is (a) C 2-6 alkynyl, (b) C 3-7 cycloalkyl optionally substituted with 1, 2 or 3 C 1-6 alkyl, or (c) C 1-8 alkyl (the C 1-8 alkyl may be substituted with 1, 2 or 3 substituents selected from the group consisting of the following (i) to (v); (i) halogen, (ii) C 6-10 aryl, (iii) C 1-6 alkoxy, (iv) C 3-7 cycloalkyl (said C 3-7 cycloalkyl is substituted with 1, 2
- R e is (a) C 1-6 alkyl, (b) C 3-7 cycloalkyl, (c) a 5- or 6-membered heteroaryl containing 1, 2 or 3 nitrogen, oxygen or sulfur atoms, or (d) C 6-10 aryl (the C 6-10 aryl is (i) halogen, (ii) C 1-6 alkyl, (iii) Halo C 1-4 alkyl, (iv) C 1-6 alkoxy and (v) may be substituted with 1, 2 or 3 substituents selected from the group consisting of haloC 1-4 alkoxy. ).
- ⁇ And m1 is 0, 1, 2 or 3, and when m1 is 2 or 3, each R 5 is independently selected.
- 4,6-bis- (2,5-dimethyl-phenyl) -1,3,5-triazin-2-ol is excluded.
- Ring Cy is the formula:
- Ring Cy is the formula:
- R 1 is (1) Chloro, (2) methyl, (3) Cyano or (4) The compound or a pharmaceutically acceptable salt thereof according to any one of [01] to [05], which is trifluoromethyl.
- R 2 is -(C n H 2n ) -R b (n is 1 or 2,-(C n H 2n ) -may be linear or branched
- R b is (a) -C (O) NR b1 R b2 , (b) -NR b5 C (O) NR b6 R b7 , (c) -NR b10 S (O) 2 R b11 or (d) -NR b14 C (O) R b15 (R b1 , R b2 , R b5 , R b6 , R b7 , R b10 , R b11 , R b14 , and R b15 are as defined in [01]. .) Or a pharmaceutically acceptable salt thereof according to any one of [01], [02], and [04] to [07].
- R 3 is (1) Halogen, (2) hydroxy, (3) C 1-6 alkyl, or (4) —OR c ⁇ R c is C 1-6 alkyl which may be substituted with 1, 2 or 3 substituents selected from the group consisting of the following (a) to (f).
- halogen (a) halogen, (b) hydroxy, (c) C 1-6 alkoxy, (d) -C (O) NR c1 R c2 (R c1 and R c2 are each independently hydrogen or C 1-6 alkyl), (e) phenyl (the phenyl is (i) halogen, (ii) hydroxy, (iii) C 1-6 alkyl, (iv) C 1-6 alkoxy and (v) may be substituted with 1, 2 or 3 substituents selected from the group consisting of haloC 1-4 alkyl.
- pyridyl (the pyridyl is (i) halogen, (ii) hydroxy, (iii) C 1-6 alkyl, (iv) C 1-6 alkoxy and (v) may be substituted with 1, 2 or 3 substituents selected from the group consisting of haloC 1-4 alkyl. ) ⁇ ,
- pyridyl is (i) halogen, (ii) hydroxy, (iii) C 1-6 alkyl, (iv) C 1-6 alkoxy and (v) may be substituted with 1, 2 or 3 substituents selected from the group consisting of haloC 1-4 alkyl.
- R e has the same definition as in [01]
- R e has the same definition as in [01]
- a pharmaceutically acceptable salt thereof according to any one of [01] to [10].
- a pharmaceutical composition comprising the compound according to any one of [01] to [12] or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- An mPGES-1 inhibitor comprising the compound according to any one of [01] to [12] or a pharmaceutically acceptable salt thereof.
- a therapeutic or prophylactic agent for glaucoma and ocular hypertension comprising a combination of the compound according to any one of [01] to [12] or a pharmaceutically acceptable salt thereof and one or more other glaucoma therapeutic agents.
- a method for inhibiting mPGES-1 comprising administering to a human a pharmaceutically effective amount of the compound according to any one of [01] to [12] or a pharmaceutically acceptable salt thereof.
- the compound of the present invention includes pain, rheumatism, fever, osteoarthritis, arteriosclerosis, Alzheimer's disease, multiple sclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma, and colon cancer. It is effective as a therapeutic or prophylactic agent for malignant tumors and diseases in which suppression of PGE2 production is effective.
- FIG. 1 shows changes in intraocular pressure from immediately before administration when a test substance (compound of Example 2-98), a positive control substance (Xalatan (registered trademark)) or a vehicle (methylcellulose, MC) is administered to cynomolgus monkeys. Indicates the width.
- Halogen is fluoro, chloro, bromo or iodo.
- C 1-6 alkyl means a linear or branched alkyl having 1 to 6 carbon atoms.
- C 1-8 alkyl means a linear or branched alkyl having 1 to 8 carbon atoms.
- C 1-6 alkoxy means alkoxy in which the alkyl moiety is “C 1-6 alkyl” as defined above.
- Halo C 1-4 alkyl means a straight or branched alkyl having 1 to 4 carbon atoms, substituted with 1 to 9 “halogen” as defined above. When a plurality of halogens are substituted, each halogen may be the same or different.
- HaloC 1-4 alkoxy means alkoxy wherein the alkyl moiety is “halo C 1-4 alkyl” as defined above.
- “Hydroxy C 1-6 alkyl” means “C 1-6 alkyl” as defined above substituted with 1 or 2 hydroxys. For example, hydroxymethyl, 2-hydroxyethyl, 1-hydroxy-1-methylethyl, 1,2-dihydroxyethyl, 3-hydroxypropyl, 1-hydroxy-2,2-dimethylpropyl, 4-hydroxybutyl, 1-hydroxy -2,2-dimethylbutyl, 5-hydroxypentyl, 6-hydroxyhexyl and the like.
- C 1-6 alkyl-carbonyl means a carbonyl to which “C 1-6 alkyl” defined above is bound. Examples include acetyl, propionyl, 2,2-dimethylpropionyl, butyryl, 3-methylbutyryl, 2,2-dimethylbutyryl, pentanoyl, 4-methylpentanoyl, hexanoyl and the like.
- C 1-6 alkyl-carbonyloxy means carbonyloxy to which “C 1-6 alkyl” defined above is bound. For example, methylcarbonyloxy, ethylcarbonyloxy, propylcarbonyloxy, isopropylcarbonyloxy, butylcarbonyloxy, isobutylcarbonyloxy, sec-butylcarbonyloxy, tert-butylcarbonyloxy, pentylcarbonyloxy, isopentylcarbonyloxy, 2-methyl Examples include butylcarbonyloxy, 1,1-dimethylpropylcarbonyloxy, neopentylcarbonyloxy, 3,3-dimethylbutylcarbonyloxy, 1-ethylpropylcarbonyloxy, hexylcarbonyloxy and the like.
- C 3-7 cycloalkyl means a 3 to 7 membered, monocyclic cycloalkyl. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
- C 6-10 aryl means 6-10 membered aryl. Examples thereof include phenyl, 1-naphthyl, 2-naphthyl and the like, and among these, phenyl is preferable.
- 5- or 6-membered heteroaryl containing 1, 2 or 3 nitrogen, oxygen or sulfur atoms means 1, 2 or selected from nitrogen, oxygen and sulfur atoms in addition to carbon atoms Means a 5- or 6-membered monocyclic heteroaryl having 3 heteroatoms;
- “4-, 5- or 6-membered, saturated heterocyclyl containing 1, 2 or 3 nitrogen atoms, oxygen atoms or sulfur atoms” is selected from nitrogen atoms, oxygen atoms and sulfur atoms in addition to carbon atoms, It means a 4, 5 or 6 membered monocyclic saturated heterocyclyl having 2 or 3 heteroatoms.
- the carbon atom of the heterocyclyl may be substituted with oxo, and when the hetero atom contains a sulfur atom, the sulfur atom may be monooxidized or dioxidized.
- the saturated heterocyclyl may be partially saturated, and examples thereof include imidazolinyl, oxazolinyl, pyrazolinyl, thiazolinyl and the like. Of these, oxetanyl is preferred.
- C 1-6 alkylsulfanyl means sulfanyl to which “C 1-6 alkyl” defined above is bound. For example, methylsulfanyl, ethylsulfanyl, propylsulfanyl, isopropylsulfanyl, n-butylsulfanyl, isobutylsulfanyl, sec-butylsulfanyl, tert-butylsulfanyl, pentylsulfanyl, 1,1-dimethylpropylsulfanyl, 2,2-dimethylpropylsulfanyl Hexylsulfanyl and the like.
- C 2-6 alkynyl means a hydrocarbon having 2 to 6 carbon atoms and having at least one triple bond in the form of a straight chain or branched chain.
- ethynyl 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 3,3-dimethylbutynyl (ie, 3,3-dimethylbut-1-yl Inyl) and the like.
- — (C n H 2n ) — means a linear or branched alkylene having n carbon atoms and 2n hydrogen atoms.
- R b15 when R 2 is (10)-(C n H 2n ) -R b and R b is (k) -NR b14 C (O) R b15 '' Alkyl (wherein the C 1-8 alkyl is substituted with 1, 2 or 3 substituents selected from the group consisting of hydroxy, halo C 1-4 alkyl, C 1-6 alkoxy and C 6-10 aryl) "Is a substitutable position of" C 1-8 alkyl "as defined above, hydroxy,” halo C 1-4 alkyl “as defined above,” C 1-6 alkoxy "as defined above and C 1-8 alkyl substituted with the same or different 1, 2 or 3 substituents selected from the group consisting of “C 6-10 aryl” as defined above, or unsubstituted C 1-8 alkyl Means.
- R b include 2-ethoxy-3-methoxypropylcarbonylamino, 1-methyl-1-methoxy
- R 2 is (10)-(C n H 2n ) -R b and R b is (k) -NR b14 C (O) R b15
- ⁇ R b14 and R b15 are bonded to R b14 Together with the nitrogen atom to which R b15 is attached may form a 4-, 5- or 6-membered lactam, ”means that R b is 2-oxo-azetidin-1-yl, 2 It means -oxo-pyrrolidin-1-yl, 2-oxo-piperidin-1-yl and the like.
- the lactam may be substituted with 1, 2 or 3 C 1-6 alkyl and / or may form a condensed ring with a benzene ring”.
- lactam (1) the lactam substitutable position is substituted with the same or different 1, 2 or 3 C 1-6 alkyl as defined above, (2) lactam condensable It means that one benzene ring is condensed at the position, and (3) one benzene ring is condensed at the condensable position of the lactam substituted with C 1-6 alkyl.
- R b examples include 3,4-dimethyl-2-oxo-pyrrolidin-1-yl, 1-oxo-1,3-dihydro-isoindol-2-yl, 3,3-dimethyl-2-oxo-2 , 3-dihydro-indol-1-yl and the like.
- R 1 is preferably chloro, methyl, cyano, or trifluoromethyl, more preferably chloro or trifluoromethyl, and even more preferably chloro.
- R 2 is preferably (1) Halogen, (2) hydroxy, (3) Carboxy, (5) C 1-6 alkoxy, (6) Halo C 1-4 alkoxy, (7) Halo C 1-4 alkyl, (8) C 1-6 alkyl-carbonyl, (9) -C (O) NR a1 R a2 (R a1 and R a2 are as defined above), or (10)-(C n H 2n ) -R b (R b is as defined above), More preferably, (10)-(C n H 2n ) -R b (R b is as defined above).
- R b is preferably (g) -NR b5 C (O) NR b6 R b7 (R b5 , R b6 and R b7 are as defined above), (h) -NR b8 R b9 (R b8 and R b9 are as defined above), (i) -NR b10 S (O) 2 R b11 (R b10 and R b11 are as defined above), (j) -NR b12 C (O) OR b13 (R b12 and R b13 are as defined above), or (k) -NR b14 C (O) R b15 (R b14 and R b15 are as defined above) And) More preferably, (k) -NR b14 C (O) R b15 (R b14 and R b15 are as defined above).
- n is preferably 1 or 2, and more preferably 1.
- R b14 is preferably hydrogen or methyl, more preferably hydrogen.
- R b15 is preferably (ii) C 1-4 alkyl (the C 1-4 alkyl may be substituted with 1 or 2 substituents selected from the group consisting of hydroxy, trifluoromethyl, C 1-4 alkoxy and phenyl) Or) (iv) C 3-7 cycloalkyl, wherein the C 3-7 cycloalkyl is selected from the group consisting of C 1-4 alkyl, halogen, hydroxy C 1-4 alkyl and trifluoromethyl; And may be substituted with 4 substituents).
- 1 or two trifluoromethyl and C 1-4 which may be C 1-4 alkyl substituted by alkoxy, or one of trifluoromethyl with substituted optionally C 3-7 cycloalkyl
- R 3 is preferably (3) C 1-6 alkyl, or (4) -OR c ⁇ R c is C 1-6 alkyl optionally substituted with 1, 2 or 3 substituents selected from the group consisting of (a) to (f) below; (a) halogen, (b) hydroxy, (c) C 1-6 alkoxy, (d) -C (O) NR c1 R c2 (R c1 and R c2 are as defined above), (e) C 6-10 aryl (the C 6-10 aryl is (i) halogen, (ii) hydroxy, (iii) C 1-6 alkyl, (iv) C 1-6 alkoxy and (v) may be substituted with 1, 2 or 3 substituents selected from the group consisting of haloC 1-4 alkyl.
- heteroaryl containing 1, 2 or 3 nitrogen, oxygen or sulfur atoms
- the heteroaryl is (i) halogen, (ii) hydroxy, (iii) C 1-6 alkyl, (iv) C 1-6 alkoxy and (v) may be substituted with 1, 2 or 3 substituents selected from the group consisting of haloC 1-4 alkyl. ) ⁇ It is.
- R c is preferably methyl optionally substituted with one or two substituents selected from the following (e) and (f): (e) C 6-10 aryl (the C 6-10 aryl is (i) halogen, (ii) hydroxy, (iii) C 1-6 alkyl, (iv) C 1-6 alkoxy and (v) may be substituted with 1, 2 or 3 substituents selected from the group consisting of haloC 1-4 alkyl.
- heteroaryl containing 1, 2 or 3 nitrogen, oxygen or sulfur atoms
- the heteroaryl is (i) halogen, (ii) hydroxy, (iii) C 1-6 alkyl, (iv) C 1-6 alkoxy and (v) may be substituted with 1, 2 or 3 substituents selected from the group consisting of haloC 1-4 alkyl.
- pyridyl (i) halogen, (ii) hydroxy, (iii) C 1-6 alkyl, (iv) C 1-6 alkoxy and (v) may be substituted with 1 or 2 substituents selected from the group consisting of haloC 1-4 alkyl. ).
- R 4 is preferably hydrogen, fluoro, chloro, or methyl, more preferably hydrogen.
- R 5 is preferably (1) Halogen, (4) C 1-6 alkyl (the C 1-6 alkyl is substituted with 1, 2 or 3 substituents selected from the group consisting of halogen, C 6-10 aryl and C 1-6 alkoxy) May be good), (5) C 3-7 cycloalkyl, (6) -OR d ⁇ R d is (a) C 2-6 alkynyl, (b) C 3-7 cycloalkyl optionally substituted with 1, 2 or 3 C 1-6 alkyl, or (c) C 1-8 alkyl (the C 1-8 alkyl may be substituted with 1, 2 or 3 substituents selected from the group consisting of the following (i) to (v); (i) halogen, (ii) C 6-10 aryl, (iii) C 1-6 alkoxy, (iv) C 3-7 cycloalkyl (said C 3-7 cycloalkyl is substituted with 1, 2 or 3 substituents selected from the group consisting of C 1-6 alky
- R e is (a) C 1-6 alkyl, (b) C 3-7 cycloalkyl, (c) a 5- or 6-membered heteroaryl containing 1, 2 or 3 nitrogen, oxygen or sulfur atoms, or (d) C 6-10 aryl (the C 6-10 aryl is (i) halogen, (ii) C 1-6 alkyl, (iii) Halo C 1-4 alkyl, (iv) C 1-6 alkoxy and (v) may be substituted with 1, 2 or 3 substituents selected from the group consisting of haloC 1-4 alkoxy. ). ⁇ It is.
- R d is preferably C 1-8 alkyl (wherein the C 1-8 alkyl is substituted with 1, 2 or 3 substituents selected from the group consisting of (i) to (v) below) May be; (i) halogen, (ii) C 6-10 aryl, (iii) C 1-6 alkoxy, (iv) C 3-7 cycloalkyl (said C 3-7 cycloalkyl is substituted with 1, 2 or 3 substituents selected from the group consisting of C 1-6 alkyl and halo C 1-4 alkyl And) (v) 4, 5 or 6 membered saturated heterocyclyl containing one oxygen atom, wherein the saturated heterocyclyl is selected from the group consisting of C 1-6 alkyl and halo C 1-4 alkyl May be substituted with one substituent).
- R e is preferably (b) C 3-7 cycloalkyl, (c) a 5- or 6-membered heteroaryl containing 1, 2 or 3 nitrogen, oxygen or sulfur atoms, or (d) C 6-10 aryl (the C 6-10 aryl is (i) halogen, (ii) C 1-6 alkyl, (iii) Halo C 1-4 alkyl, (iv) C 1-6 alkoxy and (v) may be substituted with 1, 2 or 3 substituents selected from the group consisting of haloC 1-4 alkoxy. ).
- M1 is preferably 0, 1 or 2, more preferably 1 or 2.
- R 4 and R 5 are not substituted with carbon atoms on which hydrogen atoms are represented; X, R 1 , R 2 and R 4 are the same as defined in the above formula [I],
- R 5 is (1) Halogen, (4) C 1-6 alkyl (the C 1-6 alkyl is substituted with 1, 2 or 3 substituents selected from the group consisting of halogen, C 6-10 aryl and C 1-6 alkoxy) May be good), (5) C 3-7 cycloalkyl, or (6) -OR d ⁇ R d is (a) C 2-6 alkynyl, or (c) C 1-8 alkyl (the C 1-8 alkyl may be substituted with 1, 2 or 3 substituents selected from the group consisting of the following (i) to (v); (i) halogen, (ii) C 6-10 aryl, (iii) C 1-6 alkoxy, (iv) C 3-7 cycloalkyl (said C 3-7 cycloalkyl is
- R 4 and R 5 are not substituted with carbon atoms on which hydrogen atoms are represented; X, R 3 and R 4 are as defined in the above formula [I], R 1 is chloro or trifluoromethyl; R 5 is (4) C 1-6 alkyl (the C 1-6 alkyl is substituted with 1, 2 or 3 substituents selected from the group consisting of halogen, C 6-10 aryl and C 1-6 alkoxy) May be good), (6) -OR d ⁇ R d is C 1-8 alkyl (wherein the C 1-8 alkyl may be substituted with 1, 2 or 3 substituents selected from the group consisting of (i) to (iv) below): (i) halogen, (ii) C 6-10 aryl, (iii) C 1-6 alkoxy, and (iv) C 3-7 cycloalkyl, wherein the C 3-7 cycloalkyl is selected from the group consisting of C 1-6 alkyl and halo C 1-4 al
- R e is (b) C 3-7 cycloalkyl, or (d) C 6-10 aryl (the C 6-10 aryl is (i) halogen, (ii) C 1-6 alkyl, (iii) Halo C 1-4 alkyl, (iv) C 1-6 alkoxy and (v) may be substituted with 1, 2 or 3 substituents selected from the group consisting of haloC 1-4 alkoxy. ) ⁇ m7 is 0, 1 or 2, and when m7 is 2, each R 5 is independently selected. ] It is a compound represented by these.
- R b15 is (ii) C 1-4 alkyl (the C 1-4 alkyl may be substituted with 1 or 2 substituents selected from trifluoromethyl and methoxy), or (iv) C 3-7 cycloalkyl, optionally substituted with trifluoromethyl, R 5a (1) Fluoro, (4) methyl (the methyl may be substituted with 3 fluoro), or (6) -OR d ⁇ R d is (a) C 2-4 alkynyl, or (c) one C 3-7 optionally C 1-4 alkyl optionally substituted with cycloalkyl (said C 3-7 cycloalkyl may be substituted with one trifluoromethyl.) be a ⁇ , R 5b is (1) Halogen, (4) C 1-4 alkyl, or (5) cyclopropyl, m8 is 0 or 1. ] It is a compound represented by these.
- the pharmaceutically acceptable salt of the compound represented by the formula [I] may be any salt as long as it forms a nontoxic salt with the compound of the present invention. Examples thereof include a salt with an acid, a salt with an organic acid, a salt with an inorganic base, a salt with an organic base, and a salt with an amino acid.
- Various forms of pharmaceutically acceptable salts are well known in the art and are described, for example, in the following references. (a) Berge et al., J. Pharm.
- salt with an inorganic acid examples include salts with hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, hydrobromic acid and the like.
- salts with organic acids for example, oxalic acid, maleic acid, citric acid, fumaric acid, lactic acid, malic acid, succinic acid, tartaric acid, acetic acid, trifluoroacetic acid, gluconic acid, ascorbic acid, methanesulfonic acid, benzenesulfonic acid And salts with p-toluenesulfonic acid and the like.
- a salt with an organic acid for example, adipic acid, alginic acid, 4-aminosalicylic acid, anhydromethylene citric acid, benzoic acid, calcium edetate, camphoric acid, camphor-10-sulfonic acid, carbonic acid, edetic acid, ethane -1,2-disulfonic acid, dodecylsulfuric acid, ethanesulfonic acid, glucoheptonic acid, glucuronic acid, glycolylarsanilic acid, hexylresorcinic acid, hydrofluoric acid, hydroiodic acid, hydroxy-naphthoic acid, 2- Hydroxy-1-ethanesulfonic acid, lactobionic acid, mandelic acid, methylsulfuric acid, methylnitric acid, methylenebis (salicylic acid), galactaric acid, naphthalene-2-sulfonic acid, 2-naphthoic acid,
- Examples of the salt with an inorganic base include sodium salt, potassium salt, calcium salt, magnesium salt, ammonium salt and the like. Furthermore, examples of the salt with an inorganic base include a salt with aluminum, barium, bismuth, lithium, or zinc.
- Examples of salts with organic bases include methylamine, diethylamine, trimethylamine, triethylamine, ethanolamine, diethanolamine, triethanolamine, ethylenediamine, tris (hydroxymethyl) methylamine, dicyclohexylamine, N, N'-dibenzylethylenediamine, guanidine , Salts with pyridine, picoline, choline, cinchonine, meglumine and the like.
- examples of the salt with an organic base include salts with arecoline, betaine, clemizole, N-methylglucamine, N-benzylphenethylamine, or tris (hydroxymethyl) methylamine.
- examples of the salt with amino acid include salts with lysine, arginine, aspartic acid, glutamic acid and the like.
- preferred is a salt with hydrochloric acid, sulfuric acid or p-toluenesulfonic acid.
- Each salt can be obtained by reacting the compound represented by the formula [I] with an inorganic base, organic base, inorganic acid, organic acid, or amino acid according to a known method.
- the compound represented by the formula [I] or a pharmaceutically acceptable salt thereof may exist as a solvate.
- a “solvate” is a compound represented by the formula [I] or a pharmaceutically acceptable salt thereof coordinated with a solvent molecule, and includes a hydrate.
- the solvate is preferably a pharmaceutically acceptable solvate.
- a hydrate, ethanol hydrate, dimethyl sulfoxide hydrate, etc. of the compound represented by the formula [I] or a pharmaceutically acceptable salt thereof can be mentioned.
- hemihydrate, monohydrate, dihydrate or monoethanolate of the compound represented by the formula [I], or 1 of the sodium salt of the compound represented by the formula [I] Examples thereof include hydrates or 2/3 ethanol hydrates of dihydrochloride.
- the solvate can be obtained according to a known method.
- the compound represented by the formula [I] may be labeled with an isotope (eg, 2 H, 3 H, 14 C, 35 S, etc.).
- the compound of the present invention may exist as a tautomer.
- the compounds of the invention may exist as individual tautomers or mixtures of tautomers.
- the compound represented by the formula [I] includes the following tautomers.
- the compound of the present invention may have a carbon double bond.
- the compound of the present invention may exist as E-form, Z-form, or a mixture of E-form and Z-form.
- the compound of the present invention may have a stereoisomer to be recognized as a cis / trans isomer.
- the compound of the present invention may exist as a cis form, a trans form, or a mixture of a cis form and a trans form.
- the compounds of the present invention may have one or more asymmetric carbons.
- the compound of the present invention may exist as a single enantiomer, a single diastereomer, a mixture of enantiomers or a mixture of diastereomers.
- the compounds of the present invention may exist as atropisomers. In that case, the compounds of the invention may exist as individual atropisomers or as a mixture of atropisomers.
- the compound of the present invention may contain a plurality of structural features that give rise to the above isomers simultaneously. In addition, the compound of the present invention can contain the above isomers in any ratio.
- the diastereomeric mixture can be separated into each diastereomer by a conventional method such as chromatography or crystallization.
- Each diastereomer can also be made by using a stereochemically single starting material or by a synthetic method using a stereoselective reaction.
- each enantiomer from a mixture of enantiomers can be accomplished by methods well known in the art.
- a mixture of diastereomers can be prepared by reacting a mixture of enantiomers with a compound that is a substantially pure enantiomer and is known as a chiral auxiliary.
- the diastereomeric mixture can be separated into the respective diastereomers as described above.
- the separated diastereomer can be converted to the desired enantiomer by removing the added chiral auxiliary by cleavage.
- a mixture of enantiomers of a compound can be separated directly by chromatographic methods using chiral stationary phases, well known in the art.
- stereoselective synthesis of either enantiomer of a compound by using a substantially pure optically active starting material or by using a chiral auxiliary or an asymmetric catalyst for a prochiral intermediate It can also be obtained by carrying out (asymmetric induction).
- the absolute configuration can be determined by X-ray crystallographic analysis of crystalline products or intermediates. At that time, if necessary, a crystalline product or an intermediate derivatized with a reagent having an asymmetric center whose configuration is known may be used.
- the compound represented by the formula [I] or a pharmaceutically acceptable salt thereof is preferably a substantially purified compound represented by the formula [I] or a pharmaceutically acceptable salt thereof. More preferably, it is a compound represented by the formula [I] or a pharmaceutically acceptable salt thereof purified to a purity of 80% or more.
- Examples of the “pharmaceutical composition” include tablets, capsules, granules, powders, troches, syrups, emulsions, suspensions and other oral preparations, external preparations, suppositories, injections, eye drops, and nasal preparations. And parenteral agents such as transpulmonary agents.
- the pharmaceutical composition of the present invention comprises at least one or more pharmacological compounds of the compound represented by the formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof according to a method known per se in the technical field of pharmaceutical preparations. It is produced by mixing an appropriate amount of the above-accepted carrier and the like as appropriate.
- the content of the compound represented by the formula [I] or a pharmaceutically acceptable salt or solvate thereof in the pharmaceutical composition varies depending on the dosage form, dosage, etc. To 100% by weight.
- the “pharmaceutically acceptable carrier” examples include various organic or inorganic carrier substances conventionally used as pharmaceutical materials, such as excipients, disintegrants, binders, fluidizers, lubricants and the like in solid preparations.
- a solvent, a solubilizing agent, a suspending agent, a tonicity agent, a buffering agent, a soothing agent, a surfactant, a pH adjusting agent, a thickening agent and the like in a liquid preparation can be mentioned.
- additives such as preservatives, antioxidants, colorants, sweeteners and the like are used as necessary.
- excipient examples include lactose, sucrose, D-mannitol, D-sorbitol, corn starch, dextrin, microcrystalline cellulose, crystalline cellulose, carmellose, carmellose calcium, sodium carboxymethyl starch, low substituted hydroxypropyl
- examples include cellulose and gum arabic.
- disintegrant examples include carmellose, carmellose calcium, carmellose sodium, sodium carboxymethyl starch, croscarmellose sodium, crospovidone, low-substituted hydroxypropylcellulose, hydroxypropylmethylcellulose, crystalline cellulose and the like.
- binder examples include hydroxypropylcellulose, hydroxypropylmethylcellulose, povidone, crystalline cellulose, sucrose, dextrin, starch, gelatin, carmellose sodium, gum arabic and the like.
- fluidizing agent examples include light anhydrous silicic acid, magnesium stearate and the like.
- lubricant examples include magnesium stearate, calcium stearate, talc and the like.
- solvent examples include purified water, ethanol, propylene glycol, macrogol, sesame oil, corn oil, olive oil and the like.
- dissolution aid examples include propylene glycol, D-mannitol, benzyl benzoate, ethanol, triethanolamine, sodium carbonate, sodium citrate and the like.
- suspending agent examples include benzalkonium chloride, carmellose, hydroxypropylcellulose, propylene glycol, povidone, methylcellulose, glyceryl monostearate and the like.
- isotonic agent examples include glucose, D-sorbitol, sodium chloride, D-mannitol and the like.
- buffering agent examples include sodium hydrogen phosphate, sodium acetate, sodium carbonate, sodium citrate and the like.
- Examples of the soothing agent include benzyl alcohol.
- surfactant examples include polyoxyethylene hydrogenated castor oil, polyethylene glycol monostearate, polyoxyethylene sorbitan fatty acid ester, alkyl diaminoethyl glycine, alkyl benzene sulfonate, benzethonium chloride and the like.
- pH adjuster examples include hydrochloric acid, sulfuric acid, phosphoric acid, citric acid, acetic acid, sodium hydrogen carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, monoethanolamine, triethanolamine and the like.
- viscous agent examples include polyvinyl alcohol, carboxyvinyl polymer, methyl cellulose, hydroxyethyl cellulose, polyethylene glycol, dextran, and the like.
- preservative examples include ethyl paraoxybenzoate, chlorobutanol, benzyl alcohol, sodium dehydroacetate, sorbic acid and the like.
- antioxidant examples include sodium sulfite and ascorbic acid.
- colorant examples include food dyes (eg, food red No. 2 or 3, food yellow No. 4 or 5, etc.), ⁇ -carotene and the like.
- sweetening agent examples include saccharin sodium, dipotassium glycyrrhizinate, aspartame and the like.
- the pharmaceutical composition of the present invention can be used orally or parenterally to humans as well as mammals other than humans (eg, hamsters, guinea pigs, cats, dogs, pigs, cows, horses, sheep, monkeys, etc.). (Eg, topical, rectal, intravenous administration, etc.).
- the dose varies depending on the subject of administration, disease, symptom, dosage form, administration route, etc.
- the dose for oral administration to an adult patient is as the compound of the present invention as an active ingredient.
- body weight body weight: about 60 kg
- these amounts can be administered in one to several divided doses.
- the compound represented by the above formula [I], or a pharmaceutically acceptable salt thereof, or a solvate thereof is converted into one or a plurality of other drugs (hereinafter referred to as “a drug”) by a general method performed in the pharmaceutical field. (Also referred to as a concomitant drug).
- the administration time of the compound represented by the above formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a concomitant drug is not limited, and these may be administered to a subject to be administered as a combination drug. Alternatively, both preparations may be administered simultaneously or at regular intervals. Moreover, you may use as a pharmaceutical characterized by being a kit which consists of the pharmaceutical composition of this invention, and a concomitant drug.
- the dose of the concomitant drug may be determined according to the dose used clinically, and can be appropriately selected depending on the administration subject, disease, symptom, dosage form, administration route, administration time, combination and the like.
- the administration form of the concomitant drug is not particularly limited as long as the compound of the present invention or a salt thereof, or a solvate thereof and the concomitant drug are combined.
- concomitant drugs include prostaglandin preparations, beta blockers, alpha receptor agonists, sympathomimetics, alpha blockers, carbonic anhydrase inhibitors, anticholinesterase agents, Rho kinase inhibitors, and other glaucoma treatment agents. It is done.
- prostaglandin preparations include isopropyl unoprostone, latanoprost, travoprost, tafluprost, bimatoprost and the like.
- ⁇ -blocker include timolol maleate, befnolol hydrochloride, carteolol hydrochloride, betaxolol hydrochloride, nipradilol, levobunolol hydrochloride, and the like.
- Examples of the ⁇ receptor agonist include brimonidine tartrate.
- sympathomimetic agents examples include dipivefrin hydrochloride and pilocarpine hydrochloride.
- ⁇ blockers examples include bunazosin hydrochloride.
- carbonic anhydrase inhibitors examples include dorzolamide hydrochloride and brinzolamide.
- anticholinesterase agent examples include distigmine bromide.
- Rho kinase inhibitors include, for example, ripaspil hydrochloride hydrate.
- drugs include, for example, one drug selected from latanoprost, travoprost, tafluprost, timolol maleate, dorzolamide hydrochloride, and brinzolamide, a compound represented by the above formula [I], or a pharmaceutically acceptable salt thereof Examples include an acceptable salt or a combination with a solvate thereof.
- the manufacturing method of this invention compound or its pharmacologically acceptable salt is not limited to these. Even if there is no description in the following production method, a protective group is introduced into the functional group as necessary, and deprotection is performed in a post-process; each production method and the order of the steps are changed; exemplified to promote the progress of the reaction Efficient production may be performed by appropriately using a reagent other than the reagent. In each step, post-reaction treatment may be performed by a commonly performed method, and isolation and purification may be performed as necessary by crystallization, recrystallization, distillation, liquid separation, silica gel column chromatography, preparative HPLC.
- a commonly used method such as the above may be appropriately selected and combined.
- the next step can be performed without isolation and purification.
- an intermediate capable of forming a salt may be obtained as a salt, or may be used in the reaction as a salt.
- An example of such a salt is an intermediate hydrochloride having an amino group.
- Hal 1 is chloro or bromo;
- R 6 is C 1-6 alkyl such as methyl, ethyl or benzyl;
- Z is —B (OH) 2 , —B (OR 7 ) 2 (wherein R 7 is C 1-4 alkyl or one R 7 may be bonded to the other R 7 to form a ring), -BF 3 , formula
- the compound [3] can be obtained by the Suzuki coupling reaction of the compound [1] and the compound [2].
- compound [3] can be obtained by reacting compound [1] with compound [2] in the presence of a base and a palladium catalyst in a solvent under heating.
- a ligand may be added as necessary.
- Examples of the palladium catalyst used in the reaction include palladium acetate, tetrakistriphenylphosphine palladium, bis (triphenylphosphine) palladium dichloride, (bis (diphenylphosphino) ferrocene) palladium dichloride-methylene chloride complex, and the like.
- Examples of the base used in the reaction include inorganic bases such as alkali metal salts such as potassium phosphate, sodium carbonate, sodium hydrogen carbonate, potassium carbonate, potassium acetate, sodium acetate and cesium fluoride, and organic bases such as triethylamine.
- the ligands used in the reaction are triphenylphosphine, tricyclohexylphosphine, 2,2'-bis (diphenylphosphino) -1,1'-binaphthalene, 2-dicyclohexylphosphino-2 ', 6'-dimethoxybiphenyl And organic phosphorus-based ligands.
- the solvent used in the reaction include ether solvents such as 1,4-dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, and cyclopentyl methyl ether; alcohol solvents such as methanol, ethanol, 1-propanol, and 2-propanol.
- Hydrocarbon solvents such as toluene, xylene and hexane; polar solvents such as N, N-dimethylformamide, N, N-dimethylacetamide, dimethyl sulfoxide and acetonitrile; mixed solvents thereof and mixed solvents of water and water Can be mentioned.
- Compound [1] may be a commercially available product such as 2,4-dichloro-6-methoxy-1,3,5-triazine, or obtained by appropriately converting a commercially available product by a method well known to those skilled in the art. It may be a thing.
- Suzuki coupling reaction for example, the following review is known (SUZUKI, A et al. Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds. Chem Rev. 1995, Vol.95, pages 2457-2483. ).
- the compound [5] can be obtained by the Suzuki coupling reaction of the compound [3] and the compound [4].
- compound [5] can be obtained by reacting compound [3] with compound [4] in the presence of a base and a palladium catalyst in a solvent under heating.
- a ligand may be added as necessary.
- the palladium catalyst used in the reaction include palladium acetate, tetrakistriphenylphosphine palladium, bis (triphenylphosphine) palladium dichloride, (bis (diphenylphosphino) ferrocene) palladium dichloride-methylene chloride complex, and the like.
- Examples of the base used in the reaction include inorganic bases such as alkali metal salts such as potassium phosphate, sodium carbonate, sodium hydrogen carbonate, potassium carbonate, potassium acetate, sodium acetate and cesium fluoride, and organic bases such as triethylamine.
- the ligands used in the reaction are triphenylphosphine, tricyclohexylphosphine, 2,2'-bis (diphenylphosphino) -1,1'-binaphthalene, 2-dicyclohexylphosphino-2 ', 6'-dimethoxybiphenyl And organic phosphorus-based ligands.
- solvent used in the reaction examples include ether solvents such as 1,4-dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, and cyclopentyl methyl ether; alcohol solvents such as methanol, ethanol, 1-propanol, and 2-propanol. Hydrocarbon solvents such as toluene, xylene and hexane; polar solvents such as N, N-dimethylformamide, N, N-dimethylacetamide, dimethyl sulfoxide and acetonitrile; mixed solvents thereof and mixed solvents of water and water Can be mentioned.
- ether solvents such as 1,4-dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, and cyclopentyl methyl ether
- alcohol solvents such as methanol, ethanol, 1-propanol, and 2-propanol.
- Step 1-1-3 Compound [I] can be obtained by converting alkoxy of compound [5] to hydroxy by hydrolysis.
- R 6 is C 1-6 alkyl
- compound [5] is reacted in a solvent in the presence of a base at room temperature under heating, and then the resulting solution is neutralized to give compound [I ] Can be obtained.
- the base used for the reaction include lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium methoxide and the like.
- an alcohol solvent such as methanol, ethanol, 1-propanol, 2-propanol and water
- 1,4-dioxane 1, tetrahydrofuran
- diethyl ether 1,2-dimethoxyethane
- a mixed solvent with an ether solvent such as cyclopentyl methyl ether.
- L 1 is a leaving group such as bromo, iodo, trifluoromethanesulfonyloxy, etc .
- X, R 5 and m1 have the same definition as in formula [I], and Z has the same definition as in production method 1-1.
- Step 1-2 Compound [2] can be obtained by boronating compound [6].
- compound [2] can be obtained by reacting compound [6] with a boron reagent in the presence of a base and a palladium catalyst under heating. A ligand may be added as necessary.
- boron reagent used in the reaction 4,4,4 ′, 4 ′, 5,5,5 ′, 5′-octamethyl-2,2′-bi-1,3,2-dioxaborolane, 5,5,5 Examples include ', 5'-tetramethyl-2,2'-bi-1,3,2-dioxaborinane, tetrahydroxydiboron, 4,4,5,5-tetramethyl-1,3,2-dioxaborolane, etc. .
- Examples of the palladium catalyst used in the reaction include palladium acetate, tetrakistriphenylphosphine palladium, bis (triphenylphosphine) palladium dichloride, (bis (diphenylphosphino) ferrocene) palladium dichloride-methylene chloride complex, and the like.
- Examples of the base used in the reaction include inorganic bases such as alkali metal salts such as potassium phosphate, sodium carbonate, sodium hydrogen carbonate, potassium carbonate, potassium acetate, sodium acetate and cesium fluoride, and organic bases such as triethylamine.
- the ligands used in the reaction are triphenylphosphine, tricyclohexylphosphine, 2,2'-bis (diphenylphosphino) -1,1'-binaphthalene, 2-dicyclohexylphosphino-2 ', 6'-dimethoxybiphenyl And organic phosphorus-based ligands.
- the solvent used in the reaction include ether solvents such as 1,4-dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, and cyclopentyl methyl ether; alcohol solvents such as methanol, ethanol, 1-propanol, and 2-propanol.
- Hydrocarbon solvents such as toluene, xylene and hexane; polar solvents such as N, N-dimethylformamide, N, N-dimethylacetamide, dimethyl sulfoxide and acetonitrile; mixed solvents thereof and mixed solvents of water and water Can be mentioned.
- compound [6] can be obtained by adding an organometallic reagent in a solvent at ⁇ 78 ° C. to room temperature, and then reacting the product with a boron compound at ⁇ 78 ° C. at room temperature. be able to.
- organometallic reagent used for the reaction examples include n-butyllithium, tert-butyllithium, isopropylmagnesium chloride and the like.
- boron reagent used in the reaction examples include trimethyl borate, triisopropyl borate, 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.
- ether solvents such as 1,4-dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, cyclopentyl methyl ether; hydrocarbon solvents such as toluene, xylene, hexane, and mixtures thereof A solvent is mentioned.
- Compound [6] may be a commercially available product as shown below as an example, or may be obtained by appropriately converting a commercially available product by a method well known to those skilled in the art.
- Compound [2] may be a commercially available product as shown below as an example, or may be obtained by appropriately converting a commercially available product by a method well known to those skilled in the art.
- Step 1-3 Compound [4] is compound [8a] or [8b].
- Compound [8a] or [8b] that is, compound [4] can be obtained by boronating compound [7a] or [7b] in the same manner as in step 1-2 of production method 1-2.
- Compound [7a] or [7b] may be a commercially available product such as 2-bromo-4-methylbenzonitrile or 2-bromo-3-methylphenol, or the commercially available product may be appropriately converted by a method well known to those skilled in the art. It may be obtained by conversion.
- Compound [4] may be a commercially available product as shown below as an example, or may be obtained by appropriately converting a commercially available product by a method well known to those skilled in the art.
- C 1-6 Alkyl is C 1-6 alkyl; t is 0, 1, 2 or 3, and-(C t H 2t ) -may be either linear or branched; Hal 2 is bromo or iodo; P v is a hydroxy-protecting group such as methoxymethyl; P w is an amino-protecting group such as tert-butoxycarbonyl; L 2 is a leaving group such as halogen such as chloro and bromo, methanesulfonyloxy, p-toluenesulfonyloxy; R 1 , R 4 , R 6 , R b15 , n are as defined in the formula [I], and Z is as defined in the production method 1-1. )
- Step 2-1-1 Compound [10] can be obtained by converting the ester of compound [9] to carboxy by hydrolysis.
- compound [10] can be obtained by reacting compound [9] in a solvent in the presence of a base at room temperature and under heating, and then neutralizing the resulting solution.
- the base used for the reaction include lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium methoxide and the like.
- Compound [9] may be a commercially available product as shown below, for example, or may be obtained by appropriately converting a commercially available product by a method well known to those skilled in the art.
- Step 2-1-2 Compound [11] can be obtained by converting carboxy of compound [10] to hydroxy by reduction.
- compound [11] can be obtained by reacting compound [10] with a reducing agent in a solvent under ice cooling to room temperature.
- the reducing agent used in the reaction include lithium aluminum hydride, diisobutylaluminum hydride, sodium bis (2-methoxyethoxy) aluminum hydride, and borane-tetrahydrofuran complex.
- solvent used in the reaction examples include tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, cyclopentyl methyl ether, toluene, xylene, hexane, and the like, and mixed solvents thereof.
- Step 2-1-3 Compound [12] can be obtained by protecting the hydroxy group of compound [11].
- the protection reaction may be performed by a known method according to the protecting group employed. For example, when Pv is methoxymethyl, in a solvent such as tetrahydrofuran, 1,2-dimethoxyethane, cyclopentylmethyl ether, N, N-dimethylformamide, in the presence of a base such as sodium hydride, from ice cooling to room temperature.
- Compound [12] can be obtained by reacting compound [11] with chloromethyl methyl ether.
- Step 2-1-4 Compound [13] can be obtained by boronating compound [12] in the same manner as in Step 1-2 of Production Method 1-2.
- Step 2-1-5 Compound [14] can be obtained by Suzuki coupling reaction of compound [3] and compound [13] in the same manner as in Production Method 1-1, Step 1-1-2.
- Step 2-1-6 Compound [15] can be obtained by removing Pv of compound [14] by a conventional hydroxy deprotection reaction.
- the deprotection reaction may be carried out by a known method according to the protecting group employed. For example, when Pv is methoxymethyl, chloroform, 1,4-dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, cyclopentyl methyl ether, ethyl acetate, ethanol, methanol, water, etc. alone or in a mixed solvent, What is necessary is just to process with acids, such as hydrochloric acid, trifluoroacetic acid, methanesulfonic acid.
- acid such as hydrochloric acid, trifluoroacetic acid, methanesulfonic acid.
- Step 2-1-7 Compounds hydroxy [15] to give compound [16] by converting the leaving group L 2.
- L 2 is methanesulfonyloxy
- compound [16] can be obtained by reacting compound [15] with methanesulfonyl chloride in a solvent in the presence of a base at room temperature.
- L 2 is bromo
- compound [16] can be obtained by reacting compound [15] with carbon tetrabromide in a solvent in the presence of triphenylphosphine from ice cooling to room temperature.
- the base used for the reaction include triethylamine and pyridine.
- Solvents used for the reaction include ether solvents such as 1,4-dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, cyclopentyl methyl ether; hydrocarbon solvents such as toluene, hexane, xylene; dichloromethane, chloroform, etc. And halogen solvents such as N, N-dimethylformamide, N, N-dimethylacetamide, dimethyl sulfoxide, acetonitrile and the like. Dimethyl sulfide can be used in place of the triphenylphosphine, and N-bromosuccinimide can be used in place of the carbon tetrabromide. Instead of the methanesulfonyl chloride, p-toluenesulfonyl chloride or benzenesulfonyl chloride can be used.
- ether solvents such as 1,4-diox
- Step 2-1-8 Compound [18] can be obtained by reacting compound [16] with compound [17] in a solvent in the presence of a base at room temperature to heating.
- the protective group P w include, for example, tert- butoxycarbonyl.
- the base used for the reaction include inorganic bases such as alkali metal salts such as cesium carbonate, potassium phosphate, sodium carbonate, and potassium carbonate.
- the solvent used for the reaction include polar solvents such as N, N-dimethylformamide, N, N-dimethylacetamide, dimethyl sulfoxide, and acetonitrile.
- Step 2-1-9 The protecting group P w of the compound [18], is removed by conventional methods of amine deprotection reaction to give compound [19].
- the deprotection reaction may be carried out by a known method according to the protecting group employed. For example, if P w is tert- butoxycarbonyl, in a solvent, hydrochloric acid, trifluoroacetic acid, it may be the acid treatment such as methanesulfonic acid.
- Solvents used for the reaction include ether solvents such as 1,4-dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, cyclopentyl methyl ether; hydrocarbon solvents such as toluene, hexane, xylene; dichloromethane, chloroform, etc. Halogen-based solvents; ester solvents such as ethyl acetate; and alcohol solvents such as methanol, ethanol, 1-propanol, and 2-propanol.
- ether solvents such as 1,4-dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, cyclopentyl methyl ether
- hydrocarbon solvents such as toluene, hexane, xylene
- dichloromethane chloroform, etc.
- Halogen-based solvents such as toluene, hex
- Step 2-1-10 In a conventional amide bond formation reaction, for example, compound [21] can be obtained by reacting compound [19] with compound [20] in a solvent in the presence of a condensing agent and an additive. A base may be added as necessary.
- Condensation agents used in the reaction include dicyclohexylcarbodiimide (DCC), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (WSC / HCl), diisopropylcarbodiimide, 1,1'-carbonyldiimidazole (CDI) , O- (7-azabenzotriazol-1-yl) -N, N, N ', N'-tetramethyluronium hexafluorophosphate (HATU), hexafluorophosphoric acid (benzotriazol-1-yloxy) tri Examples include pyrrolidinophosphonium (PyBOP) and diphenylphosphoryl azide.
- DCC dicyclohexylcarbodiimide
- WSC / HCl 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride
- CDI 1,1'-carbon
- Examples of the additive used for the reaction include 1-hydroxybenzotriazole (HOBt), 1-hydroxy-7-azabenzotriazole (HOAt), N-hydroxysuccinimide (HOSu), 4-dimethylaminopyridine and the like.
- Examples of the base used in the reaction include organic bases such as pyridine and triethylamine.
- Solvents used for the reaction include ether solvents such as 1,4-dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, cyclopentyl methyl ether; hydrocarbon solvents such as toluene, hexane, xylene; dichloromethane, chloroform, etc.
- Compound [20] may be a commercially available product such as cyclopentanecarboxylic acid or 1- (trifluoromethyl) cyclopropane-1-carboxylic acid, or a commercially available product may be appropriately converted by a method well known to those skilled in the art. It may be obtained.
- Step 2-1-11 Compound [21] can be expressed as Compound [22].
- compound [I-a1] can be obtained by converting alkoxy of compound [22] into hydroxy by hydrolysis.
- R x is C 1-6 alkyl or chloro;
- R 4 has the same definition as in Formula [I], and Hal 2 and t have the same definitions as in Production Method 2-1. )
- Step 2-2 Compound [10a] can be obtained by halogenating compound [24].
- compound [10a] can be obtained by reacting compound [24] with N-iodosuccinimide in an acid at room temperature.
- the acid used for the reaction include concentrated sulfuric acid.
- Compound [24] is 4-chlorophenylacetic acid, 3- (4-chlorophenyl) propionic acid, or 4- (4-chlorophenyl) butanoic acid, 4-methylphenylacetic acid, or 2- (4-methylphenyl) propionic acid.
- a commercially available product may be used, or a commercially available product may be appropriately converted by a method well known to those skilled in the art.
- Step 2-3-1 Compound [26] can be obtained by boronating compound [25] in the same manner as in Step 1-2 of Production Method 1-2.
- Compound [25] may be a commercial product such as 1- (3-bromo-4-chlorophenyl) propan-1-one or 1- (3-bromo-4-chlorophenyl) butan-1-one, or It may be obtained by appropriately converting a commercially available product by a method well known to those skilled in the art.
- Step 2-3-2 Compound [27] can be obtained by Suzuki coupling reaction of compound [3] and compound [26] in the same manner as in Production Method 1-1, Step 1-1-2.
- Step 2-3-3 Compound [28] can be obtained by converting carboxy of compound [27] to hydroxy by reduction.
- compound [28] can be obtained by reacting compound [27] with a reducing agent in a solvent under ice-cooling to room temperature.
- the reducing agent used in the reaction include sodium borohydride.
- the solvent used for the reaction include methanol, ethanol, 2-propanol, 1,4-dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, cyclopentyl methyl ether, and the like.
- Step 2-3-4 Compound [29] can be obtained by converting hydroxy of compound [28] to leaving group L 2 in the same manner as in production method 2-1, step 2-1-7.
- Step 2-3-5 Compound [30] can be obtained by reacting compound [29] with compound [17] in the same manner as in Production Method 2-1, Step 2-1-8.
- Step 2-3-6 In a similar manner as in Step 2-1-9 of the manufacturing method 2-1, by removing the protecting group P w of the compound [30], to give compound [31].
- Step 2-3-7 Compound [32] can be obtained by reacting compound [31] with compound [20] in the same manner as in Production Method 2-1, Step 2-1-10.
- Step 2-3-8 Compound [32] can be expressed as Compound [22].
- compound [I-a1] can be obtained by converting alkoxy of compound [22] into hydroxy by hydrolysis.
- step 2-1-4 In production method 2-1, compound [9] is subjected to the reaction of step 2-1-4, step 2-1-5, and step 2-1-11, whereby ring Cy in formula [I] is represented by the formula
- Step 2-1-11 the reaction of Step 2-1-11 is carried out using compound [15]. Thereafter, the product is reacted with a C 1-6 alkyl-carboxylic anhydride such as acetic anhydride or propionic anhydride to form a ring Cy in formula [I].
- a C 1-6 alkyl-carboxylic anhydride such as acetic anhydride or propionic anhydride
- R 1 , R 4 and n are as defined in the above formula [I], and C 1-6 Alkyl is as defined in the above production method 2-1. a5] can be obtained.
- compound [16] contains sodium hydride and a compound
- R 1 , R 4 , R b16 , m2, m3, m4 are as defined in the above formula [I], and C 1-6 Alkyl, L 2 , P v , t, Y are the above-mentioned production methods (It is synonymous with the definition in 2-1.)
- Step 2-4-1) Compound [36] can be obtained by reacting compound [34] with compound [35] in the presence of a base in a solvent.
- a base used for the reaction include bases such as lithium diisopropylamide and bis (trimethylsilyl) amidolithium.
- the solvent used in the reaction include ether solvents such as tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, and cyclopentyl methyl ether; hydrocarbon solvents such as toluene, hexane, and xylene, and mixed solvents thereof.
- Compound [35] may be a commercially available product such as benzylchloromethyl ether, or may be obtained by appropriately converting a commercially available product by a method well known to those skilled in the art.
- Step 2-4-2 Compound [37] can be obtained by removing P v of compound [36] in the same manner as in Step 2-1-6 of Production Method 2-1.
- Step 2-4-3 Compound [38] can be obtained by converting the ester of compound [37] to carboxy by hydrolysis in the same manner as in Production Method 2-1, Step 2-1-1.
- Step 2-4-4 Compound [39] is reacted with compound [19] in the presence of a condensing agent and an additive in a solvent in the same manner as in Production Method 2-1, Step 2-1-10. Obtainable.
- Step 2-4-5 Compound [40] can be obtained by cyclization by intramolecular Mitsunobu reaction of compound [39].
- compound [39] is mixed with azodicarboxylic acid diester (for example, diethyl azodicarboxylate, diisopropyl azodicarboxylate, bis (2-methoxyethyl) azodicarboxylate) in a solvent and phosphine such as triphenylphosphine or tributylphosphine.
- azodicarboxylic acid diester for example, diethyl azodicarboxylate, diisopropyl azodicarboxylate, bis (2-methoxyethyl) azodicarboxylate
- phosphine such as triphenylphosphine or tributylphosphine.
- Compound [40] can be obtained by reacting in the presence of.
- Solvents used for the reaction include dichloromethane, chloroform, 1,4-dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, cyclopentyl methyl ether, toluene, N, N-dimethylformamide, and the like. A mixture of seeds or more can be used.
- Step 3-1-1 Compound [42] can be obtained by protecting the hydroxy group of compound [41] in the same manner as in production method 2-1, step 2-1-3.
- Compound [41] may be a commercially available product such as 2-bromo-3-methylphenol, or may be obtained by appropriately converting a commercially available product by a method well known to those skilled in the art.
- Step 3-1-2 Compound [43] can be obtained by boronating compound [42] in the same manner as in Step 1-3 of Production Method 1-3.
- Step 3-1-3 Compound [44] can be obtained by Suzuki coupling reaction of compound [3] and compound [43] in the same manner as in Production Method 1-1, Step 1-1-2.
- Step 3-1-4 Compound [45] can be obtained by removing P v of compound [44] in the same manner as in Production Method 2-1, Step 2-1-6.
- Step 3-1-5 Compound [47] can be obtained by Mitsunobu reaction between compound [45] and compound [46].
- compound [45] is present in a solvent in the presence of an azodicarboxylic acid diester (eg, diethyl azodicarboxylate, diisopropyl azodicarboxylate, bis (2-methoxyethyl) azodicarboxylate) and a phosphine such as triphenylphosphine or tributylphosphine
- azodicarboxylic acid diester eg, diethyl azodicarboxylate, diisopropyl azodicarboxylate, bis (2-methoxyethyl) azodicarboxylate
- a phosphine such as triphenylphosphine or tributylphosphine
- Solvents used for the reaction include dichloromethane, chloroform, 1,4-dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, cyclopentyl methyl ether, toluene, N, N-dimethylformamide, and the like. A mixture of seeds or more can be used.
- Compound [46] may be a commercially available product such as benzyl alcohol or 2-pyridinemethanol, or may be obtained by appropriately converting a commercially available product by a method well known to those skilled in the art.
- Step 3-1-6 In the same manner as in Step 1-1-3 of Production Method 1-1, compound [Ib1] can be obtained by converting alkoxy of compound [47] to hydroxy by hydrolysis.
- R y is chloro or trifluoromethyl;
- R 4 has the same definition as in Formula [I], Z has the same definition as in Production Method 1-1, and
- P v has the same definition as in Production Method 2-1.
- Step 3-2-1 Compound [49] can be obtained by protecting the hydroxy group of compound [48] in the same manner as in Production Method 2-1, Step 2-1-3.
- Compound [48] may be a commercially available product as shown below as an example, or may be obtained by appropriately converting a commercially available product by a method well known to those skilled in the art.
- Step 3-2-2 Compound [43a] can be obtained by reacting compound [49] with a boron compound in a solvent in the presence of a base.
- compound [43a] can be obtained by adding a base to compound [49] in a solvent at ⁇ 78 ° C. to room temperature and then reacting the product with a boron reagent at ⁇ 78 ° C. to room temperature.
- the base used for the reaction include n-butyllithium and sec-butyllithium.
- Examples of the boron reagent used in the reaction include 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, trimethyl borate and the like.
- the solvent used in the reaction include tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, cyclopentyl methyl ether, and the like.
- L 3 is a leaving group such as trifluoromethanesulfonyloxy; P x is a protecting group for a hydroxy group such as benzyl; R 5, R 6, R e , X, Cy has the same meaning as defined in the formula [I], Hal 1, Z is defined in the same manner as in the production method 1-1, m7 is the formula [I- It is synonymous with the definition in A]. )
- Step 4-1 Compound [51] can be obtained by the Suzuki coupling reaction of compound [1] and compound [50] in the same manner as in Production Method 1-1, Step 1-1-1.
- Compound [50] may be a commercially available product such as 4- (benzyloxy) phenylboronic acid, or may be obtained by appropriately converting a commercially available product by a method well known to those skilled in the art.
- Step 4-2 Compound [52] can be obtained by the Suzuki coupling reaction of compound [4] and compound [51] in the same manner as in Production Method 1-1, Step 1-1-2.
- Step 4-3 By removing the phenol protecting group P X of the compound [52], to give compound [53].
- the deprotection reaction may be carried out by a known method according to the protecting group employed. For example, if P X is benzyl, tetrahydrofuran, ethyl acetate, ethanol, methanol, alone or mixed solvent such as water, the presence of a catalyst such as palladium-carbon or platinum carbon, it is only necessary to hydrogenation reaction.
- Step 4-4 Compound hydroxy- [53] by converting the leaving group L 3, to give compound [54].
- compound [53] when the leaving group is trifluoromethanesulfonyloxy, compound [53] is trifluoromethanesulfonic anhydride or N-phenylbis (trifluoromethanesulfonimide) in a solvent in the presence of a base under ice cooling to room temperature.
- Compound [54] can be obtained by reacting with the above.
- the base used in the reaction include organic bases such as pyridine, 2,6-lutidine and triethylamine; inorganic bases of alkali metal salts such as cesium carbonate and sodium hydride.
- Solvents used for the reaction include ether solvents such as 1,4-dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, cyclopentyl methyl ether; hydrocarbon solvents such as toluene, hexane, xylene; dichloromethane, chloroform, etc. And halogen solvents such as: polar solvents such as N, N-dimethylformamide, N, N-dimethylacetamide, dimethyl sulfoxide, acetonitrile, pyridine, etc., and these can be used alone or in admixture of two or more. .
- ether solvents such as 1,4-dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, cyclopentyl methyl ether
- hydrocarbon solvents such as toluene, hexane, xylene
- Step 4-5 Compound [56] can be obtained by Sonogashira reaction between compound [54] and compound [55].
- compound [56] can be obtained by reacting compound [54] with compound [55] in the presence of a base, a palladium catalyst and a copper catalyst in a solvent, preferably under heating.
- the palladium catalyst used in the reaction include tetrakistriphenylphosphine palladium, bis (triphenylphosphine) palladium dichloride, (bis (diphenylphosphino) ferrocene) palladium dichloride-methylene chloride complex, and the like.
- the copper catalyst used in the reaction include copper iodide and copper bromide.
- Examples of the base used for the reaction include diethylamine, dicyclohexylamine, triethylamine, N-ethyldiisopropylamine and the like.
- ether solvents such as 1,4-dioxane, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, cyclopentyl methyl ether; hydrocarbon solvents such as toluene, hexane, xylene; N, N—
- Examples include polar solvents such as dimethylformamide, N, N-dimethylacetamide, dimethyl sulfoxide, acetonitrile, and pyridine, and these can be used alone or in admixture of two or more.
- Compound [55] may be a commercially available product such as cyclohexylacetylene or 2-ethynylpyridine, or may be obtained by appropriately converting a commercially available product by a method well known to those skilled in the art.
- Sonogashira reaction for example, the following review is known (NAJERA, C et al. The Sonogashira Reaction: A Booming Methodology in Synthetic Organic Chemistry. Chem Rev. 2007, Vol. 107, pages 874-922. ).
- Step 4-6 In the same manner as in Step 1-1-3 of Production Method 1-1, compound [Ic1] can be obtained by converting alkoxy of compound [56] to hydroxy by hydrolysis.
- Mitsunobu reaction is carried out in the same manner as in production method 3-1 step 3-1-5 using compound [53] and R d OH such as cyclohexylmethanol, and the product is produced in step 4-6.
- R d OH such as cyclohexylmethanol
- the olefin reduction reaction may be a hydrogenation reaction in the presence of a catalyst such as palladium carbon or platinum carbon in a single or mixed solvent such as tetrahydrofuran, ethyl acetate, ethanol, methanol, water or the like.
- the title compound is a single stereoisomer, but the relative configuration of the tert-butyl group is undetermined.
- the precipitated solid was collected by filtration, washed with water, and dried under reduced pressure to give the title compound (0.062 g, yield 94%).
- the title compound is a single stereoisomer, but the relative configuration of the tert-butyl group is undetermined.
- Trifluoromethanesulfonic acid 4- [4-methoxy-6- (2-methoxymethoxy-6-trifluoromethylphenyl) -1,3,5-triazin-2-yl] phenyl ester
- 6-methyl-2-pyridinemethanol 0.099 g, 0.80 mmol
- triphenylphosphine 0.21 g, 0.80 mmol
- bis (2-methoxyethyl) azodicarboxylate 0.19 g, 0.80 mmol
- the reaction mixture was stirred for 10 minutes at room temperature.
- Water and ethyl acetate were added to the reaction mixture and the phases were separated. The organic layer was washed with saturated aqueous sodium hydrogen carbonate, and the organic layer was washed with saturated brine.
- sodium borohydride (0.30 g, 8.1 mmol) was added to the reaction mixture and stirred for 1 hour.
- a saturated aqueous ammonium chloride solution and ethyl acetate were added to the reaction mixture, and the mixture was separated.
- the organic layer was washed with saturated aqueous sodium hydrogen carbonate, and the organic layer was washed with saturated brine. This organic layer was dried over sodium sulfate, and then sodium sulfate was removed by filtration, followed by concentration under reduced pressure.
- biphenyl-2-yl-dicyclohexylphosphine (0.43 g, 1.2 mmol), palladium (II) acetate (0.070 g, 0.31 mmol), triethylamine (3.4 ml, 25 mmol) and 4,4,5,5 -Tetramethyl-1,3,2-dioxaborolane (2.7 ml, 18 mmol) was added, and the mixture was stirred at 80 ° C for 5 hours. Under ice-cooling, water was added dropwise to the reaction mixture, and ethyl acetate was added. After liquid separation, the organic layer was washed with saturated aqueous sodium hydrogen carbonate, and the organic layer was washed with saturated brine.
- N-chlorosuccinimide (0.91 g, 3.6 mmol) was added to a solution of 3- (tert-butyldimethylsilanyloxymethyl) -2-methyl-phenylamine (0.91 g, 3.6 mmol) in tetrahydrofuran (5.0 ml) at room temperature. g, 3.6 mmol).
- the mixture was stirred for 22 hours, n-hexane (10 ml) was added to the reaction mixture, and insoluble materials were removed by filtration.
- a solution of this residue in N, N-dimethylformamide (2.0 ml) was added with ice-cooled di-tert-butyl iminodicarboxylate (0.140 g, 0.64 mmol) and sodium hydride (0.026 g, 60 wt% oil dispersion).
- This reaction solution was added to a solution of di-tert-butyl iminodicarboxylate (0.32 g, 1.5 mmol) and cesium carbonate (1.2 g, 3.6 mmol) in N, N-dimethylformamide (3.0 ml) at room temperature. Stir for hours. Water and ethyl acetate were added to the reaction solution and the phases were separated, and the organic layer was washed with saturated brine. After drying this organic layer with magnesium sulfate, the magnesium sulfate was removed by filtration and concentrated under reduced pressure.
- a solution of this residue in N, N-dimethylformamide (1.5 ml) was added with ice-cooled di-tert-butyl iminodicarboxylate (0.089 g, 0.41 mmol) and sodium hydride (0.016 g, 60 wt% oil dispersion).
- N, N-dimethylformamide (15 ml) of 2-bromo-4-fluoro-1-trifluoromethylbenzene (1.5 g, 6.2 mmol) and sodium hydride (0.74 g, 60 wt% oil dispersion) under argon atmosphere )
- benzyl alcohol (0.64 ml, 6.2 mmol) under ice cooling, and the mixture was stirred for 0.5 hour.
- the reaction was stirred at 60 ° C. for 2 hours. Water and ethyl acetate were added to the reaction solution at room temperature, and the mixture was separated, and the organic layer was washed with saturated brine.
- N, N-dimethylformamide (3.4 g, 14 mmol) of (R) -3,3,3-trifluoro-2-hydroxy-2-methylpropionate (3.4 g, 14 mmol) obtained in (1) above 40 ml)
- sodium hydride (0.60 g, 60 wt% oil dispersion) was added to the solution under ice-cooling, and the mixture was stirred for 1 hour.
- methyl iodide 1.3 ml, 20 mmol
- Examples 1-1 to 1-267, Examples 2-1 to 2-130, and Examples 3-1 to 3-23 were obtained according to the above production method.
- Tables 1-1 to 1-34, Tables 2-1 to 2-15, and Tables 3-1 to 3-3 show the structural formulas and physical property data of Example compounds. The annotations in the table represent the following contents.
- Racemic compound D was reacted with pure enantiomeric compound E to give a diastereomeric mixture of compound F.
- Mer compound F2 was obtained.
- Compound F1 and Compound F2 are each a single stereoisomer, but the absolute configuration of the asymmetric carbon at the benzyl position has not been determined.
- the compound of Example No. 1-188 was obtained by hydrolysis of Compound F1 in the same manner as in Production Example 1 (6). Similarly, the compound of Example No. 1-189 was obtained from the compound F2.
- the compound of Example No. 1-188 and the compound of 1-189 are each a single stereoisomer, but the absolute configuration of the asymmetric carbon at the benzyl position has not been determined
- Compound N was purified by silica gel column chromatography in the same manner as in Annotation 1, and developed in the same manner as in Production Example 1 (6), with low polarity diastereomeric compound N1 (Merck TLC Silica gel 60G F254 25 Glassplates, developed)
- the compound of Example No. 1-200 and the compound of 1-201 are each a single stereoisomer, but the absolute configuration of the asymmetric carbon at the benzyl position has not been determined.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
(1)疼痛
mPGES-1ノックアウトマウスでは、WTマウスと比較して、急性炎症性疼痛モデルであるLPS刺激による痛覚反応評価における腹腔内PGE2産生量及び単位時間当たりの痛覚反応回数が有意に低下する。したがって、mPGES-1阻害剤は急性炎症性疼痛に対する鎮痛薬になると考えられる(非特許文献3、6)。
(2)リウマチ
スウェーデン人女性のmPGES-1遺伝子において、リウマチ発症リスクと重症度を上昇させるいくつかの一塩基多型が存在する。重症度を増加させる一塩基多型(Reference SNP ID number:rs23202821)を有するリウマチ患者の滑膜では、変異を有さない患者と比較してmPGES-1発現の増加が免疫組織学的に確認される(非特許文献5)。mPGES-1ノックアウトマウスでは、WTマウスと比較して、リウマチの動物モデルであるコラーゲン誘発関節炎モデルにおける関節内への炎症性細胞浸潤、関節の破壊及び四肢の腫脹が顕著に抑制される(非特許文献6)。したがって、mPGES-1阻害剤はリウマチの治療薬になると考えられる。
(3)変形性関節症
変形性関節炎症患者の半月板軟骨細胞ではmPGES-1のmRNA発現が増加している(非特許文献7)。mPGES-1阻害剤は、WTマウスと比較して、モノヨード酢酸を用いた変形性関節症モデルの痛覚反応を軽減させる(特許文献1)。したがって、mPGES-1阻害剤は変形性関節症の治療薬になると考えられる。
(4)発熱
mPGES-1ノックアウトマウスでは、WTマウスと比較して、LPS刺激による体温上昇が抑制される(非特許文献8)。したがって、mPGES-1阻害剤は解熱薬になると考えられる。
(5)アルツハイマー病
NSAIDsを長期間使用するとアルツハイマー病の発症及び進行を緩和する。mPGES-1ノックアウトマウスの初代培養脳神経細胞では、WTマウスの脳神経細胞と比較して、アミロイドβペプチド処置時のPGE2産生が抑制され、神経細胞死が起こらない(非特許文献9)。したがって、mPGES-1阻害剤はアルツハイマー病の治療薬になると考えられる。
(6)多発性硬化症
多発性硬化症患者のEP4遺伝子において、発症リスクを上昇させるいくつかの一塩基多型が存在する(Reference SNP ID number:rs9292777、rs4613763、rs1044063、rs6896969)。多発性硬化症患者脳室周囲の脱髄領域に存在するマクロファージでは、mPGES-1タンパクの発現が確認される。mPGES-1ノックアウトマウスでは、WTマウスと比較して、多発性硬化症の動物モデルである実験的自己免疫性脳脊髄炎モデルマウスの脊髄中PGE2産生が抑制され、麻痺の進行が抑制される(非特許文献10)。したがって、mPGES-1阻害剤は多発性硬化症の治療薬になると考えられる。
(7)動脈硬化
mPGES-1ノックアウトマウスでは、WTマウスと比較して、アテローム性動脈硬化症モデルである高脂肪餌負荷低密度リポタンパク質受容体欠損マウスの血管内皮細胞からのPGE2産生が低下し、アテローム形成が遅延する。血管内皮細胞からは、血小板機能抑制作用が知られるPGI2の産生が増加する(非特許文献11)。したがって、mPGES-1阻害剤は動脈硬化の予防又は治療薬になると考えらえる。
(8)緑内障、高眼圧症
緑内障とは視神経と視野に特徴的変化を生じる疾患であり、この視神経障害は通常、眼圧を十分に下降させることにより改善もしくは抑制しうる。緑内障は開放隅角緑内障と閉塞隅角緑内障に分類することができる。
mPGES-1遺伝子は、ヒト結膜において恒常的に高発現している(GEO accession No:GSE2513(Gene Expression Omnibus:http://www.ncbi.nlm.nih.gov/geo/))。緑内障患者の網膜では、健常人と比較してmPGES-1の発現が増加している。緑内障モデルである高眼圧イヌ及び高眼圧マウスの網膜では、正常動物と比較してmPGES-1の発現が増加している(GEO accession No:ヒトGSE2378、イヌGSE21879、マウスGSE3554)。
健常人にPGE2を点眼すると、点眼後2時間にわたって血管拡張をともなう眼圧の上昇が認められる(非特許文献12)。PGE2をウサギ結膜下に投与すると、毛様体の腫脹及び房水産生の増加により眼圧が上昇する(非特許文献13)。mPGES-1阻害時に増加しうるプロスタグランジンであるPGF2αやPGD2はウサギの眼圧を低下させる(非特許文献14)。PGF2α製剤は眼房水排出を促進し、眼圧を低下させる緑内障治療薬として使用されている。PGI2はウサギ眼圧に対して明確な作用を示さない。すなわち、mPGES-1阻害によるPGE2低下が房水産生を抑制するため、及び/又はシャントによるPGD2やPGF2αの増加は房水流出を促進するために、眼圧は低下すると考えられる。また、PGE2は網膜からの血管内皮細胞成長因子(VEGF)の発現を亢進させる(非特許文献15)。網膜において産生されたVEGFが前眼部へ移行することで虹彩における血管新生が生じ、隅角を閉塞することで眼圧が上昇する血管新生緑内障を生じるため、mPGES-1阻害剤は血管新生緑内障に対しても改善・予防的効果を示すと考えられる。さらに、PGE2産生が阻害されることによる抗炎症作用が考えられるため、既存のプロスタグランジン製剤(ラタノプロスト等)では慎重投与とされる、眼内炎症を有する患者にも適応可能と考えられる。したがって、mPGES-1阻害剤は様々な背景疾患を有する緑内障にも有効な治療薬になると考えられる。
(9)虚血性網膜疾患
糖尿病網膜症、糖尿病黄斑浮腫、網膜静脈閉塞症等の虚血性網膜疾患にはVEGFの過剰な分泌が中心的な役割を果たしている。PGE2はVEGFの発現を亢進させることから(非特許文献15)、mPGES-1阻害剤がこれらの病態を改善すると考えられる。
(10)全身性強皮症
全身性強皮症患者の皮膚では、健常人と比較してmPGES-1の発現が増加している。同様に、全身性強皮症モデルであるブレオマイシン誘発強皮症モデルマウスの皮膚では、正常マウスの皮膚と比較してmPGES-1の発現が増加している。mPGES-1ノックアウトマウスは、WTマウスと比較して、ブレオマイシン誘発強皮症モデルマウスの病変部の皮膚におけるマクロファージの集積が低下し、表皮の肥厚、細胞外基質の沈着及び膠原繊維量の増加が軽減した(非特許文献16)。したがって、mPGES-1阻害剤は全身性強皮症の治療薬になると考えられる。
(11)悪性腫瘍
mPGES-1ノックアウトマウスでは、WTマウスと比較して、大腸癌の動物モデルであるazoxymethane誘発大腸癌モデルマウスにおけるポリープ数及びサイズが著しく抑制された。mPGES-1ノックアウトマウスでは、WTマウスと比較して、大腸腫瘍組織におけるPGE2の産生が低下し、癌細胞の接着を阻害するPGI2やperoxisome proliferator-activated receptor γ(PPARγ)を介して細胞死を誘導するPGD2の産生量が増加した。mPGES-1ノックアウトマウスの脾臓に大腸癌又は肺癌細胞を移植したところ、WTマウスと比較して、移植後の脾臓腫瘍重量と肝臓への転移率の低下が認められた。mPGES-1ノックアウトマウスの骨髄由来マクロファージとのin vitro共培養系において肺癌細胞の増殖がWTマウスの骨髄由来マクロファージとの共培養系と比較して低下しており、宿主マクロファージ由来のPGE2が癌細胞の増殖に関与することが示された(非特許文献17)。したがって、mPGES-1阻害剤は大腸癌をはじめとする癌の増殖及び転移を抑制する抗癌薬となると考えられる。
(12)PGE2産生抑制が有効性を示す疾患
NSAIDsが有効性を示す炎症性症状及び/又はその状態と関連する痛みとして、例えば、関節炎、痛風、腎結石、尿路結石、頭痛、月経痛、歯痛、腰痛症、筋肉痛、肩関節周囲炎、頚肩腕症候群、顎関節症、及び手術後、外傷後並びに抜歯後の炎症・痛みが挙げられる。その他に、眼の急性及び慢性の非細菌性炎症が挙げられ、例えば、ブドウ膜炎、アレルギー性結膜炎及び内眼部手術における術後の炎症・眼痛が挙げられる。
NSAIDsが有効性を発揮する主な機序は、炎症促進性物質であるPGE2の産生抑制によると考えられている。mPGES-1阻害剤もPGE2の産生抑制作用を有することから、これらの疾患の治療薬になると考えられる。
すなわち、本発明は、以下のとおりである。
式[I]の化合物又はその薬学上許容される塩:
Xは、CH又はNであり、
環Cyは、
式:
式:
(1) ハロゲン、
(2) C1-6アルキル、
(3) シアノ、又は、
(4) ハロC1-4アルキルであり、
R2は、
(1) ハロゲン、
(2) ヒドロキシ、
(3) カルボキシ、
(4) C1-6アルキル、
(5) C1-6アルコキシ、
(6) ハロC1-4アルコキシ、
(7) ハロC1-4アルキル、
(8) C1-6アルキル-カルボニル、
(9) -C(O)NRa1Ra2(Ra1及びRa2は、それぞれ独立して、水素又はC1-6アルキルである。)、又は、
(10) -(CnH2n)-Rb
(nは、1、2、3又は4であり、-(CnH2n)-は直鎖状又は分枝鎖状のいずれであってもよく、
Rbは、
(a) ヒドロキシ、
(b) カルボキシ、
(c) C1-6アルコキシ、
(d) C1-6アルキル-カルボニルオキシ、
(e) -C(O)NRb1Rb2(Rb1及びRb2は、それぞれ独立して、水素又はC1-6アルキルである。)、
(f) -OC(O)NRb3Rb4(Rb3及びRb4は、それぞれ独立して、水素又はC1-6アルキルである。)、
(g) -NRb5C(O)NRb6Rb7(Rb5、Rb6及びRb7は、それぞれ独立して、水素又はC1-6アルキルである。)、
(h) -NRb8Rb9(Rb8及びRb9は、それぞれ独立して、水素、C1-6アルキル又はハロC1-4アルキルである。)、
(i) -NRb10S(O)2Rb11(Rb10及びRb11は、それぞれ独立して、水素、C1-6アルキル又はC3-7シクロアルキルである。)、
(j) -NRb12C(O)ORb13(Rb12は、水素又はC1-6アルキルであり、Rb13は、C1-6アルキルである。)、
(k) -NRb14C(O)Rb15(Rb14は、水素又はC1-6アルキルであり、
Rb15は、
(i) C6-10アリール、
(ii) C1-8アルキル(該C1-8アルキルは、ヒドロキシ、ハロC1-4アルキル、C1-6アルコキシ及びC6-10アリールからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)、
(iii) アダマンチル、又は、
(iv) C3-7シクロアルキル(該C3-7シクロアルキルは、C1-6アルキル、ハロゲン、ヒドロキシC1-6アルキル及びハロC1-4アルキルからなるグループから選択される1、2、3又は4個の置換基で置換されてもよく、及び/又は、ベンゼン環と縮合環を形成してもよい。)であるか、
或いは、Rb14とRb15は、Rb14が結合する窒素原子及びRb15が結合する炭素原子と一緒になって4、5又は6員のラクタムを形成してもよい。(該ラクタムは1、2又は3個のC1-6アルキルで置換されてもよく、及び/又は、ベンゼン環と縮合環を形成してもよい。))、
(l) 式:
(m) 式:
であり、
R3は、
(1) ハロゲン、
(2) ヒドロキシ、
(3) C1-6アルキル、又は、
(4) -ORc{Rcは、以下の(a)から(f)からなるグループから選択される1、2又は3個の置換基で置換されてもよいC1-6アルキルである;
(a) ハロゲン、
(b) ヒドロキシ、
(c) C1-6アルコキシ、
(d) -C(O)NRc1Rc2(Rc1及びRc2は、それぞれ独立して、水素又はC1-6アルキルである。)、
(e) C6-10アリール(該C6-10アリールは、
(i) ハロゲン、
(ii) ヒドロキシ、
(iii) C1-6アルキル、
(iv) C1-6アルコキシ、及び、
(v) ハロC1-4アルキルからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)、及び、
(f) 5又は6員の、1、2又は3個の窒素原子、酸素原子又は硫黄原子を含むヘテロアリール(該ヘテロアリールは、
(i) ハロゲン、
(ii) ヒドロキシ、
(iii) C1-6アルキル、
(iv) C1-6アルコキシ、及び、
(v) ハロC1-4アルキルからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)}
であり、
R4は、
(1) 水素、
(2) ハロゲン、
(3) C1-6アルキル、又は、
(4) C1-6アルコキシである。}
であり、
R5は、
(1) ハロゲン、
(2) ヒドロキシ、
(3) C1-6アルキルスルファニル、
(4) C1-6アルキル(該C1-6アルキルは、ハロゲン、C6-10アリール及びC1-6アルコキシからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)、
(5) C3-7シクロアルキル、
(6) -ORd{Rdは、
(a) C2-6アルキニル、
(b) 1、2又は3個のC1-6アルキルで置換されてもよいC3-7シクロアルキル、又は、
(c) C1-8アルキル(該C1-8アルキルは、以下の(i)から(v)からなるグループから選択される1、2又は3個の置換基で置換されてもよい;
(i) ハロゲン、
(ii) C6-10アリール、
(iii) C1-6アルコキシ、
(iv) C3-7シクロアルキル(該C3-7シクロアルキルは、C1-6アルキル及びハロC1-4アルキルからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)、及び、
(v) 4、5又は6員の、1、2又は3個の窒素原子、酸素原子又は硫黄原子を含む飽和ヘテロシクリル(該飽和ヘテロシクリルは、C1-6アルキル及びハロC1-4アルキルからなるグループから選択される1、2又は3個の置換基で置換されてもよい。))である。}、又は、
(7) 式:
(a) C1-6アルキル、
(b) C3-7シクロアルキル、
(c) 5又は6員の、1、2又は3個の窒素原子、酸素原子又は硫黄原子を含むヘテロアリール、又は、
(d) C6-10アリール(該C6-10アリールは、
(i) ハロゲン、
(ii) C1-6アルキル、
(iii) ハロC1-4アルキル、
(iv) C1-6アルコキシ、及び、
(v) ハロC1-4アルコキシからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)である。}
であり、
m1は0、1、2又は3であり、m1が2又は3のとき、各R5は独立して選ばれる。]
ただし、4,6-ビス-(2,5-ジメチル-フェニル)-1,3,5-トリアジン-2-オールは除く。
環Cyが
式:
である、[01]に記載の化合物又はその薬学上許容される塩。
環Cyが
式:
である、[01]に記載の化合物又はその薬学上許容される塩。
XがCHである、[01]から[03]のいずれかに記載の化合物又はその薬学上許容される塩。
XがNである、[01]から[03]のいずれかに記載の化合物又はその薬学上許容される塩。
R1が、
(1) クロロ、
(2) メチル、
(3) シアノ、又は、
(4) トリフルオロメチルである、[01]から[05]のいずれかに記載の化合物又はその薬学上許容される塩。
R4が水素である、[01]から[06]のいずれかに記載の化合物又はその薬学上許容される塩。
R2が、
-(CnH2n)-Rb(nは、1又は2であり、-(CnH2n)-は直鎖状又は分枝鎖状のいずれであってもよく、Rbは、
(a) -C(O)NRb1Rb2、
(b) -NRb5C(O)NRb6Rb7、
(c) -NRb10S(O)2Rb11、又は、
(d) -NRb14C(O)Rb15(Rb1、Rb2、Rb5、Rb6、Rb7、Rb10、Rb11、Rb14、及びRb15は[01]における定義と同義である。)である。)である、[01]、[02]、及び[04]から[07]のいずれかに記載の化合物又はその薬学上許容される塩。
R2が、-CH2-Rb(Rbは、[08]における定義と同義である。)である、[08]に記載の化合物又はその薬学上許容される塩。
R3が、
(1) ハロゲン、
(2) ヒドロキシ、
(3) C1-6アルキル、又は、
(4) -ORc{Rcは、以下の(a)から(f)からなるグループから選択される1、2又は3個の置換基で置換されてもよいC1-6アルキルである。
(a) ハロゲン、
(b) ヒドロキシ、
(c) C1-6アルコキシ、
(d) -C(O)NRc1Rc2(Rc1及びRc2は、それぞれ独立して、水素又はC1-6アルキルである。)、
(e) フェニル(該フェニルは、
(i) ハロゲン、
(ii) ヒドロキシ、
(iii) C1-6アルキル、
(iv) C1-6アルコキシ、及び、
(v) ハロC1-4アルキルからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)、及び、
(f) ピリジル(該ピリジルは、
(i) ハロゲン、
(ii) ヒドロキシ、
(iii) C1-6アルキル、
(iv) C1-6アルコキシ、及び、
(v) ハロC1-4アルキルからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)}である、[01]及び[03]から[09]のいずれかに記載の化合物又はその薬学上許容される塩。
m1が1であり、かつ
R5が、
式:
下記式:
[01]から[12]のいずれかに記載の化合物又はその薬学上許容される塩、及び薬学上許容される担体を含む、医薬組成物。
[01]から[12]のいずれかに記載の化合物又はその薬学上許容される塩を含む、mPGES-1阻害剤。
[01]から[12]のいずれかに記載の化合物又はその薬学上許容される塩を含む、疼痛、リウマチ、発熱、変形性関節症、動脈硬化、アルツハイマー病、多発性硬化症、緑内障、高眼圧症、虚血性網膜疾患、全身性強皮症、悪性腫瘍及びPGE2産生抑制が有効性を示す疾患の治療剤又は予防剤。
[01]から[12]のいずれかに記載の化合物又はその薬学上許容される塩、及び一種類以上の他の緑内障治療剤を組み合わせてなる緑内障及び高眼圧症の治療剤又は予防剤。
薬学上有効量の、[01]から[12]のいずれかに記載の化合物又はその薬学上許容される塩をヒトに投与することを含む、mPGES-1の阻害方法。
薬学上有効量の、[01]から[12]のいずれかに記載の化合物又はその薬学上許容される塩をヒトに投与することを含む、疼痛、リウマチ、発熱、変形性関節症、動脈硬化、アルツハイマー病、多発性硬化症、緑内障、高眼圧症、虚血性網膜疾患、全身性強皮症、悪性腫瘍及びPGE2産生抑制が有効性を示す疾患の治療方法又は予防方法。
薬学上有効量の、一種類以上の他の緑内障治療剤をさらにヒトに投与することを含む、[18]記載の緑内障及び高眼圧症の治療方法又は予防方法。
mPGES-1阻害剤を製造するための[01]から[12]のいずれかに記載の化合物又はその薬学上許容される塩の使用。
疼痛、リウマチ、発熱、変形性関節症、動脈硬化、アルツハイマー病、多発性硬化症、緑内障、高眼圧症、虚血性網膜疾患、全身性強皮症、悪性腫瘍及びPGE2産生抑制が有効性を示す疾患の治療剤又は予防剤を製造するための[01]から[12]のいずれかに記載の化合物又はその薬学上許容される塩の使用。
(1) ハロゲン、
(2) ヒドロキシ、
(3) カルボキシ、
(5) C1-6アルコキシ、
(6) ハロC1-4アルコキシ、
(7) ハロC1-4アルキル、
(8) C1-6アルキル-カルボニル、
(9) -C(O)NRa1Ra2(Ra1及びRa2は前記と同義である。)、又は、
(10) -(CnH2n)-Rb(Rbは前記と同義である。)であり、
より好ましくは、
(10) -(CnH2n)-Rb(Rbは前記と同義である。)である。
Rbは、好ましくは、
(g) -NRb5C(O)NRb6Rb7(Rb5、Rb6及びRb7は前記と同義である。)、
(h) -NRb8Rb9(Rb8及びRb9は前記と同義である。)、
(i) -NRb10S(O)2Rb11(Rb10及びRb11は前記と同義である。)、
(j) -NRb12C(O)ORb13(Rb12及びRb13は前記と同義である。)、又は
(k) -NRb14C(O)Rb15(Rb14及びRb15は前記と同義である。)であり、
より好ましくは、
(k) -NRb14C(O)Rb15(Rb14及びRb15は前記と同義である。)である。
nは、好ましくは1又は2であり、より好ましくは1である。
Rb14は、好ましくは水素又はメチルであり、より好ましくは水素である。
Rb15は、好ましくは、
(ii) C1-4アルキル(該C1-4アルキルは、ヒドロキシ、トリフルオロメチル、C1-4アルコキシ及びフェニルからなるグループから選択される1又は2個の置換基で置換されてもよい。)、又は、
(iv) C3-7シクロアルキル(該C3-7シクロアルキルは、C1-4アルキル、ハロゲン、ヒドロキシC1-4アルキル及びトリフルオロメチルからなるグループから選択される1、2、3又は4個の置換基で置換されてもよい。)であり、
より好ましくは、1又は2個のトリフルオロメチル並びにC1-4アルコキシで置換されてもよいC1-4アルキル、又は1個のトリフルオロメチルで置換されてもよいC3-7シクロアルキルであり、さらに好ましくは、tert-ブチル、3,3,3-トリフルオロ-2,2-ジメチルプロピル、3,3,3-トリフルオロ-2-メトキシ-2-メチルプロピル、3,3,3-トリフルオロ-2-メチル-2-トリフルオロメチルプロピル、又は1-トリフルオロメチルシクロプロピルである。
(3) C1-6アルキル、又は、
(4) -ORc{Rcは、以下の(a)から(f)からなるグループから選択される1、2又は3個の置換基で置換されてもよいC1-6アルキルである;
(a) ハロゲン、
(b) ヒドロキシ、
(c) C1-6アルコキシ、
(d) -C(O)NRc1Rc2(Rc1及びRc2は前記と同義である。)、
(e) C6-10アリール(該C6-10アリールは、
(i) ハロゲン、
(ii) ヒドロキシ、
(iii) C1-6アルキル、
(iv) C1-6アルコキシ、及び、
(v) ハロC1-4アルキルからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)、及び、
(f) 5又は6員の、1、2又は3個の窒素原子、酸素原子又は硫黄原子を含むヘテロアリール(該ヘテロアリールは、
(i) ハロゲン、
(ii) ヒドロキシ、
(iii) C1-6アルキル、
(iv) C1-6アルコキシ、及び、
(v) ハロC1-4アルキルからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)}
である。
Rcは、好ましくは、以下の(e)及び(f)から選択される1又は2個の置換基で置換されてもよいメチル;
(e) C6-10アリール(該C6-10アリールは、
(i) ハロゲン、
(ii) ヒドロキシ、
(iii) C1-6アルキル、
(iv) C1-6アルコキシ、及び、
(v) ハロC1-4アルキルからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)、及び、
(f) 5又は6員の、1、2又は3個の窒素原子、酸素原子又は硫黄原子を含むヘテロアリール(該ヘテロアリールは、
(i) ハロゲン、
(ii) ヒドロキシ、
(iii) C1-6アルキル、
(iv) C1-6アルコキシ、及び、
(v) ハロC1-4アルキルからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)であり、
より好ましくは、以下の(e1)及び(f1)から選択される1又は2個の置換基で置換されてもよいメチル;
(e1) フェニル(該フェニルは、
(i) ハロゲン、
(ii) ヒドロキシ、
(iii) C1-6アルキル、
(iv) C1-6アルコキシ、及び、
(v) ハロC1-4アルキルからなるグループから選択される1又は2個の置換基で置換されてもよい。)、及び、
(f1) ピリジル(該ピリジルは、
(i) ハロゲン、
(ii) ヒドロキシ、
(iii) C1-6アルキル、
(iv) C1-6アルコキシ、及び、
(v) ハロC1-4アルキルからなるグループから選択される1又は2個の置換基で置換されてもよい。)である。
(1) ハロゲン、
(4) C1-6アルキル(該C1-6アルキルは、ハロゲン、C6-10アリール及びC1-6アルコキシからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)、
(5) C3-7シクロアルキル、
(6) -ORd{Rdは、
(a) C2-6アルキニル、
(b) 1、2又は3個のC1-6アルキルで置換されてもよいC3-7シクロアルキル、又は、
(c) C1-8アルキル(該C1-8アルキルは、以下の(i)から(v)からなるグループから選択される1、2又は3個の置換基で置換されてもよい;
(i) ハロゲン、
(ii) C6-10アリール、
(iii) C1-6アルコキシ、
(iv) C3-7シクロアルキル(該C3-7シクロアルキルは、C1-6アルキル及びハロC1-4アルキルからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)、及び、
(v) 4、5又は6員の、1個の酸素原子を含む飽和ヘテロシクリル(該飽和ヘテロシクリルは、C1-6アルキル及びハロC1-4アルキルからなるグループから選択される1、2又は3個の置換基で置換されてもよい。))である。}、又は
(7) 式:
(a) C1-6アルキル、
(b) C3-7シクロアルキル、
(c) 5又は6員の、1、2又は3個の窒素原子、酸素原子又は硫黄原子を含むヘテロアリール、又は、
(d) C6-10アリール(該C6-10アリールは、
(i) ハロゲン、
(ii) C1-6アルキル、
(iii) ハロC1-4アルキル、
(iv) C1-6アルコキシ、及び、
(v) ハロC1-4アルコキシからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)である。}
である。
Rdは、好ましくは、C1-8アルキル(該C1-8アルキルは、以下の(i)から(v)からなるグループから選択される1、2又は3個の置換基で置換されてもよい;
(i) ハロゲン、
(ii) C6-10アリール、
(iii) C1-6アルコキシ、
(iv) C3-7シクロアルキル(該C3-7シクロアルキルは、C1-6アルキル及びハロC1-4アルキルからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)、及び、
(v) 4、5又は6員の、1個の酸素原子を含む飽和ヘテロシクリル(該飽和ヘテロシクリルは、C1-6アルキル及びハロC1-4アルキルからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)である。
Reは、好ましくは、
(b) C3-7シクロアルキル、
(c) 5又は6員の、1、2又は3個の窒素原子、酸素原子又は硫黄原子を含むヘテロアリール、又は、
(d) C6-10アリール(該C6-10アリールは、
(i) ハロゲン、
(ii) C1-6アルキル、
(iii) ハロC1-4アルキル、
(iv) C1-6アルコキシ、及び、
(v) ハロC1-4アルコキシからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)である。
X、R1、R2、R4は前記式[I]における定義と同様であり、
R5は、
(1) ハロゲン、
(4) C1-6アルキル(該C1-6アルキルは、ハロゲン、C6-10アリール及びC1-6アルコキシからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)、
(5) C3-7シクロアルキル、又は
(6) -ORd{Rdは、
(a) C2-6アルキニル、又は、
(c) C1-8アルキル(該C1-8アルキルは、以下の(i)から(v)からなるグループから選択される1、2又は3個の置換基で置換されてもよい;
(i) ハロゲン、
(ii) C6-10アリール、
(iii) C1-6アルコキシ、
(iv) C3-7シクロアルキル(該C3-7シクロアルキルは、C1-6アルキル及びハロC1-4アルキルからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)、及び
(v) 4、5又は6員の、1、2又は3個の窒素原子、酸素原子又は硫黄原子を含む飽和ヘテロシクリル(該飽和ヘテロシクリルは、C1-6アルキル及びハロC1-4アルキルからなるグループから選択される1、2又は3個の置換基で置換されてもよい。))である。}であり、
m7は0、1又は2であり、m7が2のとき、各R5は独立して選ばれる。]
で表される化合物である。
X、R3、R4は前記式[I]における定義と同様であり、
R1は、クロロ又はトリフルオロメチルであり、
R5は、
(4) C1-6アルキル(該C1-6アルキルは、ハロゲン、C6-10アリール及びC1-6アルコキシからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)、
(6) -ORd{Rdは、
C1-8アルキル(該C1-8アルキルは、以下の(i)から(iv)からなるグループから選択される1、2又は3個の置換基で置換されてもよい;
(i) ハロゲン、
(ii) C6-10アリール、
(iii) C1-6アルコキシ、及び
(iv) C3-7シクロアルキル(該C3-7シクロアルキルは、C1-6アルキル及びハロC1-4アルキルからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)}、又は
(7) 式:
(b) C3-7シクロアルキル、又は
(d) C6-10アリール(該C6-10アリールは、
(i) ハロゲン、
(ii) C1-6アルキル、
(iii) ハロC1-4アルキル、
(iv) C1-6アルコキシ、及び、
(v) ハロC1-4アルコキシからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)}であり、
m7は0、1又は2であり、m7が2のとき、各R5は独立して選ばれる。]
で表される化合物である。
Xは、CH又はNであり、
Rb15は、
(ii) C1-4アルキル(該C1-4アルキルは、トリフルオロメチル及びメトキシから選択される1又は2個の置換基で置換されてもよい。)、又は、
(iv) トリフルオロメチルで置換されてもよいC3-7シクロアルキル、であり、
R5aは、
(1) フルオロ、
(4) メチル(該メチルは、3個のフルオロで置換されてもよい。)、又は
(6) -ORd{Rdは、
(a) C2-4アルキニル、又は、
(c) 1個のC3-7シクロアルキルで置換されてもよいC1-4アルキル(該C3-7シクロアルキルは、1個のトリフルオロメチルで置換されてもよい。)}であり、
R5bは、
(1) ハロゲン、
(4) C1-4アルキル、又は
(5) シクロプロピルであり、
m8は0又は1である。]
で表される化合物である。
様々な形態の薬学上許容される塩が当分野で周知であり、例えば以下の参考文献に記載されている。
(a) Bergeら、J. Pharm. Sci., 66, p 1-19(1977)、
(b) Stahlら、「Handbook of Pharmaceutical Salt: Properties, Selection, and Use」(Wiley-VCH, Weinheim, Germany, 2002)、
(c) Paulekuhnら、J. Med. Chem., 50, p 6665-6672 (2007)
無機酸との塩として、例えば、塩酸、硝酸、硫酸、リン酸、臭化水素酸等との塩が挙げられる。
有機酸との塩として、例えば、シュウ酸、マレイン酸、クエン酸、フマル酸、乳酸、リンゴ酸、コハク酸、酒石酸、酢酸、トリフルオロ酢酸、グルコン酸、アスコルビン酸、メタンスルホン酸、ベンゼンスルホン酸、p-トルエンスルホン酸等との塩が挙げられる。
さらに、有機酸との塩として、例えば、アジピン酸、アルギン酸、4-アミノサリチル酸、アンヒドロメチレンクエン酸、安息香酸、エデト酸カルシウム、ショウノウ酸、カンファ-10-スルホン酸、炭酸、エデト酸、エタン-1,2-ジスルホン酸、ドデシル硫酸、エタンスルホン酸、グルコヘプトン酸、グルクロン酸、グリコリルアルサニル酸、ヘキシルレソルシン酸、フッ化水素酸、ヨウ化水素酸、ヒドロキシ-ナフトエ酸、2-ヒドロキシ-1-エタンスルホン酸、ラクトビオン酸、マンデル酸、メチル硫酸、メチル硝酸、メチレンビス(サリチル酸)、ガラクタル酸、ナフタレン-2-スルホン酸、2-ナフトエ酸、1,5-ナフタレンジスルホン酸、オレイン酸、パモ酸、パントテン酸、ペクチン酸、ピクリン酸、プロピオン酸、ポリガラクツロン酸、サリチル酸、ステアリン酸、タンニン酸、テオクル酸、チオシアン酸、またはウンデカン酸等との塩が挙げられる。
無機塩基との塩として、例えば、ナトリウム塩、カリウム塩、カルシウム塩、マグネシウム塩、アンモニウム塩等が挙げられる。
さらに、無機塩基との塩として、例えばアルミニウム、バリウム、ビスマス、リチウム、または亜鉛との塩が挙げられる。
有機塩基との塩として、例えば、メチルアミン、ジエチルアミン、トリメチルアミン、トリエチルアミン、エタノールアミン、ジエタノールアミン、トリエタノールアミン、エチレンジアミン、トリス(ヒドロキシメチル)メチルアミン、ジシクロヘキシルアミン、N,N’-ジベンジルエチレンジアミン、グアニジン、ピリジン、ピコリン、コリン、シンコニン、メグルミン等との塩が挙げられる。
さらに、有機塩基との塩として、例えば、アレコリン、ベタイン、クレミゾール、N-メチルグルカミン、N-ベンジルフェネチルアミン、または、トリス(ヒドロキシメチル)メチルアミンとの塩が挙げられる。
アミノ酸との塩として、例えば、リジン、アルギニン、アスパラギン酸、グルタミン酸等との塩が挙げられる。
上記の塩のうち、好ましくは塩酸、硫酸又はp-トルエンスルホン酸との塩である。
公知の方法に従って、式[I]で表される化合物と、無機塩基、有機塩基、無機酸、有機酸、又はアミノ酸とを反応させることにより、各々の塩を得ることができる。
公知の方法に従って、その溶媒和物を得ることができる。
本発明化合物は、炭素二重結合を有する場合がある。その場合、本発明化合物は、E体、Z体、又はE体とZ体の混合物として存在し得る。
本発明化合物は、シス/トランス異性体として認識すべき立体異性体が存在する場合がある。その場合、本発明化合物は、シス体、トランス体、又はシス体とトランス体の混合物として存在し得る。
本発明化合物は、1又はそれ以上の不斉炭素を有する場合がある。その場合、本発明化合物は、単一のエナンチオマー、単一のジアステレオマー、エナンチオマーの混合物或いはジアステレオマーの混合物として存在する場合がある。
本発明化合物は、アトロプ異性体として存在する場合がある。その場合、本発明化合物は、個々のアトロプ異性体又はアトロプ異性体の混合物として存在し得る。
本発明化合物は、上記の異性体を生じさせる構造上の特徴を同時に複数含むことがある。また、本発明化合物は、上記の異性体をあらゆる比率で含み得る。
例えば、ジアステレオマー混合物は、エナンチオマーの混合物と、実質的に純粋なエナンチオマーであってキラル補助剤(chiral auxiliary)として知られている化合物とを反応させることによって調製することができる。当該ジアステレオマー混合物は、前記の通りそれぞれのジアステレオマーに分離することができる。分離されたジアステレオマーを、付加されたキラル補助剤を開裂で除去することにより、目的のエナンチオマーに変換することができる。
また、当分野でよく知られた、キラル固定相を使用するクロマトグラフィー法によって、化合物のエナンチオマーの混合物を直接分離することもできる。
或いは、化合物のどちらか一方のエナンチオマーを、実質的に純粋な光学活性出発原料を用いることにより、又は、プロキラル(prochiral)な中間体に対しキラル補助剤や不斉触媒を用いた立体選択的合成(不斉誘導)を行うことによって得ることもできる。
β遮断薬として、例えば、マレイン酸チモロール、塩酸ベフノロール、塩酸カルテオロール、塩酸ベタキソロール、ニプラジロール、塩酸レボブノロール等が挙げられる。
下記製造方法に記載はなくとも、必要に応じて官能基に保護基を導入し、後工程で脱保護を行う;各製法及び工程の順序を入れ替える;反応の進行を促進するために、例示した試薬以外の試薬を適宜用いる等の工夫により効率よい製造を実施してもよい。
また、各工程において、反応後の処理は、通常行われる方法で行えばよく、単離精製は、必要に応じて、結晶化、再結晶、蒸留、分液、シリカゲルカラムクロマトグラフィー、分取HPLC等の慣用される方法を適宜選択し、また組み合わせて行えばよい。場合によっては、単離精製せずに次の工程に進めることができる。
また、塩を形成しうる中間体は塩として得てもよく、また塩として反応に用いてもよい。このような塩の例として、アミノ基を有する中間体の塩酸塩が挙げられる。
R6はメチル、エチル等のC1-6アルキル又はベンジル;
Zは-B(OH)2、-B(OR7)2(ここでR7はC1-4アルキル又は一方のR7が他方のR7と結合して環を形成してもよい)、-BF3、式
X、Cy、R5、m1は前記式[I]における定義と同義である。)
化合物[1]と化合物[2]との鈴木カップリング反応により、化合物[3]を得ることができる。例えば、溶媒中、加熱下で塩基及びパラジウム触媒の存在下、化合物[1]を化合物[2]と反応させることにより化合物[3]を得ることができる。必要に応じて配位子を添加しても良い。鈴木カップリング反応が二度進行することを防ぐため、化合物[2]に対して1.5当量以上の化合物[1]を用いることが好ましい。
反応に用いるパラジウム触媒としては、例えば、酢酸パラジウム、テトラキストリフェニルホスフィンパラジウム、ビス(トリフェニルホスフィン)パラジウムジクロリド、(ビス(ジフェニルホスフィノ)フェロセン)パラジウムジクロリド-塩化メチレン錯体等が挙げられる。
反応に用いる塩基としては、リン酸カリウム、炭酸ナトリウム、炭酸水素ナトリウム、炭酸カリウム、酢酸カリウム、酢酸ナトリウム、フッ化セシウム等のアルカリ金属塩等の無機塩基、トリエチルアミン等の有機塩基が挙げられる。
反応に用いる配位子としては、トリフェニルホスフィン、トリシクロヘキシルホスフィン、2,2’-ビス(ジフェニルホスフィノ)-1,1’-ビナフタレン、2-ジシクロヘキシルホスフィノ-2’,6’-ジメトキシビフェニル等の有機リン系配位子等が挙げられる。
反応に用いる溶媒としては、1,4-ジオキサン、テトラヒドロフラン、ジエチルエーテル、1,2-ジメトキシエタン、シクロペンチルメチルエーテル等のエーテル系溶媒;メタノール、エタノール、1-プロパノール、2-プロパノール等のアルコール系溶媒;トルエン、キシレン、ヘキサン等の炭化水素系溶媒;N,N-ジメチルホルムアミド、N,N-ジメチルアセトアミド、ジメチルスルホキシド、アセトニトリル等の極性溶媒;それらの混合溶媒、及びそれらと水との混合溶媒が挙げられる。
化合物[1]は2,4-ジクロロ-6-メトキシ-1,3,5-トリアジンのような市販品であってもよく、又は市販品を適宜当業者に周知の方法で変換して得られるものであってもよい。
鈴木カップリング反応については、例えば次のような総説が知られている(SUZUKI, A et al. Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds. Chem Rev. 1995, Vol.95, pages 2457-2483.)。
化合物[3]と化合物[4]との鈴木カップリング反応により、化合物[5]を得ることができる。例えば、溶媒中、加熱下で塩基及びパラジウム触媒の存在下、化合物[3]を化合物[4]と反応させることにより化合物[5]を得ることができる。必要に応じて配位子を添加しても良い。
反応に用いるパラジウム触媒としては、例えば、酢酸パラジウム、テトラキストリフェニルホスフィンパラジウム、ビス(トリフェニルホスフィン)パラジウムジクロリド、(ビス(ジフェニルホスフィノ)フェロセン)パラジウムジクロリド-塩化メチレン錯体等が挙げられる。
反応に用いる塩基としては、リン酸カリウム、炭酸ナトリウム、炭酸水素ナトリウム、炭酸カリウム、酢酸カリウム、酢酸ナトリウム、フッ化セシウム等のアルカリ金属塩等の無機塩基、トリエチルアミン等の有機塩基が挙げられる。
反応に用いる配位子としては、トリフェニルホスフィン、トリシクロヘキシルホスフィン、2,2’-ビス(ジフェニルホスフィノ)-1,1’-ビナフタレン、2-ジシクロヘキシルホスフィノ-2’,6’-ジメトキシビフェニル等の有機リン系配位子等が挙げられる。
反応に用いる溶媒としては、1,4-ジオキサン、テトラヒドロフラン、ジエチルエーテル、1,2-ジメトキシエタン、シクロペンチルメチルエーテル等のエーテル系溶媒;メタノール、エタノール、1-プロパノール、2-プロパノール等のアルコール系溶媒;トルエン、キシレン、ヘキサン等の炭化水素系溶媒;N,N-ジメチルホルムアミド、N,N-ジメチルアセトアミド、ジメチルスルホキシド、アセトニトリル等の極性溶媒;それらの混合溶媒、及びそれらと水との混合溶媒が挙げられる。
化合物[5]のアルコキシを加水分解でヒドロキシに変換することにより、化合物[I]を得ることができる。例えば、R6がC1-6アルキルの場合、化合物[5]を溶媒中、塩基の存在下、室温から加熱下で反応させた後、得られた溶液を中性にすることにより化合物[I]を得ることができる。
反応に用いる塩基としては、水酸化リチウム、水酸化ナトリウム、水酸化カリウム、ナトリウムメトキシド等が挙げられる。
反応に用いる溶媒としては、メタノール、エタノール、1-プロパノール、2-プロパノール等のアルコール系溶媒と水との混合溶媒;又はそれらと1,4-ジオキサン、テトラヒドロフラン、ジエチルエーテル、1,2-ジメトキシエタン、シクロペンチルメチルエーテル等のエーテル系溶媒との混合溶媒が挙げられる。
化合物[2]は例えば製造方法1-2により得ることができる。
X、R5、m1は前記式[I]における定義と同義であり、Zは前記製造方法1-1における定義と同義である。)
化合物[2]は化合物[6]をホウ素化することにより得ることができる。例えば、加熱下で塩基及びパラジウム触媒の存在下、化合物[6]をホウ素試薬と反応させることにより化合物[2]を得ることができる。必要に応じて配位子を添加しても良い。
反応に用いるホウ素試薬としては、4,4,4',4',5,5,5',5'-オクタメチル-2,2'-ビ-1,3,2-ジオキサボロラン、5,5,5',5'-テトラメチル-2,2'-ビ-1,3,2-ジオキサボリナン、テトラヒドロキシジボロン、4,4,5,5-テトラメチル-1,3,2-ジオキサボロラン等が挙げられる。
反応に用いるパラジウム触媒としては、例えば、酢酸パラジウム、テトラキストリフェニルホスフィンパラジウム、ビス(トリフェニルホスフィン)パラジウムジクロリド、(ビス(ジフェニルホスフィノ)フェロセン)パラジウムジクロリド-塩化メチレン錯体等が挙げられる。
反応に用いる塩基としては、リン酸カリウム、炭酸ナトリウム、炭酸水素ナトリウム、炭酸カリウム、酢酸カリウム、酢酸ナトリウム、フッ化セシウム等のアルカリ金属塩等の無機塩基、トリエチルアミン等の有機塩基が挙げられる。
反応に用いる配位子としては、トリフェニルホスフィン、トリシクロヘキシルホスフィン、2,2’-ビス(ジフェニルホスフィノ)-1,1’-ビナフタレン、2-ジシクロヘキシルホスフィノ-2’,6’-ジメトキシビフェニル等の有機リン系配位子等が挙げられる。
反応に用いる溶媒としては、1,4-ジオキサン、テトラヒドロフラン、ジエチルエーテル、1,2-ジメトキシエタン、シクロペンチルメチルエーテル等のエーテル系溶媒;メタノール、エタノール、1-プロパノール、2-プロパノール等のアルコール系溶媒;トルエン、キシレン、ヘキサン等の炭化水素系溶媒;N,N-ジメチルホルムアミド、N,N-ジメチルアセトアミド、ジメチルスルホキシド、アセトニトリル等の極性溶媒;それらの混合溶媒、及びそれらと水との混合溶媒が挙げられる。
また、化合物[6]を溶媒中、-78℃から室温下で有機金属試薬を加えた後、生成物を-78℃から室温下でホウ素化合物と反応させることによっても、化合物[2]を得ることができる。
反応に用いる有機金属試薬としては、n-ブチルリチウム、tert-ブチルリチウム、イソプロピルマグネシウムクロリド等が挙げられる。
反応に用いるホウ素試薬としては、ホウ酸トリメチル、ホウ酸トリイソプロピル、2-イソプロポキシ-4,4,5,5-テトラメチル-1,3,2-ジオキサボロラン等が挙げられる。
反応に用いる溶媒としては、1,4-ジオキサン、テトラヒドロフラン、ジエチルエーテル、1,2-ジメトキシエタン、シクロペンチルメチルエーテル等のエーテル系溶媒;トルエン、キシレン、ヘキサン等の炭化水素系溶媒、及びそれらの混合溶媒が挙げられる。
化合物[6]は、一例として以下に示すような市販品であってもよく、又は市販品を適宜当業者に周知の方法で変換して得られるものであってもよい。
化合物[4]は例えば製造方法1-3により得ることができる。
化合物[4]は化合物[8a]又は[8b]である。製造方法1-2の工程1-2と同様の方法で、化合物[7a]又は[7b]をホウ素化することにより化合物[8a]又は[8b]、すなわち化合物[4]を得ることができる。
化合物[7a]又は[7b]は、2-ブロモ-4-メチルベンゾニトリルや2-ブロモ-3-メチルフェノールような市販品であってもよく、又は市販品を適宜当業者に周知の方法で変換して得られるものであってもよい。
環Cyの置換基を適宜変換することによって、例えば式[I]において環Cyが式
である化合物[I-a1]を得ることができる。
CnH2nが直鎖状の場合は製造方法2-1が好ましく、CnH2nが分岐鎖状の場合は製造方法2-3が好ましい。
C1-6AlkylはC1-6アルキル;
tは0、1、2又は3であり、-(CtH2t)-は直鎖状又は分枝鎖状のいずれであってもよく;
Hal2はブロモ又はヨード;
Pvはメトキシメチル等のヒドロキシ基の保護基;
Pwはtert-ブトキシカルボニル等のアミノ基の保護基;
L2はクロロ、ブロモ等のハロゲン、メタンスルホニルオキシ、p-トルエンスルホニルオキシ等の脱離基;
R1、R4、R6、Rb15、nは前記式[I]における定義と同義であり、Zは前記製造方法1-1における定義と同義である。)
化合物[9]のエステルを加水分解でカルボキシに変換することにより、化合物[10]を得ることができる。例えば、化合物[9]を溶媒中、塩基の存在下、室温から加熱下で反応させた後、得られた溶液を中性にすることにより化合物[10]を得ることができる。
反応に用いる塩基としては、水酸化リチウム、水酸化ナトリウム、水酸化カリウム、ナトリウムメトキシド等が挙げられる。
反応に用いる溶媒としては、メタノール、エタノール、1-プロパノール、2-プロパノール等のアルコール系溶媒と水との混合溶媒;又はそれらと1,4-ジオキサン、テトラヒドロフラン、ジエチルエーテル、1,2-ジメトキシエタン、シクロペンチルメチルエーテル等のエーテル系溶媒との混合溶媒が挙げられる。
化合物[9]は例えば以下に示すような市販品であってもよく、又は市販品を適宜当業者に周知の方法で変換して得られるものであってもよい。
化合物[10]のカルボキシを還元でヒドロキシに変換することにより、化合物[11]を得ることができる。例えば、化合物[10]を溶媒中、氷冷下から室温下で還元剤と反応させることにより化合物[11]を得ることができる。
反応に用いる還元剤としては、水素化アルミニウムリチウム、水素化ジイソブチルアルミニウム、水素化ビス(2-メトキシエトキシ)アルミニウムナトリウム、ボラン-テトラヒドロフラン錯体等が挙げられる。
反応に用いる溶媒としては、テトラヒドロフラン、ジエチルエーテル、1,2-ジメトキシエタン、シクロペンチルメチルエーテル、トルエン、キシレン、ヘキサン等及びそれらの混合溶媒が挙げられる。
化合物[11]のヒドロキシ基を保護することにより、化合物[12]を得ることができる。保護反応は、採用される保護基に応じた公知の方法で行えばよい。
例えばPvがメトキシメチルである場合、テトラヒドロフラン、1,2-ジメトキシエタン、シクロペンチルメチルエーテル、N,N-ジメチルホルムアミド等の溶媒中、水素化ナトリウム等の塩基の存在下、氷冷から室温下で化合物[11]をクロロメチルメチルエーテルと反応させることにより、化合物[12]を得ることができる。
製造方法1-2の工程1-2と同様の方法で、化合物[12]をホウ素化することにより化合物[13]を得ることができる。
製造方法1-1の工程1-1-2と同様の方法で、化合物[3]と化合物[13]との鈴木カップリング反応により化合物[14]を得ることができる。
常法のヒドロキシ脱保護反応で、化合物[14]のPvを除去することにより、化合物[15]を得ることができる。脱保護反応は、採用される保護基に応じた公知の方法で行えばよい。
例えばPvがメトキシメチルである場合、クロロホルム、1,4-ジオキサン、テトラヒドロフラン、ジエチルエーテル、1,2-ジメトキシエタン、シクロペンチルメチルエーテル、酢酸エチル、エタノール、メタノール、水等の単独又は混合溶媒中、塩酸、トリフルオロ酢酸、メタンスルホン酸等の酸で処理をすればよい。
また、製造方法1-1の工程1-1-2と同様の方法で、化合物[3]と式
で表される化合物[23]との鈴木カップリング反応によっても、化合物[15]を得ることができる。
化合物[15]のヒドロキシを脱離基L2に変換することにより化合物[16]を得ることができる。例えば、L2がメタンスルホニルオキシである場合、化合物[15]を溶媒中、塩基存在下で、室温下でメタンスルホニルクロライドと反応させることにより、化合物[16]を得ることができる。L2がブロモである場合、化合物[15]を溶媒中、トリフェニルホスフィン存在下で、氷冷から室温下で四臭化炭素と反応させることにより、化合物[16]を得ることができる。
反応に用いる塩基としては、トリエチルアミン、ピリジン等が挙げられる。
反応に用いる溶媒としては、1,4-ジオキサン、テトラヒドロフラン、ジエチルエーテル、1,2-ジメトキシエタン、シクロペンチルメチルエーテル等のエーテル系溶媒;トルエン、ヘキサン、キシレン等の炭化水素系溶媒;ジクロロメタン、クロロホルム等のハロゲン系溶媒;N,N-ジメチルホルムアミド、N,N-ジメチルアセトアミド、ジメチルスルホキシド、アセトニトリル等の極性溶媒が挙げられる。
上記トリフェニルホスフィンに代えてジメチルスルフィドを用いることができ、上記四臭化炭素に代えてN-ブロモスクシンイミドを用いることができる。
上記メタンスルホニルクロライドに代えて、p-トルエンスルホニルクロライドや、ベンゼンスルホニルクロライドを用いることができる。
化合物[16]を溶媒中、塩基の存在下、室温から加熱下で化合物[17]と反応させることにより、化合物[18]を得ることができる。保護基Pwとしては、例えばtert-ブトキシカルボニルが挙げられる。
反応に用いる塩基としては、炭酸セシウム、リン酸カリウム、炭酸ナトリウム、炭酸カリウム等のアルカリ金属塩等の無機塩基が挙げられる。
反応に用いる溶媒としては、N,N-ジメチルホルムアミド、N,N-ジメチルアセトアミド、ジメチルスルホキシド、アセトニトリル等の極性溶媒が挙げられる。
化合物[18]の保護基Pwを、常法のアミン脱保護反応で除去することにより、化合物[19]を得ることができる。脱保護反応は、採用される保護基に応じた公知の方法で行えばよい。
例えばPwがtert-ブトキシカルボニルである場合、溶媒中、塩酸、トリフルオロ酢酸、メタンスルホン酸等の酸で処理をすればよい。
反応に用いる溶媒としては、1,4-ジオキサン、テトラヒドロフラン、ジエチルエーテル、1,2-ジメトキシエタン、シクロペンチルメチルエーテル等のエーテル系溶媒;トルエン、ヘキサン、キシレン等の炭化水素系溶媒;ジクロロメタン、クロロホルム等のハロゲン系溶媒;酢酸エチル等のエステル系溶媒;メタノール、エタノール、1-プロパノール、2-プロパノール等のアルコール系溶媒が挙げられる。
常法のアミド結合形成反応で、例えば、化合物[19]を溶媒中、縮合剤及び添加剤の存在下、化合物[20]と反応させることにより、化合物[21]を得ることができる。必要に応じて塩基を添加しても良い。
反応に用いる縮合剤としては、ジシクロヘキシルカルボジイミド(DCC)、1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド塩酸塩(WSC・HCl)、ジイソプロピルカルボジイミド、1,1’-カルボニルジイミダゾール(CDI)、O-(7-アザベンゾトリアゾール-1-イル)-N,N,N’,N’-テトラメチルウロニウムヘキサフルオロフォスフェート(HATU)、ヘキサフルオロリン酸(ベンゾトリアゾール-1-イルオキシ)トリピロリジノホスホニウム(PyBOP)又はジフェニルホスホリルアジド等が挙げられる。
反応に用いる添加剤としては、1-ヒドロキシベンゾトリアゾール(HOBt)、1-ヒドロキシ-7-アザベンゾトリアゾール(HOAt)、N-ヒドロキシコハク酸イミド(HOSu)、4-ジメチルアミノピリジン等が挙げられる。
反応に用いる塩基としては、ピリジン、トリエチルアミン等の有機塩基が挙げられる。
反応に用いる溶媒としては、1,4-ジオキサン、テトラヒドロフラン、ジエチルエーテル、1,2-ジメトキシエタン、シクロペンチルメチルエーテル等のエーテル系溶媒;トルエン、ヘキサン、キシレン等の炭化水素系溶媒;ジクロロメタン、クロロホルム等のハロゲン系溶媒;N,N-ジメチルホルムアミド、N,N-ジメチルアセトアミド、ジメチルスルホキシド、アセトニトリル、ピリジン等の極性溶媒が挙げられ、これらは単独又は2種以上を混合して使用することができる。
化合物[20]はシクロペンタンカルボン酸や1-(トリフルオロメチル)シクロプロパン-1-カルボン酸のような市販品であってもよく、又は市販品を適宜当業者に周知の方法で変換して得られるものであってもよい。
化合物[21]は化合物[22]と表記することができる。製造方法1-1の工程1-1-3と同様に、化合物[22]のアルコキシを加水分解でヒドロキシに変換することにより、化合物[I-a1]を得ることができる。
化合物[10]においてR1がC1-6アルキル又はクロロである化合物[10a]を[製造方法2-2]によっても得ることができる。
R4は前記式[I]における定義と同義であり、Hal2、tは前記製造方法2-1における定義と同義である。)
化合物[24]をハロゲン化することにより化合物[10a]を得ることができる。例えば、Hal2がヨードである場合、化合物[24]を酸中、室温下でN-ヨードスクシンイミドと反応させることにより、化合物[10a]を得ることができる。
反応に用いる酸としては、濃硫酸等が挙げられる。
化合物[24]は4-クロロフェニル酢酸、3-(4-クロロフェニル)プロピオン酸、又は4-(4-クロロフェニル)ブタン酸、4-メチルフェニル酢酸、又は2-(4-メチルフェニル)プロピオン酸のような市販品であってもよく、又は市販品を適宜当業者に周知の方法で変換して得られるものであってもよい。
R1、R4、R5、Rb15、nは前記式[I]における定義と同義であり、
Zは前記製造方法1-1における定義と同義であり、
Hal2、Y、Pw、L2は前記製造方法2-1における定義と同義である。)
製造方法1-2の工程1-2と同様の方法で、化合物[25]をホウ素化することにより化合物[26]を得ることができる。
化合物[25]は1-(3-ブロモ-4-クロロフェニル)プロパン-1-オンや1-(3-ブロモ-4-クロロフェニル)ブタン-1-オンのような市販品であってもよく、又は市販品を適宜当業者に周知の方法で変換して得られるものであってもよい。
製造方法1-1の工程1-1-2と同様の方法で、化合物[3]と化合物[26]との鈴木カップリング反応により化合物[27]を得ることができる。
化合物[27]のカルボキシを還元でヒドロキシに変換することにより、化合物[28]を得ることができる。例えば、化合物[27]を溶媒中、氷冷下から室温下で還元剤と反応させることにより化合物[28]を得ることができる。
反応に用いる還元剤としては、水素化ホウ素ナトリウム等が挙げられる。
反応に用いる溶媒としては、メタノール、エタノール、2-プロパノール、1,4-ジオキサン、テトラヒドロフラン、ジエチルエーテル、1,2-ジメトキシエタン、シクロペンチルメチルエーテル等が挙げられる。
製造方法2-1の工程2-1-7と同様の方法で、化合物[28]のヒドロキシを脱離基L2に変換することにより化合物[29]を得ることができる。
製造方法2-1の工程2-1-8と同様の方法で、化合物[29]を化合物[17]と反応させることにより、化合物[30]を得ることができる。
製造方法2-1の工程2-1-9と同様の方法で、化合物[30]の保護基Pwを除去することにより、化合物[31]を得ることができる。
製造方法2-1の工程2-1-10と同様の方法で、化合物[31]を化合物[20]と反応させることにより、化合物[32]を得ることができる。
化合物[32]は化合物[22]と表記することができる。製造方法1-1の工程1-1-3と同様に、化合物[22]のアルコキシを加水分解でヒドロキシに変換することにより、化合物[I-a1]を得ることができる。
である化合物[I-a4]を得ることができる。
である化合物[I-a6]を得ることができる。
である化合物[I-a7]を得ることができる。
である化合物[I-a8]を得ることができる。
である化合物[I-a9]を得ることができる。
で表される化合物[33]を用いて反応を行う。その後、生成物を工程2-1-11の反応に付すことにより、式[I]において環Cyが式
である化合物[I-a11]を得ることができる。
である化合物[I-a12]を得ることができる。
である化合物[I-a14]を得ることができる。
である化合物[I-a15]を得ることができる。
化合物[34]を溶媒中、塩基の存在下、化合物[35]と反応させることにより、化合物[36]を得ることができる。
反応に用いる塩基としては、リチウムジイソプロピルアミド、ビス(トリメチルシリル)アミドリチウム等の塩基が挙げられる。
反応に用いる溶媒としては、テトラヒドロフラン、ジエチルエーテル、1,2-ジメトキシエタン、シクロペンチルメチルエーテル等のエーテル系溶媒;トルエン、ヘキサン、キシレン等の炭化水素系溶媒及びそれらの混合溶媒が挙げられる。
化合物[35]はベンジルクロロメチルエ-テルのような市販品であってもよく、又は市販品を適宜当業者に周知の方法で変換して得られるものであってもよい。
製造方法2-1の工程2-1-6と同様の方法で、化合物[36]のPvを除去することにより、化合物[37]を得ることができる。
製造方法2-1の工程2-1-1と同様の方法で、化合物[37]のエステルを加水分解でカルボキシに変換することにより、化合物[38]を得ることができる。
製造方法2-1の工程2-1-10と同様の方法で、化合物[38]を溶媒中、縮合剤及び添加剤の存在下、化合物[19]と反応させることにより、化合物[39]を得ることができる。
化合物[39]の分子内光延反応で環化を行うことにより、化合物[40]を得ることができる。例えば、例えば化合物[39]を溶媒中、アゾジカルボン酸ジエステル(例えば、アゾジカルボン酸ジエチル、アゾジカルボン酸ジイソプロピル、アゾジカルボン酸ビス(2-メトキシエチル)等)とトリフェニルホスフィンやトリブチルホスフィン等のホスフィンの存在下と反応させることにより、化合物[40]を得ることができる。
反応に用いる溶媒は、ジクロロメタン、クロロホルム、1,4-ジオキサン、テトラヒドロフラン、ジエチルエーテル、1,2-ジメトキシエタン、シクロペンチルメチルエーテル、トルエン、N,N-ジメチルホルムアミド等が挙げられ、これらは単独又は2種以上を混合して使用することができる。
環Cyの置換基を適宜変換する他の方法として、例えば式[I]において環Cyが式
である化合物[I-b1]を得る製造方法3-1を挙げることができる。
[製造方法3-1]
化合物[41]を製造方法2-1の工程2-1-3と同様の方法でヒドロキシ基を保護することにより化合物[42]を得ることができる。
化合物[41]は2-ブロモ-3-メチルフェノールのような市販品であってもよく、又は市販品を適宜当業者に周知の方法で変換して得られるものであってもよい。
製造方法1-3の工程1-3と同様の方法で、化合物[42]をホウ素化することにより化合物[43]を得ることができる。
製造方法1-1の工程1-1-2と同様の方法で、化合物[3]と化合物[43]との鈴木カップリング反応により化合物[44]を得ることができる。
製造方法2-1の工程2-1-6と同様の方法で、化合物[44]のPvを除去することにより、化合物[45]を得ることができる。
化合物[45]と化合物[46]との光延反応により、化合物[47]を得ることができる。例えば化合物[45]を溶媒中、アゾジカルボン酸ジエステル(例えば、アゾジカルボン酸ジエチル、アゾジカルボン酸ジイソプロピル、アゾジカルボン酸ビス(2-メトキシエチル)等)とトリフェニルホスフィンやトリブチルホスフィン等のホスフィンの存在下で、化合物[46]と反応させることにより、化合物[47]を得ることができる。
反応に用いる溶媒は、ジクロロメタン、クロロホルム、1,4-ジオキサン、テトラヒドロフラン、ジエチルエーテル、1,2-ジメトキシエタン、シクロペンチルメチルエーテル、トルエン、N,N-ジメチルホルムアミド等が挙げられ、これらは単独又は2種以上を混合して使用することができる。
化合物[46]はベンジルアルコールや2-ピリジンメタノール等の市販品であってもよく、又は市販品を適宜当業者に周知の方法で変換して得られるものであってもよい。
製造方法1-1の工程1-1-3と同様に、化合物[47]のアルコキシを加水分解でヒドロキシに変換することにより、化合物[I-b1]を得ることができる。
である化合物[I-b2]を得ることができる。
化合物[43]においてR1がクロロ又はトリフルオロメチルである化合物[43a]を[製造方法3-2]によっても得ることができる。
R4は前記式[I]における定義と同義であり、Zは前記製造方法1-1における定義と同義であり、Pvは前記製造方法2-1における定義と同義である。)
製造方法2-1の工程2-1-3と同様の方法で化合物[48]のヒドロキシ基を保護することにより、化合物[49]を得ることができる。
化合物[48]は、一例として以下に示すような市販品であってもよく、又は市販品を適宜当業者に周知の方法で変換して得られるものであってもよい。
化合物[49]を溶媒中、塩基の存在下、ホウ素化合物と反応させることにより、化合物[43a]を得ることができる。例えば化合物[49]に溶媒中、-78℃から室温下で塩基を加えた後、-78℃から室温下で生成物をホウ素試薬と反応させることにより、化合物[43a]を得ることができる。
反応に用いられる塩基としては、n-ブチルリチウムやsec-ブチルリチウム等が挙げられる。
反応に用いられるホウ素試薬としては、2-イソプロポキシ-4,4,5,5-テトラメチル-1,3,2-ジオキサボロラン、ホウ酸トリメチル等が挙げられる。
反応に用いられる溶媒としては、テトラヒドロフラン、ジエチルエーテル、1,2-ジメトキシエタン、シクロペンチルメチルエーテル等が挙げられる。
化合物[2]の置換基を適宜変換することにより、例えば式
である化合物[I-c1]を得ることができる。
[製造方法4]
Pxはベンジル等のヒドロキシ基の保護基;
R5、R6、Re、X、Cyは前記式[I]における定義と同義であり、Hal1、Zは前記製造方法1-1における定義と同義であり、m7は前記式[I-A]における定義と同義である。)
製造方法1-1の工程1-1-1と同様の方法で、化合物[1]と化合物[50]との鈴木カップリング反応により化合物[51]を得ることができる。
化合物[50]は4-(ベンジロキシ)フェニルボロン酸のような市販品であってもよく、又は市販品を適宜当業者に周知の方法で変換して得られるものであってもよい。
製造方法1-1の工程1-1-2と同様の方法で、化合物[4]と化合物[51]との鈴木カップリング反応により化合物[52]を得ることができる。
化合物[52]のフェノール保護基PXを除去することにより、化合物[53]を得ることができる。脱保護反応は、採用される保護基に応じた公知の方法で行えばよい。
例えばPXがベンジルである場合、テトラヒドロフラン、酢酸エチル、エタノール、メタノール、水等の単独又は混合溶媒中、パラジウム炭素又はプラチナ炭素等の触媒存在下、水素添加反応させればよい。
化合物[53]のヒドロキシを脱離基L3に変換することにより、化合物[54]を得ることができる。例えば、脱離基がトリフルオロメタンスルホニルオキシである場合、化合物[53]を溶媒中、塩基の存在下、氷冷から室温下でトリフルオロメタンスルホン酸無水物又はN-フェニルビス(トリフルオロメタンスルホンイミド)等と反応させることにより化合物[54]を得ることができる。
反応に用いる塩基としては、ピリジン、2,6-ルチジン、トリエチルアミン等の有機塩基;炭酸セシウム、水素化ナトリウム等のアルカリ金属塩の無機塩基等が挙げられる。
反応に用いる溶媒としては、1,4-ジオキサン、テトラヒドロフラン、ジエチルエーテル、1,2-ジメトキシエタン、シクロペンチルメチルエーテル等のエーテル系溶媒;トルエン、ヘキサン、キシレン等の炭化水素系溶媒;ジクロロメタン、クロロホルム等のハロゲン系溶媒;N,N-ジメチルホルムアミド、N,N-ジメチルアセトアミド、ジメチルスルホキシド、アセトニトリル、ピリジン等の極性溶媒等が挙げられ、これらは単独又は2種以上を混合して使用することができる。
化合物[54]と化合物[55]との薗頭反応により、化合物[56]を得ることができる。例えば、溶媒中、好ましくは加熱下で塩基、パラジウム触媒及び銅触媒の存在下、化合物[54]を化合物[55]と反応させることにより化合物[56]を得ることができる。
反応に用いるパラジウム触媒としては、テトラキストリフェニルホスフィンパラジウム、ビス(トリフェニルホスフィン)パラジウムジクロリド、(ビス(ジフェニルホスフィノ)フェロセン)パラジウムジクロリド-塩化メチレン錯体等が挙げられる。
反応に用いる銅触媒としては、ヨウ化銅、臭化銅等が挙げられる。
反応に用いる塩基としては、ジエチルアミン、ジシクロへキシルアミン、トリエチルアミン、N-エチルジイソプロピルアミン等が挙げられる。
反応に用いる溶媒としては、1,4-ジオキサン、テトラヒドロフラン、ジエチルエーテル、1,2-ジメトキシエタン、シクロペンチルメチルエーテル等のエーテル系溶媒;トルエン、ヘキサン、キシレン等の炭化水素系溶媒;N,N-ジメチルホルムアミド、N,N-ジメチルアセトアミド、ジメチルスルホキシド、アセトニトリル、ピリジン等の極性溶媒が挙げられ、これらは単独又は2種以上を混合して使用することができる。
化合物[55]はシクロヘキシルアセチレンや2-エチニルピリジン等の市販品であってもよく、又は市販品を適宜当業者に周知の方法で変換して得られるものであってもよい。
薗頭反応については、例えば次のような総説が知られている(NAJERA, C et al. The Sonogashira Reaction: A Booming Methodology in Synthetic Organic Chemistry. Chem Rev. 2007, Vol.107, pages 874-922.)。
製造方法1-1の工程1-1-3と同様に、化合物[56]のアルコキシを加水分解でヒドロキシに変換することにより、化合物[I-c1]を得ることができる。
である化合物[I-c2]を得ることができる。
である化合物[I-c3]を得ることができる。
である化合物[57]との鈴木カップリング反応を行う。生成物を工程4-6の反応に付すことにより、式
である化合物[I-c4]を得ることができる。
である化合物[58]との鈴木カップリング反応を行う。生成物のオレフィンを還元した後、工程4-6の反応に付すことにより、式
である化合物[I-c5]を得ることができる。オレフィンの還元反応は、例えば、テトラヒドロフラン、酢酸エチル、エタノール、メタノール、水等の単独又は混合溶媒中、パラジウム炭素又はプラチナ炭素等の触媒存在下、水素添加反応させればよい。
また、実施例中、略号は以下のとおりである。
WSC・HCl: 1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド塩酸塩
HOBt・H2O:1-ヒドロキシ-1H-ベンゾトリアゾール1水和物
DMSO:ジメチルスルホキシド
M:mol/L
N-(4-クロロ-3-{4-[4-(2,2-ジメチルプロポキシ)フェニル]-6-ヒドロキシ-1,3,5-トリアジン-2-イル}ベンジル)-3,3,3-トリフルオロ-2,2-ジメチルプロピオンアミド(実施例番号1-86)の合成
1H-NMR (400MHz, CDCl3) δ: 1.06 (9H, s), 3.68 (2H, s), 4.14 (3H, s), 6.94-7.02 (2H, m), 8.42-8.46 (2H, m).
1H-NMR (400MHz, CDCl3) δ: 1.06 (9H, s), 1.75 (1H, t, J = 5.9 Hz), 3.69 (2H, s), 4.19 (3H, s), 4.77 (2H, d, J = 5.9 Hz), 6.98-7.03 (2H, m), 7.46 (1H, dd, J = 8.2, 2.2 Hz), 7.53 (1H, d, J = 8.2 Hz), 8.00 (1H, d, J = 2.2 Hz), 8.52-8.58 (2H, m).
1H-NMR (400MHz, CDCl3) δ: 1.06 (9H, s), 1.48 (18H, s), 3.69 (2H, s), 4.18 (3H, s), 4.83 (2H, s), 6.96-7.01 (2H, m), 7.39 (1H, dd, J = 8.2, 2.2 Hz), 7.48 (1H, d, J = 8.2 Hz), 7.98 (1H, d, J = 2.2 Hz), 8.51-8.57 (2H, m).
1H-NMR (400MHz, DMSO-d6) δ: 1.03 (9H, s), 3.76 (2H, s), 4.10-4.18 (2H, m), 4.14 (3H, s), 7.11-7.17 (2H, m), 7.72 (2H, d, J = 0.9 Hz), 8.13 (1H, br s), 8.40-8.58 (5H, m).
1H-NMR (400MHz, CDCl3) δ: 1.07 (9H, s), 1.44 (6H, s), 3.69 (2H, s), 4.19 (3H, s), 4.55 (2H, d, J = 5.8 Hz), 6.22 (1H, br s), 6.96-7.03 (2H, m), 7.34 (1H, dd, J = 8.3, 2.3 Hz), 7.51 (1H, d, J = 8.3 Hz), 7.91 (1H, d, J = 2.3 Hz), 8.50-8.57 (2H, m).
1H-NMR (400MHz, DMSO-d6) δ: 1.02 (9H, s), 1.37 (6H, s), 3.73 (2H, s), 4.35 (2H, d, J = 5.8 Hz), 7.08 (2H, d, J = 9.1 Hz), 7.40 (1H, dd, J = 8.3, 2.2 Hz), 7.58 (1H, d, J = 8.3 Hz), 7.62 (1H, d, J = 1.9 Hz), 8.29 (2H, d, J = 9.1 Hz), 8.62 (1H, t, J = 5.8 Hz), 13.13 (1H, s).
1-[4-クロロ-3-(4-ヒドロキシ-6-フェニル-1,3,5-トリアジン-2-イル)-ベンジル]-3,3-ジメチル-1,3-ジヒドロインドール-2-オン(実施例番号1-258)の合成
アルゴン雰囲気下、得られた[4-クロロ-3-(4-メトキシ-6-フェニル-1,3,5-トリアジン-2-イル)フェニル]メタノール(0.47 g, 1.4 mmol)及びトリフェニルホスフィン(0.56 g, 2.1 mmol)のクロロホルム(4.5 ml)溶液に、氷冷下、四臭化炭素(0.71 g, 2.1 mmol)を加えた。この反応混合物を室温にて、10分間撹拌した後、減圧濃縮した。残渣をシリカゲルカラムクロマトグラフィー(展開溶媒:n-ヘキサン/酢酸エチル=30/1から9/1)にて精製することにより表題化合物(0.49 g, 収率87%)を得た。
1H-NMR (400MHz, CDCl3) δ: 4.22 (3H, s), 4.53 (2H, s), 7.45-7.64 (5H, m), 8.06 (1H, br s), 8.57-8.63 (2H, m).
1H-NMR (400MHz, CDCl3) δ: 1.44 (6H, s), 4.18 (3H, s), 4.98 (2H, s), 6.72-6.76 (1H, m), 7.02-7.08 (1H, m), 7.13-7.19 (1H, m), 7.21-7.25 (1H, m), 7.31-7.36 (1H, m), 7.46-7.53 (3H, m), 7.55-7.61 (1H, m), 8.00 (1H, br s), 8.51-8.58 (2H, m).
1H-NMR (400MHz, DMSO-d6) δ: 1.34 (6H, s), 4.99 (2H, s), 6.97 (1H, d, J = 7.6 Hz), 7.05 (1H, t, J = 7.6 Hz), 7.20 (1H, t, J = 7.6 Hz), 7.39 (1H, d, J = 7.6 Hz), 7.48 (1H, dd, J = 8.3, 1.8 Hz), 7.55 (2H, t, J = 7.6 Hz), 7.59-7.68 (2H, m), 7.75 (1H, d, J = 1.8 Hz), 8.29 (2H, d, J = 7.6 Hz), 13.32 (1H, br s).
N-[4-クロロ-3-(4-ヒドロキシ-6-フェニル-1,3,5-トリアジン-2-イル)ベンジル]-N-エチル-3,3,3-トリフルオロ-2,2-ジメチルプロピオンアミド(実施例番号1-263)の合成
1H-NMR (400MHz, CDCl3) δ: 1.14 (3H, t, J = 7.2 Hz), 2.70 (2H, q, J = 7.2 Hz), 3.86 (2H, s), 4.22 (3H, s), 7.44 (1H, dd, J = 8.2, 2.2 Hz), 7.48-7.55 (3H, m), 7.57-7.62 (1H, m), 7.97 (1H, d, J = 2.2 Hz), 8.58-8.64 (2H, m).
1H-NMR (400MHz, CDCl3) δ: 1.20 (3H, t, J = 6.9 Hz), 1.55 (6H, s), 3.47 (2H, q, J = 6.9 Hz), 4.21 (3H, s), 4.71 (2H, s), 7.24-7.30 (1H, m), 7.45-7.63 (4H, m), 7.88 (1H,br s), 8.56-8.64 (2H, m).
1H-NMR (400MHz, DMSO-d6) δ:1.13 (3H, t, J = 6.9 Hz), 1.50 (6H, s), 3.42 (2H, br s), 4.66 (2H, s), 7.41 (1H, dd, J = 8.3, 1.8 Hz), 7.56 (2H, t, J = 7.9 Hz), 7.61-7.69 (3H, m), 8.34 (2H, d, J = 7.9 Hz), 13.33 (1H, br s).
7-tert-ブチル-2-[4-クロロ-3-(4-ヒドロキシ-6-フェニル-1,3,5-トリアジン-2-イル)ベンジル]-2-アザスピロ[3.5]ノナン-1-オン(実施例番号1-266)の合成
1H-NMR (400MHz, CDCl3) δ: 0.81 (9H, s), 0.88-0.99 (1H, m), 1.00-1.21 (4H, m), 1.68 (2H, d, J = 12.0 Hz), 2.29 (2H, d, J = 12.0 Hz), 3.36 (2H, s), 3.69 (3H, s), 4.48 (2H, br s), 7.22-7.38 (5H, m).
1H-NMR (400MHz, CDCl3)δ:0.83 (9H, s), 0.91-1.17 (5H, m), 1.64-1.78 (3H, m), 2.20-2.31 (2H, m), 3.53 (2H, d, J = 6.0 Hz), 3.73 (3H, s).
1H-NMR (400MHz, DMSO-d6) δ: 0.80 (9H, s), 0.86-1.12 (5H, m), 1.53-1.66 (2H, m), 2.00-2.13 (2H, m), 3.31 (2H, s).
アルゴン雰囲気下、得られた4-クロロ-3-(4-メトキシ-6-フェニル-1,3,5-トリアジン-2-イル)ベンジルアミン塩酸塩(0.90 g, 0.25 mmol)及び上記(3)で得られた、4-tert-ブチル-1-ヒドロキシメチル-シクロヘキサンカルボン酸(0.080 g, 0.37 mmol)のN,N-ジメチルホルムアミド(2.0 ml)溶液に、室温にて、HOBt・H2O(0.057 g, 0.37 mmol)、WSC・HCl(0.071 g, 0.37 mmol)及びトリエチルアミン(0.10 ml, 0.74 mmol)を加え、13時間撹拌した。この反応混合物に飽和重曹水及び酢酸エチルを加え、分液した後、有機層を飽和重曹水で洗浄後、有機層を飽和食塩水で洗浄した。この有機層を硫酸ナトリウムで乾燥した後、ろ過により硫酸ナトリウムを取り除き、減圧濃縮した。残渣をシリカゲルカラムクロマトグラフィー(展開溶媒:n-ヘキサン/酢酸エチル=1/2から1/3)にて精製することにより表題化合物(0.11 g, 収率81%)を得た。表題化合物は、単一の立体異性体であるが、その相対配置は未決定である。
1H-NMR (400MHz, CDCl3) δ: 0.78 (9H, s), 0.94-1.22 (5H, m), 1.66-1.75 (2H, m), 2.22-2.30 (2H, m), 2.42 (1H, t, J = 5.0 Hz), 3.52 (2H, d, J = 5.0 Hz), 4.21 (3H, s), 4.57 (2H, d, J = 5.8 Hz), 6.46 (1H, t, J = 5.8 Hz), 7.38 (1H, dd, J = 8.3, 2.3 Hz), 7.47-7.55 (3H, m), 7.57-7.62 (1H, m), 7.97 (1H, d, J = 2.3 Hz), 8.57-8.62 (2H, m).
1H-NMR (400MHz, CDCl3) δ: 0.81-1.77 (7H, m), 0.87 (9H, s), 2.03-2.12 (2H, m), 2.87 (2H, br s), 4.21 (3H, s), 4.40 (2H, br s), 7.30-7.37 (1H, m), 7.48-7.64 (4H, m), 7.90 (1H, br s), 8.57-8.63 (2H, m).
1H-NMR (400MHz, DMSO-d6) δ: 0.83 (9H, s), 0.90-0.99 (1H, m), 1.41-1.67 (6H, m), 1.96-2.03 (2H, m), 2.92 (2H, s), 4.38 (2H, s), 7.47 (1H, dd, J = 8.3, 1.8 Hz), 7.56 (2H, t, J = 7.6 Hz), 7.63-7.69 (3H, m), 8.34 (2H, d, J = 7.6 Hz), 13.34 (1H, br s).
4-[2-(6-メチルピリジン-2-イルメトキシ)-6-トリフルオロメチルフェニル]-6-(4-フェニルエチニルフェニル)-1,3,5-トリアジン-2-オール塩酸塩(実施例番号2-98)の合成
1H-NMR (400MHz, CDCl3) δ: 3.53 (3H, s), 5.29 (2H, s), 7.31-7.38 (3H, m).
1H-NMR (400MHz, CDCl3) δ: 1.39 (12H, s), 3.47 (3H, s), 5.18 (2H, s), 7.20 (1H, d, J = 8.4 Hz), 7.24-7.28 (1H, m), 7.36-7.42 (1H, m).
アルゴン雰囲気下、得られた2-(4-ベンジロキシフェニル)-4-クロロ-6-メトキシ-1,3,5-トリアジン(3.0 g, 9.2 mmol)及び上記(2)で得られた2-(2-メトキシメトキシ-6-トリフルオロメチルフェニル)-4,4,5,5-テトラメチル-1,3,2-ジオキサボロラン(2.8 g, 8.4 mmol)のN,N-ジメチルホルムアミド(25 ml)溶液に、[1,1'-ビス(ジフェニルホスフィノ)フェロセン]パラジウム(II)ジクロリド ジクロロメタン付加物(1.4 g, 1.7 mmol)、ヨウ化銅(I)(0.48 g, 2.5 mmol)及び2M炭酸ナトリウム水溶液(13 ml, 25 mmol)を加え、115℃にて、45分間撹拌した。この反応混合物に水及び酢酸エチルを加え、撹拌後、不溶物をセライトろ過で取り除き、酢酸エチルで溶出した。ろ液を分液した後、有機層を飽和重曹水で洗浄後、有機層を飽和食塩水で洗浄した。この有機層を硫酸ナトリウムで乾燥した後、ろ過により硫酸ナトリウムを取り除き、減圧濃縮した。残渣をシリカゲルカラムクロマトグラフィー(展開溶媒:n-ヘキサン/酢酸エチル=7/2)にて精製することにより表題化合物(2.0 g, 収率47%)を得た。
1H-NMR (400MHz, DMSO-d6) δ: 3.39 (3H, s), 4.14 (3H, s), 5.13 (2H, s), 5.15 (2H, s), 7.02-7.08 (2H, m), 7.30-7.46 (7H, m), 7.48-7.55 (1H, m), 8.47-8.52 (2H, m).
1H-NMR(400MHz, CDCl3)δ:3.39 (3H, s), 4.14 (4H, s), 5.13 (2H, s), 5.39 (1H, br s), 6.87-6.93 (2H, m), 7.40-7.45 (2H, m), 7.48-7.55 (1H, m), 8.43-8.48 (2H, m).
1H-NMR (400MHz, CDCl3)δ: 3.39 (3H, s), 4.17 (3H, s), 5.13 (2H, s), 7.37-7.48 (4H, m), 7.51-7.58 (1H, m), 8.61-8.67 (2H, m).
1H-NMR (400MHz, DMSO-d6) δ: 3.40 (3H, s), 4.17 (3H, s), 5.14 (2H, s), 7.34-7.39 (3H, m), 7.42-7.47 (2H, m), 7.50-7.59 (3H, m), 7.62-7.67 (2H, m), 8.50-8.55 (2H, m).
1H-NMR (400MHz, CDCl3) δ: 4.23 (3H, s), 7.25-7.30 (1H, m), 7.36-7.40 (3H, m), 7.43-7.47 (1H, m), 7.50-7.60 (3H, m), 7.67-7.72 (2H, m), 8.48-8.52 (2H, m), 12.43 (1H, br s)
1H-NMR (400MHz, CDCl3) δ: 2.51 (3H, s), 4.17 (3H, s), 5.21 (2H, s), 6.96-7.01 (1H, m), 7.02-7.07 (1H, m), 7.20-7.25 (1H, m), 7.33-7.42 (5H, m), 7.47-7.59 (3H, m), 7.62-7.68 (2H, m), 8.52-8.57 (2H, m).
1H-NMR (400MHz, DMSO-d6) δ: 2.43 (3H, s), 5.31 (2H, s), 7.07-7.17 (2H, m), 7.43-7.49 (3H, m), 7.50-7.68 (5H, m), 7.69-7.82 (3H, m), 8.32-8.38 (2H, m), 13.63 (1H, br s).
1H-NMR (400MHz, DMSO-d6) δ: 2.48 (3H, s), 5.37 (2H, s), 7.23 (1H, d, J = 7.3 Hz), 7.28 (1H, d, J = 7.3 Hz), 7.48-7.45 (3H, m), 7.56 (1H, d, J = 7.9 Hz), 7.64-7.59 (2H, m), 7.67 (1H, d, J = 8.6 Hz), 7.82-7.72 (4H, m), 8.35 (2H, dd, J = 6.8, 2.0 Hz).
2-[4-クロロ-2-メチル-5-(4,4,5,5-テトラメチル[1,3,2]ジオキサボロラン-2-イル)ベンジロキシ]テトラヒドロピランの合成
1H-NMR (CDCl3) δ: 2.58 (3H, s), 7.38 (1H, br s), 8.50 (1H, s).
1H-NMR (400MHz,CDCl3) δ: 1.60 (1H, t, J = 5.7 Hz), 2.26 (3H, s), 4.63 (2H, d, J = 5.6 Hz), 7.25-7.26 (1H, m), 7.84 (1H, br s).
1H-NMR (400MHz, CDCl3) δ: 1.51-1.92 (6H, m), 2.26 (3H, s), 3.52-3.59 (1H, m), 3.85-3.91 (1H, m), 4.38 (1H, d, J = 12.6 Hz), 4.67-4.72 (2H, m), 7.25 (1H, br s), 7.82 (1H, br s).
1H-NMR (400MHz, CDCl3) δ: 1.36 (12H, s), 1.47-1.90 (6H, m), 2.34 (3H, s), 3.52-3.59 (1H, m), 3.88-3.95 (1H, m), 4.42 (1H, d, J = 11.6 Hz), 4.67 (1H, t, J = 3.5 Hz), 4.74 (1H, d, J = 11.6 Hz), 7.18 (1H, br s), 7.63 (1H, br s).
tert-ブチル-(4-クロロ-3-ヨード-2-メチルベンジロキシ)ジメチルシランの合成
1H-NMR(400MHz, CDCl3)δ:0.08 (6H, s), 0.92 (9H, s), 2.11 (3H, s), 4.01 (2H, br s), 4.60-4.69 (2H, m), 6.77 (1H, d, J = 8.4 Hz), 7.11 (1H, d, J = 8.4 Hz).
1H-NMR(400MHz, CDCl3)δ:0.10 (6H, s), 0.93 (9H, s), 2.47 (3H, s), 4.68 (2H, s), 7.30 (1H, d, J = 8.4 Hz), 7.35 (1H, d, J = 8.1 Hz).
2-(6-クロロ-2-メトキシメトキシ-3-メチルフェニル)-4,4,5,5-テトラメチル[1,3,2]ジオキサボロランの合成
1H-NMR(400MHz, CDCl3)δ:2.20 (3H, s), 3.48 (3H, s), 5.18 (2H, s), 6.89 (1H, dd, J = 7.9, 2.0 Hz), 7.03-7.07 (2H, m).
1H-NMR (400MHz, CDCl3) δ: 1.40 (12H, s), 2.27 (3H, s), 3.55 (3H, s), 5.03 (2H, s), 7.01 (1H, d, J = 8.2 Hz), 7.07-7.11 (1H, m).
N-{4-クロロ-3-[4-(4-イソブチルフェニル)-6-ヒドロキシ-1,3,5-トリアジン-2-イル]ベンジル}-2,2-ジメチルプロピオンアミド(実施例番号1-51)の合成
1H-NMR (CDCl3) δ: 0.93 (6H, d, J = 6.6 Hz), 1.77 (1H, t, J = 6.1 Hz), 1.90-1.97 (1H, m), 2.57 (2H, d, J = 7.3 Hz), 4.21 (3H, s), 4.77 (2H, d, J = 6.1 Hz), 7.29 (2H, d, J = 8.3 Hz), 7.47 (1H, dd, J = 8.3, 2.1 Hz), 7.54 (1H, d, J = 8.3 Hz), 8.01 (1H, d, J = 2.1 Hz), 8.51 (2H, d, J = 8.3 Hz).
1H-NMR (CDCl3) δ: 0.93 (6H, d, J= 6.6 Hz), 1.47 (18H, s), 1.88-1.98 (1H, m), 2.57 (2H, d, J = 7.3 Hz), 4.19 (3H, s), 4.83 (2H, s), 7.28 (2H, d, J = 8.4 Hz), 7.39 (1H, dd, J = 8.4, 2.3 Hz), 7.48 (1H, d, J = 8.4 Hz), 8.00 (1H, d, J = 2.3 Hz), 8.50 (2H, dt, J = 8.4, 1.8 Hz).
1H-NMR (CDCl3) δ: 0.93 (6H, d, J= 6.6 Hz), 1.24 (9H, s), 1.88-1.99 (1H, m), 2.57 (2H, d, J = 7.1 Hz), 4.20 (3H, s), 4.50 (2H, d, J = 6.0 Hz), 5.98 (1H, br s), 7.29 (2H, d, J = 8.3 Hz), 7.36 (1H, dd, J = 8.2, 2.3 Hz), 7.51 (1H, d, J = 8.2 Hz), 7.92 (1H, d, J = 2.3 Hz), 8.50 (2H, d, J = 8.3 Hz).
N-{4-クロロ-3-[4-(3-フルオロ-4-メチルフェニル)-6-ヒドロキシ-1,3,5-トリアジン-2-イル]ベンジル}-3,3,3-トリフルオロ-2,2-ジメチルプロピオンアミド(実施例番号1-81)の合成
1H-NMR (CDCl3) δ: 2.37 (3H, d, J= 2.1 Hz), 4.17 (3H, s), 7.32 (1H, t, J= 7.9 Hz), 8.12 (1H, dd, J = 10.7, 1.7 Hz), 8.19 (1H, dd, J= 7.9, 1.7 Hz).
1H-NMR (CDCl3) δ: 1.76 (1H, t, J= 5.8 Hz), 2.37 (3H, d, J = 1.9 Hz), 4.21 (3H, s), 4.78 (2H, d, J= 5.8 Hz), 7.33 (1H, t, J = 7.9 Hz), 7.47 (1H, dd, J = 8.1, 2.2 Hz), 7.54 (1H, d, J = 8.1 Hz), 8.02 (1H, d, J = 2.2 Hz), 8.23 (1H, dd, J = 10.7, 1.6 Hz), 8.29 (1H, dd, J = 7.9, 1.6 Hz).
1H-NMR (CDCl3) δ: 1.48 (18H, s), 2.37 (3H, d, J = 1.6 Hz), 4.19 (3H, s), 4.83 (2H, s), 7.31 (1H, t, J = 7.9 Hz), 7.40 (1H, dd, J = 8.4, 2.3 Hz), 7.49 (1H, d, J = 8.4 Hz), 8.00 (1H, d, J = 2.3 Hz), 8.22 (1H, dd, J = 10.7, 1.6 Hz), 8.28 (1H, dd, J = 7.9, 1.6 Hz).
1H-NMR (DMSO-D6) δ: 2.36 (3H, d, J= 1.4 Hz), 4.13-4.19 (2H, m), 4.17 (3H, s), 7.55 (1H, t, J = 8.0 Hz), 7.71 (1H, dd, J = 8.1, 2.1 Hz), 7.75 (1H, d, J = 8.1 Hz), 8.16-8.20 (2H, m), 8.27 (1H, dd, J = 7.9, 1.6 Hz), 8.38 (3H, br s).
1H-NMR (CDCl3) δ: 1.45 (6H, s), 2.37 (3H, d, J = 1.9 Hz), 4.20 (3H, s), 4.55 (2H, d, J = 5.8 Hz), 6.23 (1H, br s), 7.30-7.37 (2H, m), 7.52 (1H, d, J = 8.4 Hz), 7.93 (1H, d, J = 2.3 Hz), 8.22 (1H, dd, J = 10.7, 1.6 Hz), 8.28 (1H, dd, J = 7.9, 1.6 Hz).
N-{4-クロロ-3-[4-ヒドロキシ-6-(4-イソプロピルフェニル)-1,3,5-トリアジン-2-イル]ベンジル}-3,3,3-トリフルオロ-2,2-ジメチルプロピオンアミド(実施例番号1-98)の合成
1H-NMR (CDCl3) δ: 1.29 (6H, d, J= 7.1 Hz), 2.99-3.02 (1H, m), 4.16 (3H, s), 7.34-7.38 (2H, m), 8.39-8.43 (2H, m).
1H-NMR (CDCl3) δ: 1.30 (6H, d, J= 7.1 Hz), 1.77 (1H, t, J = 6.1 Hz), 2.95-3.07 (1H, m), 4.20 (3H, s), 4.77 (2H, d, J = 6.1 Hz), 7.35-7.39 (2H, m), 7.46 (1H, dd, J = 8.2, 2.2 Hz), 7.54 (1H, d, J = 8.2 Hz), 8.01 (1H, dd, J = 2.2, 0.4 Hz), 8.50-8.54 (2H, m).
この残渣のN,N-ジメチルホルムアミド(1.5 ml)溶液を、氷冷下、イミノジカルボン酸ジ-tert-ブチル(0.089 g, 0.41 mmol)及び水素化ナトリウム(0.016 g, 60重量%オイルディスパージョン)のN,N-ジメチルホルムアミド(0.70 ml)溶液に加え、室温にて、15分間撹拌した。この反応液に水及び酢酸エチルを加え、分液した。有機層を水で洗浄後、有機層を飽和食塩水で洗浄した。この有機層を硫酸ナトリウムで乾燥した後、ろ過により硫酸ナトリウムを取り除き、減圧濃縮した。残渣をシリカゲルカラムクロマトグラフィー(展開溶媒:n-ヘキサン/酢酸エチル=5/1)にて精製することにより表題化合物(0.20 g, 収率85%)を得た。
1H-NMR (CDCl3) δ: 1.30 (6H, d, J= 7.0 Hz), 1.47 (18H, s), 2.94-3.05 (1H, m), 4.19 (3H, s), 4.83 (2H, s), 7.34-7.41 (3H, m), 7.48 (1H, d, J = 8.4 Hz), 8.00 (1H, d, J = 2.3 Hz), 8.49-8.53 (2H, m).
1H-NMR (CDCl3) δ: 1.30 (6H, d, J= 6.8 Hz), 1.44 (6H, s), 2.95-3.05 (1H, m), 4.18 (3H, s), 4.53 (2H, d, J = 5.7 Hz), 6.34 (1H, br s), 7.30-7.39 (3H, m), 7.50 (1H, d, J = 8.4 Hz), 7.91 (1H, d, J = 2.2 Hz), 8.49-8.53 (2H, m).
N-{4-クロロ-3-[4-ヒドロキシ-6-(4-イソブトキシフェニル)-1,3,5-トリアジン-2-イル]ベンジル}-3,3,3-トリフルオロ-2,2-ジメチルプロピオンアミド(実施例番号1-109)の合成
1H-NMR (CDCl3) δ: 1.05 (6H, d, J= 6.7 Hz), 2.07-2.17 (1H, m), 3.81 (2H, d, J = 6.5 Hz), 4.14 (3H, s), 6.95-7.00 (2H, m), 8.42-8.46 (2H, m).
1H-NMR (CDCl3) δ: 1.05 (6H, d, J= 6.7 Hz), 1.77 (1H, t, J = 5.9 Hz), 2.08-2.18 (1H, m), 3.82 (2H, d, J= 6.5 Hz), 4.19 (3H, s), 4.77 (2H, d, J= 5.9 Hz), 6.98-7.01 (2H, m), 7.46 (1H, dd, J = 8.2, 2.2 Hz), 7.53 (1H, d, J = 8.2 Hz), 8.00 (1H, d, J= 2.2 Hz), 8.55 (2H, m).
1H-NMR (CDCl3) δ: 1.05 (6H, d, J= 6.7 Hz), 1.47 (18H, s), 2.08-2.18 (1H, m), 3.82 (2H, d, J = 6.5 Hz), 4.18 (3H, s), 4.82 (2H, s), 6.96-7.00 (2H, m), 7.39 (1H, dd, J= 8.3, 2.3 Hz), 7.48 (1H, d, J= 8.3 Hz), 7.99 (1H, d, J = 2.3 Hz), 8.52-8.56 (2H, m).
1H-NMR (DMSO-D6) δ: 1.01 (6H, d, J= 6.8 Hz), 2.01-2.11 (1H, m), 3.88 (2H, d, J = 6.4 Hz), 4.14 (3H, s), 4.12-4.17 (2H, m), 7.12-7.15 (2H, m), 7.72 (2H, br s), 8.13 (1H, br s), 8.40-8.51 (5H, m).
1H-NMR (CDCl3) δ: 1.06 (6H, d, J= 6.8 Hz), 1.44 (6H, br s), 2.08-2.18 (1H, m), 3.82 (2H, d, J = 6.6 Hz), 4.19 (3H, s), 4.55 (2H, d, J = 5.7 Hz), 6.21 (1H, br s), 6.97-7.01 (2H, m), 7.34 (1H, dd, J= 8.3, 2.3 Hz), 7.51 (1H, d, J= 8.3 Hz), 7.91 (1H, d, J = 2.3 Hz), 8.53-8.55 (2H, m).
N-{4-クロロ-3-[4-ヒドロキシ-6-(4-プロポキシフェニル)-1,3,5-トリアジン-2-イル]ベンジル}-3,3,3-トリフルオロ-2,2-ジメチルプロピオンアミド(実施例番号1-122)の合成
1H-NMR (CDCl3) δ: 1.06 (3H, t, J= 7.4 Hz), 1.83-1.87 (2H, m), 4.02 (2H, t, J = 6.6 Hz), 4.14 (3H, s), 6.96-6.99 (2H, m), 8.43-8.45 (2H, m).
1H-NMR (CDCl3) δ: 1.07 (3H, t, J= 7.4 Hz), 1.77 (1H, t, J = 5.8 Hz), 1.84-1.87 (2H, m), 4.02 (2H, t, J= 6.6 Hz), 4.19 (3H, s), 4.77 (2H, d, J= 5.8 Hz), 7.00 (2H, d, J = 8.7 Hz), 7.45 (1H, dd, J = 8.3, 1.9 Hz), 7.53 (1H, d, J = 8.3 Hz), 8.00 (1H, d, J = 1.9 Hz), 8.55 (2H, d, J = 8.7 Hz).
1H-NMR (DMSO-D6) δ: 1.00 (3H, t, J= 7.4 Hz), 1.73-1.83 (2H, m), 4.06 (2H, t, J = 6.5 Hz), 4.12-4.18 (2H, m), 4.14 (3H, s), 7.12-7.16 (2H, m), 7.69-7.74 (2H, m), 8.13 (1H, br s), 8.44 (3H, br s), 8.45-8.50 (2H, m).
1H-NMR (DMSO-D6) δ: 1.00 (3H, t, J= 7.3 Hz), 1.39 (6H, s), 1.73-1.83 (2H, m), 4.05 (2H, t, J = 6.5 Hz), 4.11 (3H, s), 4.39 (2H, d, J = 5.9 Hz), 7.10-7.14 (2H, m), 7.44 (1H, dd, J = 8.1, 2.3 Hz), 7.61 (1H, d, J = 8.1 Hz), 7.86 (1H, d, J = 2.3 Hz), 8.42-8.47 (2H, m), 8.66 (1H, t, J = 5.9 Hz).
N-(4-クロロ-3-{4-ヒドロキシ-6-[4-(1-メチルシクロプロピルメトキシ)フェニル]-1,3,5-トリアジン-2-イル}ベンジル)-3,3,3-トリフルオロ-2,2-ジメチルプロピオンアミド(実施例番号1-128)の合成
1H-NMR (DMSO-D6) δ: 1.42 (18H, s), 3.41 (3H, s), 4.12 (3H, s), 4.77 (2H, s), 5.32 (2H, s), 7.18-7.23 (2H, m), 7.45 (1H, dd, J = 8.2, 2.3 Hz), 7.65 (1H, d, J = 8.2 Hz), 7.91 (1H, d, J= 2.3 Hz), 8.43-8.47 (2H, m).
1H-NMR (DMSO-D6) δ: 1.39 (6H, s), 1.59 (6H, s), 4.15 (3H, s), 4.40 (2H, d, J = 6.0 Hz), 7.39-7.47 (3H, m), 7.62 (1H, d, J = 8.4 Hz), 7.88 (1H, d, J = 2.1 Hz), 8.55-8.60 (2H, m), 8.66 (1H, t, J = 6.0 Hz).
1H-NMR (DMSO-D6) δ: 1.38 (6H, s), 4.10 (3H, s), 4.39 (2H, d, J = 6.2 Hz), 6.91-6.95 (2H, m), 7.42 (1H, dd, J = 8.3, 2.3 Hz), 7.60 (1H, d, J = 8.3 Hz), 7.84 (1H, d, J = 2.3 Hz), 8.34-8.39 (2H, m), 8.65 (1H, t, J = 6.2 Hz), 10.38 (1H, br s).
1H-NMR (DMSO-D6) δ: 0.42 (2H, dd, J= 5.6, 4.0 Hz), 0.56 (2H, dd, J= 5.4, 4.2 Hz), 1.20 (3H, s), 1.39 (6H, s), 3.88 (2H, s), 4.11 (3H, s), 4.39 (2H, d, J = 5.9 Hz), 7.09-7.14 (2H, m), 7.43 (1H, dd, J = 8.2, 2.1 Hz), 7.60 (1H, d, J = 8.2 Hz), 7.85 (1H, d, J = 2.1 Hz), 8.41-8.46 (2H, m), 8.66 (1H, t, J= 5.9 Hz).
N-{4-クロロ-3-[4-(3-クロロ-4-メチルフェニル)-6-ヒドロキシ-1,3,5-トリアジン-2-イル]ベンジル}-3,3,3-トリフルオロ-2,2-ジメチルプロピオンアミド(実施例番号1-129)の合成
1H-NMR (CDCl3) δ: 2.47 (3H, s), 4.17 (3H, s), 7.37 (1H, d, J = 8.0 Hz), 8.28 (1H, dd, J = 8.0, 1.8 Hz), 8.47 (1H, d, J = 1.8 Hz).
1H-NMR (CDCl3) δ: 1.81 (1H, t, J= 5.9 Hz), 2.47 (3H, s), 4.21 (3H, s), 4.78 (2H, d, J = 5.9 Hz), 7.37 (1H, d, J= 7.9 Hz), 7.47 (1H, dd, J = 8.1, 2.2 Hz), 7.54 (1H, d, J = 8.1 Hz), 8.01 (1H, d, J = 2.2 Hz), 8.38 (1H, dd, J = 7.9, 1.8 Hz), 8.57 (1H, d, J = 1.8 Hz).
1H-NMR (DMSO-D6) δ: 2.46 (3H, s), 4.12-4.21 (5H, m), 7.62 (1H, d, J = 8.0 Hz), 7.73-7.75 (2H, m), 8.17 (1H, br s), 8.38 (1H, dd, J = 8.0, 1.6 Hz), 8.47 (1H, d, J = 1.6 Hz) , 8.48 (3H, br s).
1H-NMR (CDCl3) δ: 1.45 (6H, s), 2.47 (3H, s), 4.21 (3H, s), 4.56 (2H, d, J = 5.6 Hz), 6.24 (1H, br s), 7.34-7.39 (2H, m), 7.52 (1H, d, J= 8.2 Hz), 7.92 (1H, d, J = 2.3 Hz), 8.38 (1H, dd, J = 8.2, 1.8 Hz), 8.56 (1H, d, J = 1.8 Hz).
N-{4-クロロ-3-[4-ヒドロキシ-6-(3-イソプロピル-4-トリフルオロメチルフェニル)-1,3,5-トリアジン-2-イル]ベンジル}-3,3,3-トリフルオロ-2,2-ジメチルプロピオンアミド(実施例番号1-130)の合成
1H-NMR (CDCl3) δ: 5.08 (2H, s), 6.93 (1H, dd, J = 8.8, 2.4 Hz), 7.30 (1H, d, J = 2.4 Hz), 7.33-7.41 (5H, m), 7.57 (1H, d, J = 8.8 Hz).
1H-NMR (CDCl3) δ: 2.04 (3H, s), 4.88 (1H, br s), 5.08 (2H, s), 5.18 (1H, br s), 6.82 (1H, d, J = 2.6 Hz), 6.89 (1H, dd, J = 8.8, 2.6 Hz), 7.31-7.42 (5H, m), 7.54 (1H, d, J= 8.8 Hz).
1H-NMR (CDCl3) δ: 1.23 (6H, d, J= 6.7 Hz), 3.24-3.35 (1H, m), 5.04 (1H, br s), 6.66 (1H, dd, J = 8.6, 2.6 Hz), 6.87 (1H, d, J = 2.6 Hz), 7.46 (1H, d, J = 8.6 Hz).
1H-NMR (CDCl3) δ: 1.28 (6H, d, J= 6.7 Hz), 3.34-3.46 (1H, m), 7.19 (1H, dd, J = 8.8, 2.4 Hz), 7.34 (1H, d, J = 2.4 Hz), 7.70 (1H, d, J= 8.8 Hz).
1H-NMR (CDCl3) δ: 1.29 (6H, d, J= 7.0 Hz), 1.36 (12H, s), 3.29-3.40 (1H, m), 7.57 (1H, d, J = 7.9 Hz), 7.68 (1H, d, J = 7.9 Hz), 7.88 (1H, br s).
1H-NMR (CDCl3) δ: 1.36 (6H, d, J= 6.8 Hz), 1.79 (1H, t, J = 6.0 Hz), 3.37-3.48 (1H, m), 4.24 (3H, s), 4.79 (2H, d, J = 6.0 Hz), 7.49 (1H, dd, J = 8.4, 2.2 Hz), 7.57 (1H, d, J = 8.4 Hz), 7.75 (1H, d, J= 8.4 Hz), 8.07 (1H, d, J = 2.2 Hz), 8.47 (1H, d, J = 8.4 Hz), 8.73 (1H, br s).
1H-NMR (DMSO-D6) δ: 1.33 (6H, d, J= 6.7 Hz), 3.28-3.40 (1H, m), 4.13-4.22 (5H, m), 7.73 (1H, dd, J = 8.2, 2.2 Hz), 7.77 (1H, d, J = 8.3 Hz), 7.92 (1H, d, J = 8.3 Hz), 8.20 (1H, d, J = 2.2 Hz), 8.35 (3H, br s), 8.48 (1H, d, J = 8.8 Hz), 8.70 (1H, s).
1H-NMR (CDCl3) δ: 1.35 (6H, d, J= 6.0 Hz), 1.44 (6H, br s), 3.37-3.49 (1H, m), 4.23 (3H, s), 4.56 (2H, d, J = 5.8 Hz), 6.25 (1H, br s), 7.37 (1H, dd, J = 8.4, 2.3 Hz), 7.54 (1H, d, J = 8.4 Hz), 7.74 (1H, d, J = 8.4 Hz), 7.96 (1H, d, J = 2.3 Hz), 8.46 (1H, d, J = 8.4 Hz), 8.72 (1H, br s).
N-{3-[4-(4-ブトキシフェニル)-6-ヒドロキシ-1,3,5-トリアジン-2-イル]-4-クロロベンジル}-3,3,3-トリフルオロ-2,2-ジメチルプロピオンアミド(実施例番号1-131)の合成
N-{4-クロロ-3-[4-(3-シクロプロピル-4-フルオロフェニル)-6-ヒドロキシ-1,3,5-トリアジン-2-イル]ベンジル}-3,3,3-トリフルオロ-2,2-ジメチルプロピオンアミド(実施例番号1-135)の合成
1H-NMR (CDCl3) δ: 0.83-0.88 (2H, m), 1.01-1.07 (2H, m), 1.79 (1H, t, J = 6.0 Hz), 2.10-2.19 (1H, m), 4.20 (3H, s), 4.77 (2H, d, J = 6.0 Hz), 7.13 (1H, t, J = 9.2 Hz), 7.47 (1H, d, J = 8.1 Hz), 7.54 (1H, d, J = 8.1 Hz), 8.01 (1H, br s), 8.20 (1H, d, J = 7.6 Hz), 8.38-8.41 (1H, m).
1H-NMR (CDCl3) δ: 0.84-0.88 (2H, m), 1.01-1.07 (2H, m), 1.47 (18H, s), 2.09-2.18 (1H, m), 4.18 (3H, s), 4.83 (2H, s), 7.11 (1H, dd, J = 9.7, 8.6 Hz), 7.40 (1H, dd, J = 8.3, 2.2 Hz), 7.49 (1H, d, J = 8.3 Hz), 8.00 (1H, d, J= 2.2 Hz), 8.19 (1H, dd, J = 7.5, 2.2 Hz), 8.36-8.41 (1H, m).
1H-NMR (DMSO-D6) δ: 0.78-0.83 (2H, m), 1.05-1.10 (2H, m), 2.10-2.19 (1H, m), 4.16 (3H, s), 4.16 (2H, s), 7.39 (1H, dd, J = 9.9, 8.7 Hz), 7.71 (1H, dd, J = 8.4, 2.1 Hz), 7.75 (1H, d, J = 8.4 Hz), 8.13 (1H, dd, J = 7.7, 2.1 Hz), 8.16 (1H, d, J = 2.1 Hz), 8.35-8.37 (4H, m).
1H-NMR (CDCl3) δ: 0.82-0.87 (2H, m), 1.01-1.05 (2H, m), 1.43 (6H, s), 2.10-2.16 (1H, m), 4.18 (3H, s), 4.54 (2H, d, J = 5.6 Hz), 6.21 (1H, br s), 7.11 (1H, t, J = 9.2 Hz), 7.34 (1H, d, J = 8.3 Hz), 7.51 (1H, d, J = 8.3 Hz), 7.90 (1H, s), 8.18 (1H, d, J = 7.7 Hz), 8.36-8.40 (1H, m).
(R)-N-{4-クロロ-3-[4-(4-クロロ-3-メチルフェニル)-6-ヒドロキシ-1,3,5-トリアジン-2-イル]ベンジル}-3,3,3-トリフルオロ-2-メトキシ-2-メチルプロピオンアミド(実施例番号1-136)の合成
1H-NMR (CDCl3) δ: 1.60 (3H, s), 3.78 (1H, s), 5.31 (2H, s), 7.33-7.42 (5H, m).
1H-NMR (CDCl3) δ: 1.59 (3H, s), 3.40 (3H, s), 5.26 (2H, s), 7.31-7.37 (5H, m).
1H-NMR (CDCl3) δ: 1.68 (3H, s), 3.54 (3H, s).
1H-NMR (CDCl3) δ: 2.47 (3H, s), 4.17 (3H, s), 7.47 (1H, d, J = 8.4 Hz), 8.26 (1H, dd, J = 8.4, 2.1 Hz), 8.36 (1H, d, J = 2.1 Hz).
1H-NMR (CDCl3) δ: 1.79 (1H, t, J= 5.3 Hz), 2.48 (3H, s), 4.21 (3H, s), 4.78 (2H, d, J = 5.3 Hz), 7.45-7.50 (2H, m), 7.54 (1H, d, J = 8.1 Hz), 8.01 (1H, d, J = 2.1 Hz), 8.37 (1H, dd, J = 8.4, 2.1 Hz), 8.46 (1H, d, J = 2.1 Hz).
1H-NMR (DMSO-D6) δ: 2.47 (3H, s), 4.13-4.19 (5H, m), 7.67 (1H, d, J = 8.3 Hz), 7.71-7.76 (2H, m), 8.16 (1H, d, J = 1.6 Hz), 8.35 (1H, dd, J = 8.3, 1.6 Hz), 8.41-8.50 (4H, m).
1H-NMR (CDCl3) δ: 1.66 (3H, s), 2.48 (3H, s), 3.45 (3H, s), 4.20 (3H, s), 4.48 (1H, dd, J = 15.1, 5.8 Hz), 4.63 (1H, dd, J = 15.1, 6.5 Hz), 7.16 (1H, br s), 7.37 (1H, dd, J= 8.3, 2.3 Hz), 7.48 (1H, d, J= 8.3 Hz), 7.53 (1H, d, J = 8.3 Hz), 7.92 (1H, d, J = 2.3 Hz), 8.36 (1H, dd, J = 8.3, 2.0 Hz), 8.46 (1H, d, J = 2.0 Hz).
(R)-N-{4-クロロ-3-[4-ヒドロキシ-6-(4-プロポキシフェニル)-1,3,5-トリアジン-2-イル]ベンジル}-3,3,3-トリフルオロ-2-メトキシ-2-メチルプロピオンアミド(実施例番号1-137)の合成
1H-NMR (CDCl3) δ: 1.07 (3H, t, J= 7.4 Hz), 1.66 (3H, br s), 1.81-1.90 (2H, m), 3.45 (3H, br s), 4.02 (2H, t, J = 6.5 Hz), 4.19 (3H, s), 4.50 (1H, dd, J = 15.0, 5.8 Hz), 4.59 (1H, dd, J = 15.0, 6.3 Hz), 6.97-7.02 (2H, m), 7.14 (1H, br s), 7.35 (1H, dd, J= 8.3, 2.3 Hz), 7.51 (1H, d, J= 8.3 Hz), 7.92 (1H, d, J = 2.3 Hz), 8.52-8.56 (2H, m).
N-{4-クロロ-3-[4-(3,4-ジメチルフェニル)-6-ヒドロキシ-1,3,5-トリアジン-2-イル]ベンジル}-3,3,3-トリフルオロ-2,2-ジメチルプロピオンアミド(実施例番号1-150)の合成
1H-NMR (CDCl3) δ: 2.35 (6H, s), 4.16 (3H, s), 7.26 (3H, d, J = 7.8 Hz), 8.22 (1H, dd, J = 7.8, 2.1 Hz), 8.25 (1H, d, J = 2.1 Hz).
1H-NMR (CDCl3) δ: 1.87 (1H, t, J= 5.0 Hz), 2.35 (3H, s), 2.36 (3H, s), 4.20 (3H, s), 4.76 (2H, d, J = 5.0 Hz), 7.27 (2H, d, J = 8.2 Hz), 7.45 (1H, dd, J = 8.4, 1.6 Hz), 7.53 (1H, d, J = 8.4 Hz), 7.99 (1H, d, J = 1.6 Hz), 8.33 (1H, d, J = 8.2 Hz), 8.35 (1H, br s).
1H-NMR (DMSO-D6) δ: 2.34 (3H, s), 2.35 (3H, s), 4.12-4.19 (5H, m), 7.38 (1H, d, J = 7.9 Hz), 7.69-7.75 (2H, m), 8.12 (1H, d, J = 1.9 Hz), 8.26 (1H, dd, J = 7.9, 1.6 Hz), 8.29 (1H, br s), 8.44 (3H, br s).
1H-NMR (CDCl3) δ: 1.44 (6H, s), 2.36 (3H, s), 2.37 (3H, s), 4.20 (3H, s), 4.55 (2H, d, J = 5.7 Hz), 6.22 (1H, br s), 7.27 (3H, d, J = 7.8 Hz), 7.35 (1H, dd, J = 8.2, 2.2 Hz), 7.52 (1H, d, J = 8.2 Hz), 7.91 (1H, d, J = 2.2 Hz), 8.32 (1H, dd, J = 7.8, 1.7 Hz), 8.35 (1H, br s).
N-{4-クロロ-3-[4-(4-シクロプロピルメトキシフェニル)-6-ヒドロキシ-1,3,5-トリアジン-2-イル]ベンジル}-3,3,3-トリフルオロ-2-メチル-2-トリフルオロメチルプロピオンアミド(実施例番号1-169)の合成
1H-NMR (CDCl3) δ: 0.36-0.41 (2H, m), 0.65-0.71 (2H, m), 1.25-1.36 (1H, m), 3.90 (2H, d, J = 7.0 Hz), 4.14 (3H, s), 6.96-7.00 (2H, m), 8.42-8.47 (2H, m).
1H-NMR (CDCl3) δ: 0.37-0.41 (2H, m), 0.65-0.71 (2H, m), 1.27-1.36 (1H, m), 1.76 (1H, t, J = 6.0 Hz), 3.90 (2H, d, J = 6.7 Hz), 4.19 (3H, s), 4.77 (2H, d, J = 6.0 Hz), 6.98-7.02 (2H, m), 7.46 (1H, dd, J= 8.1, 1.9 Hz), 7.53 (1H, d, J= 8.1 Hz), 8.00 (1H, d, J = 1.9 Hz), 8.53-8.57 (2H, m).
1H-NMR (DMSO-D6) δ: 0.34-0.39 (2H, m), 0.57-0.63 (2H, m), 1.21-1.32 (1H, m), 3.95 (2H, d, J = 7.0 Hz), 4.11-4.18 (5H, m), 7.11-7.15 (2H, m), 7.70-7.74 (2H, m), 8.13 (1H, br s), 8.42-8.53 (5H, m).
1H-NMR (CDCl3) δ: 0.36-0.41 (2H, m), 0.65-0.71 (2H, m), 1.26-1.35 (2H, m), 1.70 (3H, s), 3.90 (2H, d, J= 6.7 Hz), 4.19 (3H, s), 4.61 (2H, d, J= 5.8 Hz), 6.49 (1H, br s), 6.98-7.02 (2H, m), 7.32 (1H, dd, J = 8.5, 2.1 Hz), 7.53 (1H, d, J = 8.5 Hz), 7.92 (1H, d, J = 2.1 Hz), 8.52-8.56 (2H, m).
1-トリフルオロメチルシクロプロパンカルボン酸 4-クロロ-3-[4-ヒドロキシ-6-(4-イソブトキシフェニル)-1,3,5-トリアジン-2-イル]ベンジルアミド(実施例番号1-178)の合成
1H-NMR (DMSO-D6) δ: 1.01 (6H, d, J= 6.9 Hz), 1.23-1.27 (2H, m), 1.30-1.36 (2H, m), 2.00-2.11 (1H, m), 3.87 (2H, d, J = 6.4 Hz), 4.12 (3H, s), 4.37 (2H, d, J = 5.9 Hz), 7.11-7.15 (2H, m), 7.43 (1H, dd, J = 8.2, 2.1 Hz), 7.60 (1H, d, J = 8.2 Hz), 7.85 (1H, d, J = 2.1 Hz), 8.43-8.47 (2H, m), 8.50 (1H, t, J= 5.9 Hz).
N-(4-クロロ-3-{4-[4-((S)-1-シクロプロピルエトキシ)フェニル]-6-ヒドロキシ-1,3,5-トリアジン-2-イル}ベンジル)-3,3,3-トリフルオロ-2,2-ジメチルプロピオンアミド(実施例番号1-184)の合成
1H-NMR (CDCl3) δ: 0.28-0.36 (1H, m), 0.38-0.45 (1H, m), 0.53-0.63 (2H, m), 1.12-1.21 (1H, m), 1.41 (3H, d, J= 6.0 Hz), 1.44 (6H, s), 3.95-4.05 (1H, m), 4.18 (3H, s), 4.54 (2H, d, J = 5.6 Hz), 6.20 (1H, br s), 6.95-7.00 (2H, m), 7.34 (1H, dd, J = 8.3, 1.9 Hz), 7.51 (1H, d, J = 8.3 Hz), 7.91 (1H, d, J = 1.9 Hz), 8.50-8.55 (2H, m).
N-(4-クロロ-3-{4-[4-((R)-1-シクロプロピルエトキシ)フェニル]-6-ヒドロキシ-1,3,5-トリアジン-2-イル}ベンジル)-3,3,3-トリフルオロ-2,2-ジメチルプロピオンアミド(実施例番号1-185)の合成
1H-NMR (CDCl3) δ: 0.28-0.36 (1H, m), 0.38-0.45 (1H, m), 0.53-0.63 (2H, m), 1.12-1.21 (1H, m), 1.41 (3H, d, J= 6.0 Hz), 1.44 (6H, s), 3.95-4.05 (1H, m), 4.18 (3H, s), 4.54 (2H, d, J = 5.6 Hz), 6.20 (1H, br s), 6.95-7.00 (2H, m), 7.34 (1H, dd, J = 8.3, 1.9 Hz), 7.51 (1H, d, J = 8.3 Hz), 7.91 (1H, d, J = 1.9 Hz), 8.50-8.55 (2H, m).
2,4-ジクロロ-6-メトキシ-1,3,5-トリアジン、4-(2,2-ジメチルプロポキシ)フェニルボロン酸に替えて4-フルオロ-3-メチルフェニルボロン酸、及び2-クロロ-5-ヒドロキシメチルフェニルボロン酸に替えて5-アセチル-2-クロロフェニルボロン酸を用いて、製造例1の(1)及び(2)と同様の方法で、化合物Aを得た。
化合物Aのカルボニル基を水素化ホウ素ナトリウムで還元することにより、ラセミ体の化合物Bを得た。
化合物Bを製造例1の(3)及び(4)と同様の方法でラセミ体の化合物Dを得た。
ラセミ体の化合物Dを純粋なエナンチオマーの化合物Eと反応させることにより、ジアステレオマー混合物の化合物Fを得た。
化合物Fをシリカゲルカラムクロマトグラフィーで精製することにより、低極性ジアステレオマーの化合物F1(Merck TLC Silica gel 60G F254 25 Glassplates、展開溶媒:n-ヘキサン/酢酸エチル=2/1)と高極性ジアステレオマーの化合物F2を得た。化合物F1と化合物F2はそれぞれ単一の立体異性体であるが、ベンジル位の不斉炭素の絶対立体配置は未決定である。
製造例1の(6)と同様の方法で、化合物F1の加水分解反応により、実施例番号1-188の化合物を得た。同様に化合物F2から実施例番号1-189の化合物を得た。実施例番号1-188の化合物と1-189の化合物はそれぞれ単一の立体異性体であるが、ベンジル位の不斉炭素の絶対立体配置は未決定である。
2,4-ジクロロ-6-メトキシ-1,3,5-トリアジン、4-(2,2-ジメチルプロポキシ)フェニルボロン酸、及び2-クロロ-5-ヒドロキシメチルフェニルボロン酸に替えて5-アセチル-2-クロロフェニルボロン酸を用いて、製造例1の(1)及び(2)と同様の方法で、化合物Jを得た。
化合物Jのカルボニル基を水素化ホウ素ナトリウムで還元することにより、ラセミ体の化合物Kを得た。
化合物Kを製造例1の(3)及び(4)と同様の方法でラセミ体の化合物Mを得た。
ラセミ体の化合物Mを純粋なエナンチオマーの化合物Eと反応させることにより、ジアステレオマー混合物の化合物Nを得た。
化合物Nを注釈1と同様の方法によりシリカゲルカラムクロマトグラフィーで精製し、製造例1の(6)と同様の方法で、低極性ジアステレオマーの化合物N1(Merck TLC Silica gel 60G F254 25 Glassplates、展開溶媒:n-ヘキサン/酢酸エチル=2/1)から実施例番号1-200の化合物を得て、高極性ジアステレオマーの化合物N2から実施例番号1-201の化合物を得た。実施例番号1-200の化合物と1-201の化合物はそれぞれ単一の立体異性体であるが、ベンジル位の不斉炭素の絶対立体配置は未決定である。
単一の立体異性体であるが、その相対配置は未決定である。
単一の立体異性体であるが、tert-ブチル基の相対配置は未決定である。
単一の立体異性体であるが、メトキシ基の相対配置は未決定である。
被験物質のヒトmPGES-1酵素阻害活性は、Xuらの報告に準じて評価した(XU, D et al. MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J Pharmacol Exp Ther. Sep 2008, Vol.326, No.3, pages 754-763.)。すなわち、被験物質存在下でヒトmPGES-1により産生されるPGE2量を、HTRF(homogeneous time resolved fluorescence)法で測定することにより、被験物質のヒトmPGES-1酵素阻害活性を求めた。
PCR(Polymerase Chain Reaction)法により、自社で調製したヒトmPGES-1発現プラスミドDNA(pME-18S/iPGES-1)を鋳型として、翻訳開始コドンの直前にBamHI認識切断配列を、翻訳終止コドンの直下にEcoRI認識切断配列を付加したヒトmPGES-1を含むDNA断片を増幅した。精製したDNA断片をBamHI及びEcoRIで消化し、同様にBamHI及びEcoRIで消化したpcDNA3.1(+)(Invitrogen、型番V790-20)にDNA Ligation kit ver.2.1(タカラバイオ、型番6022)を用いて連結した。得られたLigation産物で形質転換した大腸菌DH5α(TOYOBO、型番DNA-903)から、ヒトmPGES-1発現プラスミドDNAを単離した。ベクターにクローニングしたヒトmPGES-1の塩基配列を、BigDye Terminator v3.1 Cycle Sequencing Kit(Applied Biosystems、品番4337455)を用いたDye Terminator法によって決定した。決定した配列はNCBI Reference Databaseに登録されているヒトmPGES-1(Accession number NM_004878)の蛋白質翻訳領域の配列と同一であった。
ヒトmPGES-1発現プラスミドDNAを、遺伝子導入試薬(FreeStyle MAX Reagent(Invitrogen、品番16447-100))を用いてチャイニーズハムスター卵巣由来細胞(FreeStyle CHO-S Cell、Invitrogen、品番R800-07)にトランスフェクションし、8 mmol/L L-グルタミンを含む培地(GIBCO FreeStyle CHO Expression Medium、Invitrogen、品番12651-022)で48時間振盪培養した(8% CO2、37℃)。
CHO-S細胞をHomogenate Buffer(100 mmol/L リン酸カリウム(pH7.4)、250 mmol/L Sucrose、100 mmol/L EDTA、コンプリート EDTA free(Roche、品番1873580))に懸濁した。Ultrasonic disruptor UD-201(トミー精工)を用いて、output:3、duty cycle:50で30秒間、懸濁した細胞を破砕した。遠心分離(1,000×g、5分、4℃)で沈殿を除去した後、上清を遠心分離(5,000×g、10分、4℃)した。その上清に対してさらに遠心分離(105,000×g、60分、4℃)を行った。得られた沈殿をResuspension Buffer(100 mmol/L リン酸カリウム(pH 7.4)、250 mmol/L スクロース、100 mmol/L EDTA、10% グリセロール)で懸濁し、ミクロソーム画分とした。
ミクロソーム画分のタンパク質濃度は、Bradford法(Protein Assay Kit、Bio-Rad)で測定した。ミクロソーム画分は、液体窒素を用いて急速凍結した後、-80℃で保存した。ラビット抗mPGES-1ポリクローナル抗体(ThermoFisher Scientific、品番PA1-10264)を用いたWestern Blotにより、ミクロソーム画分のヒトmPGES-1を検出した。
96穴V底プレート(Corning、品番3363)に、0.1 mol/L リン酸カリウム、pH 7.4(以下KPBと記載する)で希釈した被験物質溶液もしくはDMSO(ナカライテスク、品番13407-45)を5μL/wellずつ添加した。反応時における最終DMSO濃度は2%(v/v)とした。更に、還元型GSH(12.5 mmol/L KPB溶液、SIGMA、品番G6529-25G)で、タンパク濃度が5μg/mLとなるように希釈した、ヒトmPGES-1を発現させたCHO-S細胞のミクロソーム画分を20μL/wellずつ添加した。用いたミクロソーム画分量は、以下に示す反応条件下で産生されるPGE2量と用いるミクロソーム画分量が直線性を示す範囲内のミクロソーム画分量である。ブランクには、還元型GSH(12.5 mmol/L KPB溶液)を20μL/wellずつ添加した。室温で10分間静置した後、PGH2(冷却したアセトンで100μg/mLに溶解したPGH2を、10μg/mLになるようにD-PBS(-)(日研生物医学研究所、品番CM6201)で希釈したもの、Cayman Chemical、品番17020)を25μL/wellずつ添加し、室温で45秒間静置した。塩化スズ(II)二水和物(2 mg/mL 10 mmol/Lクエン酸溶液、和光純薬工業、品番204-01562)を50μL/wellずつ添加し、プレートを軽く振盪し、酵素反応を停止させた。
上記酵素反応液中のPGE2濃度を、Prostaglandin E2 assay(CISbio Bioassays、品番62P2APEC)を用いて、取扱い説明書に従い、測定した。検量線用標品は、PGE2(Cayman Chemical、品番14010)を用いた。RUBYstar(BMG Labtech)を用いて、337 nmの励起光に対する620 nmと665 nmの時間分解蛍光を測定した。PGE2濃度はPGE2検量線から外挿した。各処置をしたウェルのPGE2濃度の平均値をデータとした。
被験物質のmPGES-1酵素阻害活性(%)は、下記式1に従い、算出した。
[式1]
mPGES-1酵素阻害活性(%)=(PGE2A - PGE2X)/(PGE2A - PGE2B)× 100
PGE2A:媒体溶液処置ウェルのPGE2濃度
PGE2B:ブランクウェルのPGE2濃度
PGE2X:被験物質処置ウェルのPGE2濃度
被験物質のIC50値(50%阻害濃度)は、下記式2に従い、算出した。
[式2]
IC50値=10{log10(D / E) × (50 - G) / (F - G) + log10(E)}
D:50%阻害を挟む2点のうち、50%以上の阻害活性を示した被験物質濃度
E:50%阻害を挟む2点のうち、50%以下の阻害活性を示した被験物質濃度
F:被験物質濃度がDの時のmPGES-1酵素阻害活性(%)
G:被験物質濃度がEの時のmPGES-1酵素阻害活性(%)
結果を表4-1から4-9に示した。
本試験は、雄性カニクイザルを用いて行った。個体間差及び投与日間差の影響を排除するため、表5に示すように、クロスオーバー試験にて評価した。
被験物質(実施例2-98の化合物)は、0.5%メチルセルロース(和光純薬工業)に懸濁し、ポリプロピレン製注射筒(滅菌済ディスポーザブル製品、ニプロ株式会社)及び胃カテーテル(ネラトンA型9号、株式会社イズモヘルス)を用い、強制経口投与した。投与量は、個体ごとに投与前日の体重を基準として、10 mg/kg/5mL(N=1)又は30 mg/kg/5mL(N=4)とした。対照物質群には、被験物質と同様の方法で媒体(0.5%メチルセルロース(MC))を投与した。陽性対照物質としてキサラタン(登録商標)点眼液0.005%(Pfizer社、一般名:ラタノプロスト)を用いた。陽性対照物質は、マイクロピペットを用いて一眼あたり20μLを点眼投与した。点眼後、約15秒間下眼瞼を軽く押さえて涙嚢部を軽く固定した。反対眼も同様に処理した。眼圧測定は、投与直前、投与2、4、8、12及び24時間後に実施した。眼圧測定前は、動物をモンキーチェアに固定し、眼科用表面麻酔剤(ベノキシール(登録商標)点眼液0.4%、参天製薬株式会社、一般名:オキシブプロカイン塩酸塩)を点眼投与して局所麻酔した。開瞼器(株式会社はんだや)を装着後、空圧圧平式眼圧計(Model30 Classic、ライカート社)を用いて両目の眼圧を測定した。
被験物質の消失を確認するため、第3クール投与24時間後の眼圧測定後、無麻酔にてヘパリンナトリウムで処理したポリプロピレン製注射筒及び23ゲージの注射針(いずれも滅菌済ディスポーザブル製品)を用いて大腿静脈より1 mLの採血を行い、被験物質の血漿中未変化体濃度を測定した。
測定眼ごとに、各測定時点における投与直前値からの眼圧差(ΔmmHg;小数点第1位まで)を求めた後、左右眼の平均値を算出してその個体の評価データとした。群ごとに眼圧差の平均値及び標準偏差(小数点第2位まで)を算出し、対照物質群と、被験物質投与群又は陽性対照物質投与群について、F検定による等分散性の検定(有意水準5%)を行い、分散が等しい場合はStudentのt検定を、分散が等しくない場合はAspin-Welchのt検定を行った。また、各群で最大眼圧下降幅(ΔmmHg;投与直前値からの最大下降値、小数点第1位まで)を求め、同様に群間で比較した。検定はいずれも両側で、有意水準5%で対照物質群との差が認められた場合に有意な変動とし、図1中には5%と1%に区別して示した。なお、被験物質10 mg/kg投与群は1頭であることから、統計学的解析から除外した。
被験物質を0.5%ポリソルベート80(フルカ)を含有した生理食塩水に溶解し、0.003%点眼溶液(pH 7.0~8.0)を調製した。マイクロピペットを用いてHartley系雄性モルモットに一眼あたり20 μLを点眼投与した。点眼後、約15秒間下眼瞼を軽く押さえて涙嚢部を軽く固定した。反対眼も同様に処理した。対照物質群には、被験物質と同様の方法で媒体(0.5%ポリソルベート含有生理食塩水)を投与した。点眼23時間後にモルモットの両眼にミドリンP(登録商標)0.5%点眼液(参天製薬株式会社、一般名:トロピカミド/フェニレフリン塩酸塩)を一滴ずつ滴下し、散瞳させた。モルモットをエスカイン(登録商標)吸入麻酔薬(Pfizer社、一般名:イソフルラン)で麻酔し、両眼の角膜を30Gの注射針で穿刺し、漏出した房水(一次房水)を採取した。さらに1時間後(点眼投与24時間後)に再度モルモットをイソフルランで麻酔し、同様にして二次房水を採取した。各群4匹8眼より得た二次房水中のプロスタグランジン類の濃度をLC/MS/MS システム(超高速液体クロマトグラフ:株式会社島津製作所社製Nexera(登録商標)、質量分析計:AB SCIEX社製QTRAP(登録商標)5500)にて測定し、全プロスタグランジンの濃度の和に対する各プロスタグランジンの濃度比を算出した。結果を表6に示した。
本試験は、雄性カニクイザルを用いて行う。個体間差及び投与日間差の影響を排除するため、表7に示すように、クロスオーバー試験にて評価する。
被験物質は、0.5%ポリソルベート80(フルカ)を含有した生理食塩水に溶解し、0.1%点眼溶液(pH 7.9~8.1)を調製する。対照物質群には、被験物質と同様の方法で媒体(0.5%ポリソルベート含有生理食塩水)を投与する。陽性対照物質としてキサラタン(登録商標)点眼液0.005%(Pfizer社、一般名:ラタノプロスト)を用いる。被験物質は、マイクロピペットを用いて一眼あたり30μLを5分間隔で5回点眼投与した後に媒体を1回投与する(一眼あたり計6回点眼)。媒体群及び陽性対照物質群は各々を1回投与後に,媒体を5回投与する(一眼あたり計6回点眼)。被験物質と陽性対照物質の併用群は陽性対照物質を点眼後に被験物質を5回点眼する(一眼あたり計6回点眼)。各回の点眼後、約15秒間下眼瞼を軽く押さえて涙嚢部を軽く固定する。反対眼も同様に処理する。眼圧測定は、投与直前、投与2、4、8、12及び24時間後に実施する。眼圧測定前は、動物をモンキーチェアに固定し、眼科用表面麻酔剤(ベノキシール(登録商標)点眼液0.4%、参天製薬株式会社、一般名:オキシブプロカイン塩酸塩)を点眼投与して局所麻酔する。開瞼器(株式会社はんだや)を装着後、空圧圧平式眼圧計(Model30 Classic、ライカート社)を用いて両目の眼圧を測定する。
測定眼ごとに、各測定時点における投与直前値からの眼圧差(ΔmmHg;小数点第1位まで)を求めた後、左右眼の平均値を算出してその個体の評価データとする。群ごとに眼圧差の平均値及び標準偏差(小数点第2位まで)を算出し、対照物質群と、被験物質投与群又は陽性対照物質投与群について、F検定による等分散性の検定(有意水準5%)を行い、分散が等しい場合はStudentのt検定を、分散が等しくない場合はAspin-Welchのt検定を行う。また、各群で最大眼圧下降幅(ΔmmHg;投与直前値からの最大下降値、小数点第1位まで)を求め、同様に群間で比較する。検定はいずれも両側で、有意水準5%で対照物質群との差が認められた場合に有意な変動とする。
製剤例1(カプセルの製造)
1)実施例1-86の化合物 30 mg
2)微結晶セルロース 10 mg
3)乳糖 19 mg
4)ステアリン酸マグネシウム 1 mg
1)、2)、3)及び4)を混合して、ゼラチンカプセルに充填する。
製剤例2(錠剤の製造)
1)実施例1-86の化合物 10 g
2)乳糖 50 g
3)トウモロコシデンプン 15 g
4)カルメロースカルシウム 44 g
5)ステアリン酸マグネシウム 1 g
1)、2)、3)の全量及び30 gの4)を水で練合し、真空乾燥後、整粒を行う。この整粒末に14 gの4)及び1 gの5)を混合し、打錠機により打錠する。このようにして、1錠あたり実施例1-86の化合物10 mgを含有する錠剤1000錠を得る。
製剤例3(点眼剤の製造)
点眼剤100 mL中
1)実施例1-86の化合物 100 mg
2)ポリソルベート80 500 mg
3)塩化ナトリウム 900 mg
4)水酸化ナトリウム 適量
5)滅菌精製水 適量
以上の成分を無菌的に混和してpH 7.9~8.1とし、点眼剤とする。
製剤例4(点眼剤の製造)
点眼剤100 mL中
1)実施例1-86の化合物 100 mg
2)ポリソルベート80 100 mg
3)リン酸二水素ナトリウム二水和物 100 mg
4)塩化ナトリウム 900 mg
5)塩化ベンザルコニウム 5 mg
6)水酸化ナトリウム 適量
7)滅菌精製水 適量
以上の成分を無菌的に混和してpH 7.9~8.1とし、点眼剤とする。
製剤例5(点眼剤の製造)
点眼剤100 mL中
1)実施例1-86の化合物 100 mg
2)ホウ酸 700 mg
3)ホウ砂 適量
4)塩化ナトリウム 500 mg
5)エデト酸ナトリウム 0.05 mg
6)塩化ベンザルコニウム 0.0005 mg
7)滅菌精製水 適量
以上の成分を無菌的に混和してpH 7.9~8.1とし、点眼剤とする。
本出願は、日本国で2014年2月20日に出願された特願2014-031035を基礎としており、その内容は本明細書にすべて包含されるものである。
Claims (21)
- 式[I]の化合物又はその薬学上許容される塩:
Xは、CH又はNであり、
環Cyは、
式:
式:
(1) ハロゲン、
(2) C1-6アルキル、
(3) シアノ、又は、
(4) ハロC1-4アルキルであり、
R2は、
(1) ハロゲン、
(2) ヒドロキシ、
(3) カルボキシ、
(4) C1-6アルキル、
(5) C1-6アルコキシ、
(6) ハロC1-4アルコキシ、
(7) ハロC1-4アルキル、
(8) C1-6アルキル-カルボニル、
(9) -C(O)NRa1Ra2(Ra1及びRa2は、それぞれ独立して、水素又はC1-6アルキルである。)、又は、
(10) -(CnH2n)-Rb
(nは、1、2、3又は4であり、-(CnH2n)-は直鎖状又は分枝鎖状のいずれであってもよく、
Rbは、
(a) ヒドロキシ、
(b) カルボキシ、
(c) C1-6アルコキシ、
(d) C1-6アルキル-カルボニルオキシ、
(e) -C(O)NRb1Rb2(Rb1及びRb2は、それぞれ独立して、水素又はC1-6アルキルである。)、
(f) -OC(O)NRb3Rb4(Rb3及びRb4は、それぞれ独立して、水素又はC1-6アルキルである。)、
(g) -NRb5C(O)NRb6Rb7(Rb5、Rb6及びRb7は、それぞれ独立して、水素又はC1-6アルキルである。)、
(h) -NRb8Rb9(Rb8及びRb9は、それぞれ独立して、水素、C1-6アルキル又はハロC1-4アルキルである。)、
(i) -NRb10S(O)2Rb11(Rb10及びRb11は、それぞれ独立して、水素、C1-6アルキル又はC3-7シクロアルキルである。)、
(j) -NRb12C(O)ORb13(Rb12は、水素又はC1-6アルキルであり、Rb13は、C1-6アルキルである。)、
(k) -NRb14C(O)Rb15(Rb14は、水素又はC1-6アルキルであり、
Rb15は、
(i) C6-10アリール、
(ii) C1-8アルキル(該C1-8アルキルは、ヒドロキシ、ハロC1-4アルキル、C1-6アルコキシ及びC6-10アリールからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)、
(iii) アダマンチル、又は、
(iv) C3-7シクロアルキル(該C3-7シクロアルキルは、C1-6アルキル、ハロゲン、ヒドロキシC1-6アルキル及びハロC1-4アルキルからなるグループから選択される1、2、3又は4個の置換基で置換されてもよく、及び/又は、ベンゼン環と縮合環を形成してもよい。)であるか、
或いは、Rb14とRb15は、Rb14が結合する窒素原子及びRb15が結合する炭素原子と一緒になって4、5又は6員のラクタムを形成してもよい。(該ラクタムは1、2又は3個のC1-6アルキルで置換されてもよく、及び/又は、ベンゼン環と縮合環を形成してもよい。))、
(l) 式:
(m) 式:
であり、
R3は、
(1) ハロゲン、
(2) ヒドロキシ、
(3) C1-6アルキル、又は、
(4) -ORc{Rcは、以下の(a)から(f)からなるグループから選択される1、2又は3個の置換基で置換されてもよいC1-6アルキルである;
(a) ハロゲン、
(b) ヒドロキシ、
(c) C1-6アルコキシ、
(d) -C(O)NRc1Rc2(Rc1及びRc2は、それぞれ独立して、水素又はC1-6アルキルである。)、
(e) C6-10アリール(該C6-10アリールは、
(i) ハロゲン、
(ii) ヒドロキシ、
(iii) C1-6アルキル、
(iv) C1-6アルコキシ、及び、
(v) ハロC1-4アルキルからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)、及び、
(f) 5又は6員の、1、2又は3個の窒素原子、酸素原子又は硫黄原子を含むヘテロアリール(該ヘテロアリールは、
(i) ハロゲン、
(ii) ヒドロキシ、
(iii) C1-6アルキル、
(iv) C1-6アルコキシ、及び、
(v) ハロC1-4アルキルからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)}であり、
R4は、
(1) 水素、
(2) ハロゲン、
(3) C1-6アルキル、又は、
(4) C1-6アルコキシである。}
であり、
R5は、
(1) ハロゲン、
(2) ヒドロキシ、
(3) C1-6アルキルスルファニル、
(4) C1-6アルキル(該C1-6アルキルは、ハロゲン、C6-10アリール及びC1-6アルコキシからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)、
(5) C3-7シクロアルキル、
(6) -ORd{Rdは、
(a) C2-6アルキニル、
(b) 1、2又は3個のC1-6アルキルで置換されてもよいC3-7シクロアルキル、又は、
(c) C1-8アルキル(該C1-8アルキルは、以下の(i)から(v)からなるグループから選択される1、2又は3個の置換基で置換されてもよい;
(i) ハロゲン、
(ii) C6-10アリール、
(iii) C1-6アルコキシ、
(iv) C3-7シクロアルキル(該C3-7シクロアルキルは、C1-6アルキル及びハロC1-4アルキルからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)、及び、
(v) 4、5又は6員の、1、2又は3個の窒素原子、酸素原子又は硫黄原子を含む飽和ヘテロシクリル(該飽和ヘテロシクリルは、C1-6アルキル及びハロC1-4アルキルからなるグループから選択される1、2又は3個の置換基で置換されてもよい。))である。}、又は、
(7) 式:
(a) C1-6アルキル、
(b) C3-7シクロアルキル、
(c) 5又は6員の、1、2又は3個の窒素原子、酸素原子又は硫黄原子を含むヘテロアリール、又は、
(d) C6-10アリール(該C6-10アリールは、
(i) ハロゲン、
(ii) C1-6アルキル、
(iii) ハロC1-4アルキル、
(iv) C1-6アルコキシ、及び、
(v) ハロC1-4アルコキシからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)である。}であり、
m1は0、1、2又は3であり、m1が2又は3のとき、各R5は独立して選ばれる。]
ただし、4,6-ビス-(2,5-ジメチル-フェニル)-1,3,5-トリアジン-2-オールは除く。 - XがCHである、請求項1から3のいずれか一項に記載の化合物又はその薬学上許容される塩。
- XがNである、請求項1から3のいずれか一項に記載の化合物又はその薬学上許容される塩。
- R1が、
(1) クロロ、
(2) メチル、
(3) シアノ、又は、
(4) トリフルオロメチルである、請求項1から5のいずれか一項に記載の化合物又はその薬学上許容される塩。 - R4が水素である、請求項1から6のいずれか一項に記載の化合物又はその薬学上許容される塩。
- R2が、
-(CnH2n)-Rb(nは、1又は2であり、-(CnH2n)-は直鎖状又は分枝鎖状のいずれであってもよく、Rbは、
(a) -C(O)NRb1Rb2、
(b) -NRb5C(O)NRb6Rb7、
(c) -NRb10S(O)2Rb11、又は、
(d) -NRb14C(O)Rb15(Rb1、Rb2、Rb5、Rb6、Rb7、Rb10、Rb11、Rb14、及びRb15は請求項1における定義と同義である。)である。)である、請求項1、2、及び4から7のいずれか一項に記載の化合物又はその薬学上許容される塩。 - R2が、-CH2-Rb(Rbは、請求項8における定義と同義である。)である、請求項8に記載の化合物又はその薬学上許容される塩。
- R3が、
(1) ハロゲン、
(2) ヒドロキシ、
(3) C1-6アルキル、又は、
(4) -ORc{Rcは、以下の(a)から(f)からなるグループから選択される1、2又は3個の置換基で置換されてもよいC1-6アルキルである。
(a) ハロゲン、
(b) ヒドロキシ、
(c) C1-6アルコキシ、
(d) -C(O)NRc1Rc2(Rc1及びRc2は、それぞれ独立して、水素又はC1-6アルキルである。)、
(e) フェニル(該フェニルは、
(i) ハロゲン、
(ii) ヒドロキシ、
(iii) C1-6アルキル、
(iv) C1-6アルコキシ、及び、
(v) ハロC1-4アルキルからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)、及び、
(f) ピリジル(該ピリジルは、
(i) ハロゲン、
(ii) ヒドロキシ、
(iii) C1-6アルキル、
(iv) C1-6アルコキシ、及び、
(v) ハロC1-4アルキルからなるグループから選択される1、2又は3個の置換基で置換されてもよい。)}である、請求項1及び3から9のいずれか一項に記載の化合物又はその薬学上許容される塩。 - 請求項1から12のいずれか一項に記載の化合物又はその薬学上許容される塩、及び薬学上許容される担体を含む、医薬組成物。
- 請求項1から12のいずれか一項に記載の化合物又はその薬学上許容される塩を含む、mPGES-1阻害剤。
- 請求項1から12のいずれか一項に記載の化合物又はその薬学上許容される塩を含む、疼痛、リウマチ、発熱、変形性関節症、動脈硬化、アルツハイマー病、多発性硬化症、緑内障、高眼圧症、虚血性網膜疾患、全身性強皮症及び悪性腫瘍の治療剤又は予防剤。
- 請求項1から12のいずれか一項に記載の化合物又はその薬学上許容される塩、及び一種類以上の他の緑内障治療剤を組み合わせてなる緑内障及び高眼圧症の治療剤又は予防剤。
- 薬学上有効量の、請求項1から12のいずれか一項に記載の化合物又はその薬学上許容される塩をヒトに投与することを含む、mPGES-1の阻害方法。
- 薬学上有効量の、請求項1から12のいずれか一項に記載の化合物又はその薬学上許容される塩をヒトに投与することを含む、疼痛、リウマチ、発熱、変形性関節症、動脈硬化、アルツハイマー病、多発性硬化症、緑内障、高眼圧症、虚血性網膜疾患、全身性強皮症及び悪性腫瘍の治療方法又は予防方法。
- 薬学上有効量の、一種類以上の他の緑内障治療剤をさらにヒトに投与することを含む、請求項18記載の緑内障及び高眼圧症の治療方法又は予防方法。
- mPGES-1阻害剤を製造するための請求項1から12のいずれか一項に記載の化合物又はその薬学上許容される塩の使用。
- 疼痛、リウマチ、発熱、変形性関節症、動脈硬化、アルツハイマー病、多発性硬化症、緑内障、高眼圧症、虚血性網膜疾患、全身性強皮症及び悪性腫瘍の治療剤又は予防剤を製造するための請求項1から12のいずれか一項に記載の化合物又はその薬学上許容される塩の使用。
Priority Applications (25)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2015219920A AU2015219920B2 (en) | 2014-02-20 | 2015-02-19 | Triazine compound and use thereof for medical purposes |
DK15751885.3T DK3109240T3 (en) | 2014-02-20 | 2015-02-19 | TRIAZINE CONNECTION AND ITS USE FOR MEDICAL PURPOSES |
PL15751885T PL3109240T3 (pl) | 2014-02-20 | 2015-02-19 | Związek triazynowy i jego zastosowanie do celów medycznych |
KR1020167025241A KR102360699B1 (ko) | 2014-02-20 | 2015-02-19 | 트리아진 화합물 및 그의 의약 용도 |
RS20181563A RS58235B1 (sr) | 2014-02-20 | 2015-02-19 | Triazin jedinjenje i njegova upotreba u medicinske svrhe |
PE2021000546A PE20211548A1 (es) | 2014-02-20 | 2015-02-19 | Compuesto de triazina y su uso para fines medicos |
MX2016010875A MX369217B (es) | 2014-02-20 | 2015-02-19 | Compuesto de triazina y su uso para propositos medicos. |
ES15751885T ES2704922T3 (es) | 2014-02-20 | 2015-02-19 | Compuesto de triazina y uso del mismo con fines médicos |
SG11201606902QA SG11201606902QA (en) | 2014-02-20 | 2015-02-19 | Triazine compound and use thereof for medical purposes |
EP15751885.3A EP3109240B1 (en) | 2014-02-20 | 2015-02-19 | Triazine compound and use thereof for medical purposes |
CN201580020793.6A CN106232585B (zh) | 2014-02-20 | 2015-02-19 | 三嗪化合物和其药物用途 |
RU2016137263A RU2692789C2 (ru) | 2014-02-20 | 2015-02-19 | Соединение триазина и его применение в медицинских целях |
LTEP15751885.3T LT3109240T (lt) | 2014-02-20 | 2015-02-19 | Triazino junginys ir jo panaudojimas medicinos reikmėms |
CA2936408A CA2936408C (en) | 2014-02-20 | 2015-02-19 | Triazine compounds and pharmaceutical use thereof |
MYPI2016703028A MY183605A (en) | 2014-02-20 | 2015-02-19 | Triazine compound and use thereof for medical purposes |
NZ721718A NZ721718B2 (en) | 2014-02-20 | 2015-02-19 | Triazine compound and use thereof for medical purposes |
EP18201469.6A EP3456713A1 (en) | 2014-02-20 | 2015-02-19 | Process for the preparation of triazine derivatives |
SI201530563T SI3109240T1 (sl) | 2014-02-20 | 2015-02-19 | Triazinska spojina in njena uporaba v medicinske namene |
BR112016018341-0A BR112016018341B1 (pt) | 2014-02-20 | 2015-02-19 | Composto de triazina, seu uso para propósitos médicos, composição farmacêutica, inibidor de mpges1 e agente profilático ou terapêutico |
IL24731916A IL247319B (en) | 2014-02-20 | 2016-08-17 | History of 2-hydroxy-6,4-diphenyl-[5,3,1]triazine as mpges-1 inhibitors |
SA516371701A SA516371701B1 (ar) | 2014-02-20 | 2016-08-18 | مركب ترايازين واستخدامه للأغراض الطبية |
PH12016501651A PH12016501651A1 (en) | 2014-02-20 | 2016-08-18 | Triazine compound and use thereof for medical purposes |
ZA2016/06449A ZA201606449B (en) | 2014-02-20 | 2016-09-19 | Triazine compound and use thereof for medical purposes |
HRP20182134TT HRP20182134T1 (hr) | 2014-02-20 | 2018-12-17 | Triazinski spoj i njegova upotreba u medicinske svrhe |
CY20181101359T CY1121261T1 (el) | 2014-02-20 | 2018-12-19 | Ενωση τριαζινης και χρηση εξ αυτης για ιατρικους σκοπους |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-031035 | 2014-02-20 | ||
JP2014031035 | 2014-02-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015125842A1 true WO2015125842A1 (ja) | 2015-08-27 |
Family
ID=53878341
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/054519 WO2015125842A1 (ja) | 2014-02-20 | 2015-02-19 | トリアジン化合物及びその医薬用途 |
Country Status (31)
Country | Link |
---|---|
US (3) | US20150266834A1 (ja) |
EP (2) | EP3456713A1 (ja) |
JP (4) | JP6461637B2 (ja) |
KR (1) | KR102360699B1 (ja) |
CN (1) | CN106232585B (ja) |
AR (1) | AR099498A1 (ja) |
AU (1) | AU2015219920B2 (ja) |
BR (1) | BR112016018341B1 (ja) |
CA (1) | CA2936408C (ja) |
CL (1) | CL2016002091A1 (ja) |
CY (1) | CY1121261T1 (ja) |
DK (1) | DK3109240T3 (ja) |
ES (1) | ES2704922T3 (ja) |
HR (1) | HRP20182134T1 (ja) |
IL (1) | IL247319B (ja) |
LT (1) | LT3109240T (ja) |
MX (1) | MX369217B (ja) |
MY (1) | MY183605A (ja) |
PE (2) | PE20161236A1 (ja) |
PH (1) | PH12016501651A1 (ja) |
PL (1) | PL3109240T3 (ja) |
PT (1) | PT3109240T (ja) |
RS (1) | RS58235B1 (ja) |
RU (1) | RU2692789C2 (ja) |
SA (1) | SA516371701B1 (ja) |
SG (1) | SG11201606902QA (ja) |
SI (1) | SI3109240T1 (ja) |
TR (1) | TR201821158T4 (ja) |
TW (1) | TWI651310B (ja) |
WO (1) | WO2015125842A1 (ja) |
ZA (1) | ZA201606449B (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017030115A1 (ja) * | 2015-08-17 | 2017-02-23 | 日本たばこ産業株式会社 | ヒドロキシトリアジン化合物及びその医薬用途 |
WO2017073709A1 (ja) | 2015-10-29 | 2017-05-04 | あすか製薬株式会社 | ピリミジン誘導体 |
AU2015371822B2 (en) * | 2014-12-24 | 2020-04-09 | National Institute Of Biological Sciences, Beijing | Necrosis inhibitors |
WO2022168808A1 (ja) | 2021-02-02 | 2022-08-11 | あすか製薬株式会社 | ピリミジン誘導体 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
TWI651310B (zh) * | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
JP6478255B2 (ja) * | 2015-03-04 | 2019-03-06 | 株式会社島津製作所 | 蛍光誘導体化試薬及びアミン分析方法 |
GB201603311D0 (en) * | 2016-02-25 | 2016-04-13 | Jakobsson Per Johan | New uses and methods |
JP7036792B2 (ja) * | 2016-08-01 | 2022-03-15 | アプティニックス インコーポレイテッド | スピロ-ラクタムnmda受容体修飾因子およびその使用 |
US11370790B2 (en) | 2016-08-01 | 2022-06-28 | Aptinyx Inc. | Spiro-lactam NMDA modulators and methods of using same |
CN110799506B (zh) * | 2017-06-26 | 2024-03-01 | 默克专利有限公司 | 用于制备被取代的含氮杂环化合物的方法 |
CA3148435A1 (en) * | 2019-07-22 | 2021-01-28 | Angion Biomedica Corp. | Ethynylheterocycles as rho-associated coiled-coil kinase (rock) inhibitors |
US11786538B2 (en) * | 2019-12-11 | 2023-10-17 | Somerset Therapeutics, Llc | Low benzalkonium chloride bimatoprost ophthalmic compositions with effective penetration and preservation properties |
KR102157466B1 (ko) * | 2020-05-19 | 2020-09-17 | 동아대학교 산학협력단 | 헥사하이드로트리아진 유도체를 포함하는 방광암의 예방, 개선 또는 치료용 조성물 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002514195A (ja) * | 1996-12-05 | 2002-05-14 | アムジエン・インコーポレーテツド | 置換ピリミジン化合物およびそれの使用 |
WO2011037610A1 (en) * | 2009-09-23 | 2011-03-31 | Albert Einstein College Of Medicine Of Yeshiva University | Prostaglandin transporter inhibitors and uses thereof |
JP2011525905A (ja) * | 2008-06-26 | 2011-09-29 | 田辺三菱製薬株式会社 | 神経変性疾患治療用のgsk3−ベータ阻害剤としての4−(ピリジン−4−イル)−1h−(1,3,5)トリアジン−2−オン誘導体 |
JP2012511517A (ja) * | 2008-12-10 | 2012-05-24 | 上海特化医薬科技有限公司 | フェニルピリミドン骨格を有する化合物、その薬剤組成物、その製造方法及び用途 |
WO2012161965A1 (en) * | 2011-05-26 | 2012-11-29 | Eli Lilly And Company | Novel imidazole derivatives useful for the treatment of arthritis |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0051067A1 (en) * | 1980-04-22 | 1982-05-12 | Commonwealth Scientific And Industrial Research Organisation | Triazine synthesis |
DE19543730A1 (de) * | 1995-11-23 | 1997-05-28 | Ciba Geigy Ag | Bis-Resorcinyl-Triazine |
AU733877C (en) * | 1996-12-05 | 2003-05-08 | Amgen, Inc. | Substituted pyrimidine compounds and their use |
US20040082627A1 (en) * | 2002-06-21 | 2004-04-29 | Darrow James W. | Certain aromatic monocycles as kinase modulators |
FR2983859B1 (fr) * | 2011-12-12 | 2014-01-17 | Sanofi Sa | Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique |
EP2800743B1 (en) * | 2012-01-06 | 2018-04-04 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
TWI568722B (zh) * | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲mPGES-1抑制劑之三唑酮化合物 |
JP2014031035A (ja) | 2012-08-01 | 2014-02-20 | Yamaha Motor Co Ltd | 原動機付き鞍乗型車両 |
TWI651310B (zh) * | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
CN105586773A (zh) * | 2014-11-13 | 2016-05-18 | 东丽纤维研究所(中国)有限公司 | 一种拒水抗紫外纺织品及其生产方法和用途 |
-
2015
- 2015-02-17 TW TW104105551A patent/TWI651310B/zh active
- 2015-02-19 ES ES15751885T patent/ES2704922T3/es active Active
- 2015-02-19 AU AU2015219920A patent/AU2015219920B2/en not_active Ceased
- 2015-02-19 EP EP18201469.6A patent/EP3456713A1/en not_active Withdrawn
- 2015-02-19 RU RU2016137263A patent/RU2692789C2/ru active
- 2015-02-19 SI SI201530563T patent/SI3109240T1/sl unknown
- 2015-02-19 KR KR1020167025241A patent/KR102360699B1/ko active IP Right Grant
- 2015-02-19 AR ARP150100484A patent/AR099498A1/es active IP Right Grant
- 2015-02-19 DK DK15751885.3T patent/DK3109240T3/en active
- 2015-02-19 SG SG11201606902QA patent/SG11201606902QA/en unknown
- 2015-02-19 TR TR2018/21158T patent/TR201821158T4/tr unknown
- 2015-02-19 US US14/626,243 patent/US20150266834A1/en not_active Abandoned
- 2015-02-19 PT PT15751885T patent/PT3109240T/pt unknown
- 2015-02-19 CN CN201580020793.6A patent/CN106232585B/zh active Active
- 2015-02-19 JP JP2015030157A patent/JP6461637B2/ja active Active
- 2015-02-19 PE PE2016001506A patent/PE20161236A1/es unknown
- 2015-02-19 PL PL15751885T patent/PL3109240T3/pl unknown
- 2015-02-19 EP EP15751885.3A patent/EP3109240B1/en active Active
- 2015-02-19 PE PE2021000546A patent/PE20211548A1/es unknown
- 2015-02-19 MX MX2016010875A patent/MX369217B/es active IP Right Grant
- 2015-02-19 LT LTEP15751885.3T patent/LT3109240T/lt unknown
- 2015-02-19 BR BR112016018341-0A patent/BR112016018341B1/pt active IP Right Grant
- 2015-02-19 WO PCT/JP2015/054519 patent/WO2015125842A1/ja active Application Filing
- 2015-02-19 RS RS20181563A patent/RS58235B1/sr unknown
- 2015-02-19 CA CA2936408A patent/CA2936408C/en active Active
- 2015-02-19 MY MYPI2016703028A patent/MY183605A/en unknown
-
2016
- 2016-08-17 IL IL24731916A patent/IL247319B/en active IP Right Grant
- 2016-08-18 SA SA516371701A patent/SA516371701B1/ar unknown
- 2016-08-18 CL CL2016002091A patent/CL2016002091A1/es unknown
- 2016-08-18 PH PH12016501651A patent/PH12016501651A1/en unknown
- 2016-09-19 ZA ZA2016/06449A patent/ZA201606449B/en unknown
-
2018
- 2018-12-17 HR HRP20182134TT patent/HRP20182134T1/hr unknown
- 2018-12-19 CY CY20181101359T patent/CY1121261T1/el unknown
- 2018-12-26 JP JP2018241974A patent/JP2019065036A/ja active Pending
-
2019
- 2019-04-26 US US16/396,503 patent/US20200087266A1/en not_active Abandoned
-
2021
- 2021-01-05 JP JP2021000347A patent/JP2021054856A/ja not_active Ceased
-
2022
- 2022-01-14 US US17/575,931 patent/US20230011968A1/en active Pending
- 2022-06-17 JP JP2022097960A patent/JP2022120173A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002514195A (ja) * | 1996-12-05 | 2002-05-14 | アムジエン・インコーポレーテツド | 置換ピリミジン化合物およびそれの使用 |
JP2011525905A (ja) * | 2008-06-26 | 2011-09-29 | 田辺三菱製薬株式会社 | 神経変性疾患治療用のgsk3−ベータ阻害剤としての4−(ピリジン−4−イル)−1h−(1,3,5)トリアジン−2−オン誘導体 |
JP2012511517A (ja) * | 2008-12-10 | 2012-05-24 | 上海特化医薬科技有限公司 | フェニルピリミドン骨格を有する化合物、その薬剤組成物、その製造方法及び用途 |
WO2011037610A1 (en) * | 2009-09-23 | 2011-03-31 | Albert Einstein College Of Medicine Of Yeshiva University | Prostaglandin transporter inhibitors and uses thereof |
WO2012161965A1 (en) * | 2011-05-26 | 2012-11-29 | Eli Lilly And Company | Novel imidazole derivatives useful for the treatment of arthritis |
Non-Patent Citations (1)
Title |
---|
HAMDY,N.A. ET AL., EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 44, 2009, pages 4547 - 4556, XP055221516 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015371822B2 (en) * | 2014-12-24 | 2020-04-09 | National Institute Of Biological Sciences, Beijing | Necrosis inhibitors |
CN108137515A (zh) * | 2015-08-17 | 2018-06-08 | 日本烟草产业株式会社 | 羟基三嗪化合物和其医药用途 |
WO2017030115A1 (ja) * | 2015-08-17 | 2017-02-23 | 日本たばこ産業株式会社 | ヒドロキシトリアジン化合物及びその医薬用途 |
AU2016309337B2 (en) * | 2015-08-17 | 2021-03-04 | Japan Tobacco Inc. | Hydroxytriazine compound and medical use thereof |
CN108137515B (zh) * | 2015-08-17 | 2021-07-06 | 日本烟草产业株式会社 | 羟基三嗪化合物和其医药用途 |
EP4046991A1 (en) | 2015-08-17 | 2022-08-24 | Japan Tobacco Inc. | Hydroxytriazine compounds and pharmaceutical use thereof |
CN108137513A (zh) * | 2015-10-29 | 2018-06-08 | Aska 制药株式会社 | 嘧啶衍生物 |
KR20180067678A (ko) | 2015-10-29 | 2018-06-20 | 아스카 세이야쿠 가부시키가이샤 | 피리미딘 유도체 |
JPWO2017073709A1 (ja) * | 2015-10-29 | 2018-08-23 | あすか製薬株式会社 | ピリミジン誘導体 |
WO2017073709A1 (ja) | 2015-10-29 | 2017-05-04 | あすか製薬株式会社 | ピリミジン誘導体 |
US10710967B2 (en) | 2015-10-29 | 2020-07-14 | Aska Pharmaceutical Co., Ltd. | Pyrimidine derivative |
CN108137513B (zh) * | 2015-10-29 | 2022-03-01 | Aska 制药株式会社 | 嘧啶衍生物 |
WO2022168808A1 (ja) | 2021-02-02 | 2022-08-11 | あすか製薬株式会社 | ピリミジン誘導体 |
KR20230142739A (ko) | 2021-02-02 | 2023-10-11 | 아스카 세이야쿠 가부시키가이샤 | 피리미딘 유도체 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015125842A1 (ja) | トリアジン化合物及びその医薬用途 | |
JP5685203B2 (ja) | カルシウムチャネル遮断薬またはナトリウムチャネル遮断薬としてのアリール置換カルボキサミド誘導体 | |
JP2024019449A (ja) | ヒドロキシトリアジン化合物及びその医薬用途 | |
JP2007015928A (ja) | 新規オレフィン誘導体 | |
RU2772907C2 (ru) | Соединение гидрокситриазина и его применение в медицинских целях | |
WO2022037601A1 (zh) | 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在制备治疗癌症和炎症药物中的用途 | |
JPWO2009048123A1 (ja) | ビス(トリメチルシリル)フェニル化合物又はその塩、及びその用途 | |
NZ721718B2 (en) | Triazine compound and use thereof for medical purposes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15751885 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2936408 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2015219920 Country of ref document: AU Date of ref document: 20150219 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 247319 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12016501651 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 001506-2016 Country of ref document: PE Ref document number: MX/A/2016/010875 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016018341 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20167025241 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015751885 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015751885 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016137263 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: NC2016/0002011 Country of ref document: CO |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
ENP | Entry into the national phase |
Ref document number: 112016018341 Country of ref document: BR Kind code of ref document: A2 Effective date: 20160809 |